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ii. 
Abstrac t 
This thesis reports studies carried out to investigate further 
the effect of alteration of the platelet cholesterol content on 
platelet function. Recent research has shown that cholesterol - 
enriched human platelets were capable of synthesising greater 
quantities of pro- aggregating compounds compared to control and 
cholesterol- depleted platelets. Phospholipase A2 activity in the 
platelet membrane may be an important rate limiting step in the 
metabolism of arachidonic acid to pro- aggregating compounds for 
example thromboxane A2. Thus in the present project, cholesterol - 
enriched platelets have been investigated with particular reference 
to phospholipase A2 activity. 
Rat platelets were enriched with and depleted of cholesterol by 
in vitro incubation with cholesterol -rich and cholesterol -poor 
phospholipid liposome suspensions respectively. Aggregation studies 
shoved that cholesterol- enriched rat platelets (in platelet -liposome 
mixtures) were more sensitive to collagen and ADP induced aggregation. 
Phospholipase A2 assays were carried out by analysing the conversion 
of phosphatidylcholine containing a radiolabelled sn -2 fatty acid. 
Rat platelets were resuspended once, and no difference in phospholipase 
A2 activity was detected between cholesterol- enriched and cholesterol 
normal platelets. 
Rabbits were fed a cholesterol -rich diet for 4 weeks. Platelets 
isolated from cholesterol fed rabbits had a significantly higher 
cholesterol :phospholipid molar ratio than platelets from rabbits 
fed a normal diet. The once resuspended cholesterol- enriched rabbit 
platelets showed significantly higher phospholipase A2 activity 
compared to control platelets treated in the same way. Also, the 
cholesterol- enriched rabbit platelets were observed to have a more 
active arachidonic acid metabolic pathway, as assayed by measuring 
arachidonic acid induced thromboxane A2 and MDA production. 
Platelets were also examined from hypercholesterolaemic human 
subjects and compared with platelets from normal human subjects. 
In these experiments, no d if fer ences were detected in cholesterol 
content or phospholipase A2 activities of crude platelet membrane 
fractions prepared from these platelets. This may have been due to 
this assay not being suitable for the very labile human platelet 
phospholipase A2 activity. 
(rude platelet membrane fractions were also prepared from rat 
platelets with altered cholesterol content. Phospholipase A2 assays 
consistently showed that the activity was significantly higher in 
cholesterol -enriched rat platelet membrane fractions than in control 
platelet membrane fractions. These results and those from the 
rabbit platelet experiments suggested that platelet hyper sensi ti vi ty 
induced by cholesterol -enrichment may be mediated partly through 
hyperactivity of the membrane bound phospholipase A2. 
Rat platelets were also enriched with cholesterol analogues which 
were different from cholesterol only in that they had side chains 
of reduced length. The analogues studied were pregn -5 -en- 30-ol, 
chol- 5- en- 3ß -ol, and 27 norcholest- 5- en- 3/ -ol. These analogues 
were readily taken up by the platelets on incubation with analogue 
loaded liposome suspensions. Aggregation tests and scanning electron 
microscopy indicated that major changes occurred in the physiology 
of platelets enriched with analogues which had a side chain 3 or 
more carbon atoms shorter than cholesterol. Enrichment of rat 
platelets with the analogue which had a side chain shorter by one 
carbon atom had the same effects as cholesterol- enrichment. 
These platelets became hypersensitive to collagen induced aggregation. 
iv. 
The results presented in this thesis suggest that the activity 
of phospholipase A2 may be influenced by the membrane cholesterol 
content, and clearly indicate a requirement by the platelet membrane 
of a sterol of precise dimensions to maintain normal platelet function. 
v. 
Abbrevia tions 
C21- analogue, C21- sterol pregn- 5 -en -3,g -ol 
C24- analogue, C24- sterol chol- 5- en -3ß -ol 
C24- analogue, C25 sterol 27 norcholest- 5 -en -30 -ol 
cholesterol cholest- 5- en -3R -ol 
ADP adenosine 5'- diphosphate 
cAMP adenosine 3,5'- monophosphate 
ATP adenosine 5'- triphosphate 
HHT 12 L- hydroxy- 5,8,10- heptadecatrienoic acid 
HETE 12 L- hydroxy- 5,8,10,14 -eicosatetraenoic acid 




HMG CoA 3- hydroxy- 3- methylglutaryl- coenzyme A 
LDL low density lipoprotein 
EDTA ethylenediamine tetra -acetate (disodium salt) 
Tris 2- amino- 2- hydroxymethyl propane- 1,3 -diol 
DPPC phosphatidylcholine 
Lecithin, PC phosphatidylcholine 
[114C]oleoyl PC 1-acyl-2- [1-14C]oleoyl phosphatidylcholine 
[1-14C]arachidonyl PC 1-acy1-2- [1-14C]arachidonyl 








sarcopla smic ret icu lue 
thin layer chromatography 
platelet rich plasma 
platelet poor plasma 
phosphatidylinositol 
dimethylsuiphoxide 
fatty.acid free albumin 
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1.1 Outline of Introduction 
There are various areas of research which are of interest to the 
studies carried out and presented in this thesis. The introductory 
chapter has been divided into sections in order to review the different 
fields of research with clarity and emphasis. 
The first section reviews briefly some of the research carried out 
on artificial membrane systems to investigate the effect of cholesterol. 
The second section discusses some examples of studies carried out on 
more complex biological (i.e. natural) membranes. In this section, 
studies performed to investigate the effects of cholesterol on red 
blood cells are discussed as these studies preceeded research into the 
effects of cholesterol on'platelets. This latter research is discussed 
later in the chapter (see Section 1.6) after the sections discussing 
platelet function (1.4) and platelet arachidonic acid metabolism (1.5). 
In Section 1.6, the research which has been carried out into the effect 
of alteration of platelet cholesterol content is discussed. In this 
section, research carried out on platelets from subjects with hyper - 
cholesterolaemia is also reviewed. The relevance of the research 
project presented in this thesis to clinical studies is suggested. 
The final section briefly outlines the strategy of this project. 
1.2 Distribution of Cholesterol and its effect on Artificial Membranes 
Cholesterol is an important component of mammalian cell membranes. 
It is not present in bacterial cells, but related sterols are present 
in plants and fungi of yeast. These sterols possess a double bond in 
the side chain at the 22nd carbon atom and/or a methyl or ethyl group 
at the 24th carbon atom (see Figure 1.1). Stigmasterol and sitosterol 
are found in plants, and ergosterol is found in fungi and yeast. 
The quantity of cholesterol found in mammalian cell membranes varies 
depending on the source. Some membranes contain high levels of 
2. 
plasma 
cholesterol, for example liver cellhrmbranes have been reported to 
contain a cholesterol to phospholipid molar ratio of 0.83 (Dorling 
and Le Page, 1973). The ratio in erythrocyte membranes was also high 
at 0.90 while the ratio in subcellular membranes, nuclei, mitochondria 
and microsomes from liver, ranged from 0.11 to 0.33 (Ashworth and 
Green, 1966). Cholesterol is therefore a major component of cell 
membranes, and research into its role in membranes has received much 
attention. 
Initial studies concentrated on examining the role of cholesterol 
in artificial membrane systems, since biological membranes are highly 
complex. In such artificial systems, the interaction of cholesterol 
with membrane components, particularly phospholipid, has been 
investigated. The model systems developed have included monolayers 
and liposomes consisting of phospholipid and various quantities of 
cholesterol. Several physical techniques have been used in these 
studies including electron paramagnetic resonance (epr), nuclear 
magnetic resonance (nmr), spectroscopy, X -ray diffraction, and 
differential scanning calorimetry (for review see Demel and De Kruyff, 
1976). 
The overall effect of incorporation of cholesterol is considered 
to be the production of a state of intermediate fluidity in membranes 
between a crystalline or liquid lipid matrix as reviewed by Oldfield 
and Chapman (1972). In order to determine more precisely the 
interaction of cholesterol with phospholipids, Hubbell and McConnell 
(1971) studied the molecular motion of spin labelled phospholipids in 
phospholipid bilayers containing cholesterol. This spin label was 
attached at different points along the hydrocarbon fatty acyl chain, 
and epr spectroscopy showed that a fluidity gradient existed in the 
bilayer. The central hydrophobic core was fluid in comparison to the 
3. 
polar region at the surface of the bilayer which was more rigid. The 
fluidity gradient may arise in a bilayer because the overall motion of 
the acyl chain is composed of rotations about the individual carbon - 
carbon bonds. These rotations are transitions between trans and cis 
conformations. If it is assumed that the fatty acyl chains of the 
phospholipid molecule are anchored at the polar interface of the 
bilayer, the chances of trans configuration of a carbon -carbon bond 
increases with the length of the hydrocarbon chain with a consequent 
increase in membrane fluidity. 
Bruckdorfer et al. (1968) showed that the sterol nucleus structure 
was critical for interaction of sterol with phospholipid. These 
workers showed that cholesterol was incorporated into phosphatidyl- 
choline dispersions much more readily than similar sterols studied, 
which suggested that cholesterol interacted most favourably with the 
ïri'o IiposoMes 
phospholipid. Demel et al. (1972) showed that incorporationrof 38- 
hydroxysterols such as cholesterol, lathosterol, 7- dehydrocholesterol 
and ß -norcholesterol caused the most pronounced reduction in permeability 
to glucose, glycerol and Rb +. These 
workers showed that the 3 -hydroxycholesterols, epicholesterol and 
androstan -3x -ol had no effect on permeability of these materials. 
In the same study, neither coprostan ©l (which has a non -planar sterol 
nucleus) nor androstan-3(9-ol (which has no side chain at the 17th 
carbon atom) had any effect on permeability. 
A structural analysis of egg lecithin -cholesterol bilayers was 
carried out by Franks (1976) using X -ray diffraction, and by Worcester 
and Franks (1976) using neutron diffraction. By interpretation of 
electron density profiles derived from bilayers, Franks (1976) 
concluded that the hydroxyl group at the 3rd carbon atom was positioned 
near the water interface. The phospholipid head group was suggested 
4. 
to lie in the bilayer plane, and the results implied that the hydroxyl 
group of the cholesterol molecule was positioned adjacent to the sn -2 
carbonyl oxygen. Schwartz and Paltauf (1977) showed that hydrogen 
bonding existed between the hydroxyl group of the cholesterol molecule 
and the sn -2 carbonyl oxygen of the fatty acid molecule. These 
workers compared the passive diffusion of Na +, Cl , and glucose 
across the membrane of single walled liposomes formed from cholesterol 
and diether phosphatidylcholine (which contained no ester carbonyl 
group), 1- ether -2 -ester phosphatidylcholine and diester phosphatidyl- 
choline. Replacement of the ester groups by the ether groups which 
cannot hydrogen bond removed the cholesterol mediated reduction in 
glucose and Na+ permeability. The hydrogen bonding can only take 
place when the sterol contains an equatorial hydroxyl group (4). 
An axial hydroxyl group (30ç) cannot hydrogen bond with the sn -2 carbonyl 
oxygen because the O -H -O bond angle is not consistent with hydrogen 
bond formation. 
However, more recently Clejan et al. (1979) investigated further 
the hydrogen bond between the 32- hydroxyl group of cholesterol and the 
carbonyl oxygen at the 2 position of PC. These workers suggested that 
similarities between the effects of sterols on the initial rates and 
reflection coefficients of polar nonelectrolyte diffusion in diester -PC 
bilayers and those from phospholipids lacking acyl groups indicated 
that carbonyl oxygens of the fatty acyl groups in the 1 and 2 positions 
of PC are not essential to obtain interaction with cholesterol. These 
results are therefore hot in agreement with the results of Schwartz 
and Paltauf (1977) discussed above (see review by Szoka and 
Papahadjopoulos, 1980). 
The results from the studies discussed above suggested that 
permeability of sterol -phospholipid liposomes depends on certain 
5. 
structural requirements of the sterol molecule. These are 1) a planar 
sterol nucleus 2) possibly a 30- hydroxyl group although there is some 
dispute about this and 3) an intact side chain at C17. 
The importance of the side chain (indicated above) in the cholesterol 
molecule has been investigated. Edwards and Green (1972) showed that 
the incorporation of sterols into liposomes depended on the structure 
of the side chain. Campesterol (with an additional methyl group 
branch in the side chain at the 24th carbon atom), and sitosterol 
(an additional ethyl group at C24) were compared with cholesterol for 
incorporation into phospholipid liposomes. It was shown that the 
ability of these sterols to enter liposomes decreased in the order 
cholesterol, campesterol and sitosterol. 
It was shown by Stevens and Green (1972) that the length and degree 
of branching of the ester of the testosterone molecule influenced its 
incorporation into phosphatidylcholìne liposomes. Maximum incorporation 
was obtained with testosterone octanoate which has an unbranched eight 
carbon side chain. The side chain of cholesterol has eight carbon atoms 
but because of branching in two places the total length is six carbons. 
Thus the value of the data from the study of Stevens and Green (1972) 
is questionable because the testosterone octanoate molecule would be 
considerably longer than cholesterol, and testosterone esters are not 
closely analogous to cholesterol in their molecular shape and polarity. 
Suckling and Boyd (1976) carried out a spin label study to 
investigate the interactions of the cholesterol side chain with egg 
phosphatidylcholine liposomes. Analogues of cholesterol were synthesized 
which retained the cholest- 5 -en -3ß -ol ring system but which had side 
chains of varying lengths (see Figure 1 .2 ). The effect of sterols on 
the order parameters of two spin labels in liposomes were examined 
with proportions of sterol-to phospholipid from 0 to 50 mol per cent. 
Figure 1.2. Structures of cholesterol analogues synthesised by Craig 




















The spin labels used were sterols either with the spin label rigidly fixed 
in the ring system, or with the label incorporated into the side chain. 
The results showed that the order parameters in liposomes containing 
cholesterol or the C26- sterol analogue were very similar and increased 
with increasing proportion of sterol. The C19 -, C21- and C24- sterol 
analogues showed reduced order parameters when the concentration of 
sterol was above 40 mol per cent when studied with the compound spin 
labelled in the sterol ring. When studied with the spin- labelled side 
chain compound, the C19- analogue showed less ordering above 20 mol 
per cent than the other analogues. The C24- and C21- analogues again 
showed less ordering above 40 mol per cent compared to cholesterol or 
the C26- analogue. This ordering was however much greater than that 
observed for the C19- analogue. 
The results from the study discussed above showed therefore that 
reduction in the side chain length by one carbon atom did not alter 
the ordering of the phospholipid bilayer. Reduction in length by 
three carbon atoms was shown to reduce ordering at concentrations of 
sterol above 40 mol per cent. The results suggested that the fluid 
core of the bilayer was markedly influenced by the sterol side chain 
length, and that the bilayer area around the sterol ring was influenced 
at higher concentrations of sterol. Craig et al. (1978) showed that 
the complete side chain of cholesterol was required for maximum ordering 
in liposomes. In this study, the effect on ordering of phospholipid 
bilayers was examined using analogues which contained longer side chains 
as well as shorter side chains than cholesterol. The sterols used were 
C25 -, C28 -, and 
C29- analogues as shown in Figure 1.2. It was shown 
that the ordering of phospholipid bilayers was reduced when these 
analogues were incorporated instead of cholesterol. Taken together 
the results obtained with these analogues suggested that the complete 
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side chain of cholesterol has a specific role to play in the interaction 
with phospholipid. The cholesterol molecule must be the optimum size to 
fit into the bilayer to give the maximum possible interaction with the 
phospholipid. 
In a further investigation, Suckling et al. (1979) showed that 
cholesterol incorporation caused the greatest rigidifying effect in a 
phospholipid bilayer compared to the sterol analogues and this was shown 
by several methods. For example, one method showed that the rate of 
osmotic shrinking of phosphatidylcholine liposomes was substantially 
reduced with cholesterol incorporation compared to that observed with 
any of the sterol analogues. Properties of phospholipid monolayers 
were also examined in this study. Cholesterol was observed to cause 
substantial condensation of the monolayer when surface pressure - 
area measurements of the spread films were made. This effect was 
observed with all the analogues, although the effect was reduced when 
C19- or C21- analogues were incorporated into the monolayer. These 
findings suggested that a side chain of moderate length was required 
and that the ring structure alone was not sufficient for structural 
stability. In monolayers, the C28 -, and C29- analogues behaved no 
differently from cholesterol. This suggested that the extra length 
of side chain was permitted to extend freely in space above the 
subphase. In bilayers however, the cholesterol molecule fitted precisely. 
1.3 Effect of Cholesterol in Biological Membranes 
Biological membranes have been shown to contain varying quantities 
of cholesterol depending on the source as discussed above. Since it 
had been revealed that cholesterol incorporation had a profound effect 
on the physical properties of phospholipid bilayers, research into the 
effect of cholesterol in biological membranes has been extensive in 
recent years. Klappauf and Schubert (1977) for example demonstrated 
8. 
that Band 3 protein from human erythrocyte membranes interacted strongly 
with cholesterol. In this study, the protein was extracted without the 
use of detergents. The Band 3 protein was injected underneath monolayers 
of different phospholipids (representing the main phospholipid classes 
of the erythrocyte membrane) and of cholesterol and a pronounced 
increase in monolayer surface pressure was observed. Thus the effect 
of cholesterol was studied on a purified natural component. The pressure 
and rate of change of pressure were much larger for monolayers of 
cholesterol than phospholipid, over the whole range of protein 
concentration used. This indicated a stronger interaction of Band 3 
protein with cholesterol than with phospholipid. 
The effect of cholesterol on membrane components has also been 
investigated in intact membranes. It was reported that an increase in 
the proportion of cholesterol to phospholipid in sarcoplasmic reticulum 
(SR) from rabbit hind leg muscle caused a decrease in the activity of 
the Cat +- ATPase (Madden et al., 1979). The activity returned to normal 
when excess cholesterol was removed from the SR preparation. Cholesterol 
was delivered and removed from SR by incubating with cholesterol -rich 
and cholesterol -poor liposomes. The workers suggested that cholesterol 
interacted with the protein in some way to modulate its activity. 
Warren et al. (1975) had however previously reported that cholesterol 
was excluded from the phospholipid annulus surrounding the Cat +- ATPase 
from the same source. This annulus consisted of 30 phospholipid 
molecules (Hesketh et al., 1976) which normally excluded cholesterol 
and buffered the protein against bulk membrane perturbations. 
The results of Madden et al. (1979) and Hesketh et al. (1976) therefore 
disagree on the interaction of cholesterol with this membrane protein. 
It is possible that the differences in the preparations were responsible 
for the different results. Madden et al. (1979) altered the cholesterol 
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content of native SR membranes with cholesterol rich phospholipid 
dispersions. Warren et al. (1975) and Hesketh et al. (1976) purified 
the enzyme and reconstituted the preparation with specific phospholipids 
with or without cholesterol. 
Recently Johannsson et al. (1981) have suggested that the inhibition 
of the Ca2 + -ATPase seen by Madden et al. (1979) by cholesterol enrichment 
is explained by the spontaneous uncoupling of thermally unstable SR. 
Johannsson et al. (1981) showed that when dithiothreitol was present 
in the incubation medium, no inhibition by cholesterol could be seen. 
However Madden et al. (1981) reinvestigated the problem, and prepared 
Ca2 + -ATPase by the method of Warren et al. (1975), and studied the 
activity in the presence and absence of dithiothreitol. They observed 
that in the presence of dithiothreitol, and on addition of A23187, 
a calcium ionophore, cholesterol enriched SR vesicles showed a smaller 
increase in Ca 
2+ 
-ATPase activity than did control SR vesicles. These 
workers could not say whether the effect of cholesterol was due to 
either a change in bulk fluidity or a direct effect on the hydrophobic 
region of the protein. They suggested that because A23187 completely 
collapsed the Ca2+ gradient, a cholesterol induced alteration of 
membrane fluidity would not have caused the observed effect. They 
suggested that collapsing the Ca2+ gradient in coupled preparations 
of SR with a Ca2+ ionophore allowed expression of the maximum catalytic 
activity and unmaskeathe inhibitory effect of cholesterol on the Ca 
2+ 
- 
ATPase. Thus cholesterol was demonstrated to influence this membrane 
protein in a manner which remains unclear. 
Recently, further investigations of the influence of cholesterol 
on erythrocyte membrane proteins have been carried out. Borochov et al. 
(1979) enriched and depleted erythrocyte membranes of cholesterol and 
the effects on membrane proteins were assessed using a membrane- 
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impermeant sulfhydryl reagent. Reaction of this probe with intact cells 
facing 
enabled quantification of outward A sulfhydryl groups and reaction with 
leaky ghost membranes permitted quantification of inwcìrdfacif9 sulfhydryl 
groups. They showed that cholesterol enrichment enhanced the surface 
labelling of Bands 1, 2, 3, and 5, decreased the labelling of Band 6 
and did not alter significantly that of Band 4. Thus changes in 
erythrocyte membrane cholesterol altered the availability of sulfhydryl 
groups at the membrane surface. Nigg and Cherry (1979) investigated 
the influence of cholesterol on the rotational diffusion of Band 3 in 
human erythrocyte membranes. These workers observed flash- induced 
dichroism of an eosin probe in membranes of various cholesterol content. 
They showed no significant changes in the rotational diffusion of the 
protein following variation of membrane cholesterol:phospholipid molar 
ratios over the range 0.34 -1.66. In view of the results obtained by 
Borochov et al. (1979) that the number of Band 3 sulfhydryl groups 
exposed increased 100 per cent when cells were cholesterol enriched 
compared to cholesterol depleted, the mechanism of cholesterol interaction 
with this protein remains unclear. The results presented by Nigg and 
Cherry (1979) suggested the lack of interaction of cholesterol with 
Band 3, whereas the work of Klappauf and Schubert (1977) suggested this 
protein interacted strongly with cholesterol. The difference in 
results may be due to the artificial system used by Klappauf and 
Schubert as opposed to the natural membrane environment studied by Nigg 
and Cherry. 
A recent study was carried out by Lange et al. (1980) to investigate 
the effect of cholesterol on the contour and stability of the isolated 
red cell membrane by cholesterol oxidase digestion. They showed that 
the cholesterol:phospholipid molar ratio in intact red cell membranes 
was equal to or just less than 0.8, and that these membranes were 
11. 
resistant to cholesterol oxidase digestion. Enrichment of the membranes 
to a molar ratio of 0.9 rendered the entire cholesterol pool available 
for oxidation. Cholesterol depletion of enriched membranes reversed 
this susceptibility. These workers suggested that red cell membrane 
cholesterol is maintained in vivo just below a critical level at which 
important organizational changes can occur. 
Experiments such as those described above have therefore shown that 
membrane properties can be influenced by the cholesterol content. 
Studies of a more applied nature have been carried out to investigate the 
reasons for abnormal membrane architecture occasionally found in the 
red cells of diseased subjects. Cooper (1969) studied the sera and 
red cells from three patients with severe liver disease and found 
abnormal red cells with spill projections in the blood of these patients. 
The term "spur cell" has been applied to these bizarre red cells to 
distinguish them from the morphologically similar but chemically 
different acanthocytes seen in patients with abetalipoproteinaemia 
(Ways et al., 1963). Cooper (1972) showed that the unesterified 
cholesterol content of spur cells averaged 52 per cent higher than in 
red cells from normal subjects. It was possible that the unusual 
membrane architecture was due in part to the raised cholesterol 
content. Cooper et al. (1972) showed that when normal red cells were 
incubated in spur cell serum, the cholesterol content increased and 
the cells took on a spur cell like appearance. Conversely, spur cells 
incubated in normal serum lost cholesterol and took on a normal red 
' cell appearance. In a further investigation, Cooper et al. (1972) 
analysed the lipoproteins and red cells from patients with alcoholic 
cirrhosis of the liver. They showed that there was no correlation 
between serum cholesterol concentration and red cell content of.free 
cholesterol. However, they observed a close relationship between red 
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cell and serum (or isolated LDL) free cholesterol when considered in 
relation to the content of phospholipid in each. In view of this close 
relationship, Cooper et al. (1975) undertook to establish an artificial 
system that reproduced the cholesterol disproportion in the serum of 
patients with spur cells in order to study this factor in the absence 
of other possible influencing factors. These workers prepared cholesterol - 
phosphatidylcholine dispersions to incubate with red cells in order to 
alter their cholesterol content in vitro. They showed that when normal 
red cells were incubated with cholesterol -rich dispersions they developed 
spur cell like morphology concomitant with becoming enriched with 
cholesterol. The same study showed that spur cells incubated in a 
cholesterol depleted medium gave rise to morphologically normal red 
cells which had a normal cholesterol content. Recently Cooper et al. 
(1978) showed that the membrane fluidity of red cells was decreased as 
a result of cholesterol enrichment by this in vitro technique. 
1.4 Platelet Function 
Platelets are cytoplasmic fragments of megakaryocytes of the bone 
marrow (Tavassoli, 1980). They have a longitudinal diameter of about 
2 p and are therefore considerably smaller than red blood cells which 
have a diameter of approximately 8 
F. 
Like red cells in humans they 
are anucleate. Platelet counts in humans normally range from 200- 
500 x 109 /litre of blood. Platelets have a half life of about 5 days, 
are normally disc shaped, and are carried by the blood through the 
intact blood vessels. When a blood vessel is cut to expose a damaged 
endothelial lining, the platelets quickly adhere to components which 
are normally hidden. In this process, platelets undergo a change 
from their disc shape to produce many long pseudopodia -like extensions 
from the plasma membrane. The pseudopodia from many platelets interconnect 
to combine many platelets to form a haemostatic plug at the site of 
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injury to arrest bleeding. Platelets act in the body as the first line 
of haemostatic defence. Clotting factors in the plasma also contribute 
to the formation of the clot to prevent blood loss and to the 
stabilization of the initial platelet plug. It is believed that 
several stimuli may activate platelets to aggregate in vivo. Collagen 
revealed by damaged intima may stimulate platelets (Haft, 1979) but 
it has also been suggested that ADP from damaged red cells may activate 
platelets in the locality of the wound (Garder et al., 1961). Thrombin 
is a very potent platelet aggregating agent, and this is an important 
clotting factor. Thrombin, formed from prothrombin (which circulates 
in the blood) by the action of prothrombin activator, induces the 
proteolysis and polymerization of fibrinogen to fibrin threads. Fibrin 
plays an important role in the stabilization of a newly formed clot 
(see for example Jackson and Nemerson, 1980). 
The process of platelet aggregation has been extensively studied 
in vitro. Researchers have become interested in this phenomenon because 
platelet aggregation leads to the formation of thrombi. Thrombi 
consist largely of platelets, and platelets are therefore implicated 
in the development of thrombosis and atherosclerosis. The method 
commonly used to study platelet aggregation in vitro is the turbidimetric 
assay. This was developed by Born (1962) and he used this method to 
study the aggregation and disaggregation of platelets when stimulated 
with ADP. The optical density of platelet rich plasma (PRP) was 
recorded at 600 nm when stimulated with ADP. Born showed that the 
optical density of a sample of PRP decreased rapidly after addition 
of ADP. Figure 1.3 shows a typical aggregation trace of rat PRP 
recorded by this method. With a sufficiently low concentration of ADP, 
the optical density can be observed to increase again, the whole process 
taking 2 to 3 minutes. 
Figure 1.3 Aggregation of rat platelets 
A Aggregation induced by ADP (0.12 41) 
B Aggregation induced by collagen (2 ilg /ml) 







The decrease in optical density occurs as a result of the formation 
of platelet aggregates such that the number of individual platelets in 
suspension decreases. The increase in optical density concomitant with 
disaggregation is a result of dispersion of aggregates such that the 
number of individual platelets in suspension increases. Disaggregation 
may be complete so that the optical density returns to the same level 
as the unstimulated PRP. 
Born and Cross (1963) further investigated the aggregation of 
platelets by this method. They showed that it could be used quantitatively 
and that the method was highly reproducible. To study platelet 
aggregation by this method, there are several important criteria. 
The PRP sample must. be placed in a cuvette which is made of a substance 
which itself does not activate platelets. Platelets adhere to glass 
surfaces, possibly due to the presence of surface changes, therefore 
glass must be siliconised. The PRP sample must be stirred. Born and 
Cross (1963) showed that stirring at 1000 rpm gave the maximum decrease 
in optical density to a given dose of ADP. In this study, Born and 
Cross obtained PRP by centrifugation of blood samples taken into anti- 
coagulant to prevent clotting. Concentrations of suitable anticoagulants 
are used to prevent clotting but which do not inhibit platelet 
aggregation as studied by this in vitro method. 
It can be seen from Figure 1.3 that the different inducers of 
aggregation, ADP and collagen, give rise to slightly different patterns 
of aggregation. Aggregation of platelets in response to ADP is almost 
instantaneous, whereas aggregation in response to collagen occurs after 
a time lag of 1 to 2 minutes. Aggregation to both agents is preceeded 
by an apparent increase in optical density. This is more obvious with 
the collagen induced aggregation. This is a transient swelling of 
platelets from the normal disc shape. The small oscillations of the 
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PRP sample observed prior to stimulation is caused by oscillation of the 
disc shaped platelets being stirred in the light path. This oscillation 
is reduced because the platelets swell and become spherical. Following 
the swelling phase a rapid decrease in optical density occurs which is 
due to the formation of pseudopedia and the aggregation of platelets 
as mentioned above. Platelets contain various components which are 
secreted when activated by a suitable stimulus. In particular, platelets 
contain dense granules andoc- granules. The sequence of events occurring 
after stimulation is described as the basic platelet reaction (Holmsen 
et al., 1977). This sequence is shape change, aggregation, dense granule 
secretion ands- granule secretion. The stage at which this sequence 
terminates depends on the strength of the stimulus. 
In human platelets, aggregation in vitro occurs in two waves. 
Primary, or first wave aggregation is reversible. With a strong stimulus 
disaggregation does not occur, and second wave irreversible aggregation 
proceeds, with the secretion of granules. Rat platelets do not have a 
biphasic aggregation pattern. They undergo a single wave of aggregation 
which is reversible with a low dose of inducer, and irreversible with a 
high dose. Most aggregating agents can induce dense granule secretion, 
but only strong agents induce secretion ofoc -granules. Collagen is 
believed to be a strong aggregating agent, whereas ADP is a weak agent 
and does not induceoc- granule secretion (Holmsen et al., 1977), but it 
can induce the second wave of aggregation in human platelets. In human 
platelets, dense granules contain ADP and serotonin which may contribute 
to inducing aggregation of neighbouring platelets. pt. -granules contain 
fibrinogen and various acid hydrolases. Fibrinogen from platelets may 
be important in collagen induced aggregation (Solum and Stormorh en, 1965). 
In view of the formation of pseudopodia by aggregating platelets, the 
possibility of the involvement of a contractile system was investigated 
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(for example Luscher and Bettex -Galland, 1972). The system is believed 
to be similar to that of muscle cells, except that there appear to be 
two pools of contractile proteins in platelets, one in the membrane and 
the other in the cytoplasm. 
Platelets are stimulated to aggregate by a great variety of agents. 
These may be subdivided into three classes (Luscher and Massini, 1975), 
namely proteolytic enzymes, "large molecules" or complexes of molecules, 
and low molecular weight substances. Thrombin is a proteolytic enzyme 
which is a strong platelet stimulator. Collagen has been regarded as 
an example of a "large molecule ". It is necessary that the polymerised 
form of collagen is present to stimulate platelets. The carbohydrate 
moiety of the collagen molecule is not considered important in platelet 
activation (Muggii and Baumgartner, 1973). However the ordered, fibrillar, 
quaternary structure of collagen is required for the stimulation of 
platelets to aggregate (Gordon, 1979). Low molecular weight molecules 
include adrenaline, 5- hydroxytryptamine and ADP. These substances are 
released by activated platelets. Indeed, collagen induced stimulation 
of rabbit platelets was reported to act by causing the release of ADP 
from the platelets themselves (Hovig, 1963). It has been shown by 
Haslam (1964) that ADP was of importance in the aggregation of platelets 
by utilizing pyruvate kinase and phosphoenol pyruvate to remove low 
concentrations of ADP. Haslam showed that for thrombin, trypsin and ADP 
induced aggregation, the aggregation decreased with increasing 
concentrations of pyruvate kinase and phosphoenolpyruvate. This 
suggested that ADP played a very significant role in platelet aggregation. 
It was suggested by Luscher and Massini (1975) that there may be a 
common pathway of membrane reactivity leading to platelet activation, 
and for many of the events of the basic platelet reaction, the availability 
of calcium ions within the cell is essential. It has been well 
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established that an increase in the platelet cAMP level will prevent the 
onset of platelet activation. It is possible that cAMP is an important 
secondary messenger which maintains platelet integrity. It has been 
suggested that cAMP plays this role by preventing the mobilization of 
calcium from, or by inducing the sequestration of calcium by internal 
organelles (Gerrard et al., 1978). Haslam et al. (1978) suggested that 
CAMP has a "unidirectional" control of platelet function. 
Much research has been carried out to investigate the factors 
involved in the irreversible aggregation of platelets. There is much 
evidence that ADP is necessary for this process to occur, but the 
synthesis of various prostaglandins has also been shown to take place 
concomitantly with irreversible aggregation. Thrombin induced aggregation 
has been shown to occur without prostaglandin synthesis however (Smith 
et al., 1975), but Marcus (1978) reviewed much work which demonstrated 
that products of arachidonic acid metabolism are important mediators of 
platelet function. 
1.5 Arachidonic Acid Metabolism in Platelets 
The metabolic pathway of arachidonic acid in platelets is summarized 
in Figure 1.4. It has been shown that human platelets synthesize 
prostaglandins E2 and F2 during aggregation induced by various agents 
(Smith and Willis, 1970 and Smith et al., 1973). Hamberg et al. 
(1975) identified a new biologically active compound which was synthesized 
by platelets from prostaglandin endoperoxides which had in turn been 
synthesized from arachidonic acid. This compound was called thromboxane 
A2 and was formed by platelets which were incubated with arachidonic 
acid to induce irreversi,ble aggregation and serotonin release. This 
work complemented previous work by Hamberg et al. (1974) who showed 
that human platelets produced equimolar amounts of HETEHHT and 
thromboxane B2 (see Figure 1.4). The lipoxygenase enzyme, which 
Figure 1.4. Metabolism of arachidonic acid in platelets 
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synthesises HETE from arachidonic acid, was identified by Nugteren 
(1975). Approximately 100x more of these compounds were synthesized 
than of either PGF2 or PGE2. Gorman et al. (1977a) showed that 
platelets incubated with a specific thromboxane A2 synthetase inhibitor 
(9,11 -azoprosta- 5,13 -dienoic acid) selectively inhibited the second wave 
of both ADP or adrenaline induced aggregation. This coincided with a 
shift of metabolism of PGH2 away from thromboxane A2 to PGE2. It was 
possible that thromboxane A2 mediated events which occurred in 
platelets undergoing irreversible aggregation. Best et al. (1980) 
demonstrated that although the processes of thromboxane production, 
release of dense granule constituents and aggregation may often by 
intimately linked, each process can occur independently of the other 
depending upon the stimulus used. Very recent evidence suggests that 
thromboxane A2 synthesis is not required for aggregation induced by 
various agonists, but that synthesis of the endoperoxide PGH2 is more 
important (Westwick et al., 1981). 
The endoperoxides PGH2 and PGG2 were found to be potent inducers 
of platelet aggregation by Nugteren and Hazelhof (1973) and Malmsten 
et al. (1974). A detailed discussion of this work was published by 
Marcus (1978). Hamberg and Samuelsson (1974) showed that malondialdehyde 
(MDA) was also a product of arachidonic acid metabolism in platelets, 
and it was shown by Ingerman et al. (1975) that about one hundred times 
more MDA was produced than PGE2 by platelets in PRP. 
Free arachidonic acid is required for platelets to synthesize 
thromboxane A2. Arachidonic acid is located in platelets esterified 
to the sn -2 hydroxyl group of the glycerol moiety of platelet membrane 
phospholipids. No free arachidonic acid is available in normal 
platelets (Marcus et al., 1969). There are believed to be two 
important enzymes responsible for the release of arachidonic acid 
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from platelet phospholipids (Billah et al., 1980). Firstly a phospho- 
lipase A2 exists in platelets to hydrolyse the sn -2 ester bond to 
provide free arachidonic acid and the corresponding lysophospholipid. 
Secondly, a phospholipase C enzyme exists which is specific for 
phosphatidylinositol, removing the polar head group to form the diacyl- 
glycerol (Bell et al., 1979). This diacylglycerol is then either 
phosphorylated to phosphatidic acid by a diacylglycerol kinase (Billah 
et al., 1979) or hydrolysed by diacylglycerol lipase (Bell et al., 
1979) to provide free arachidonic acid. Arachidonic acid is made 
available by either pathway for oxygenation by a cyclooxygenase to 
ultimately form thromboxane, or by a lipoxygenase to HETE (Nugteren, 
1975) (Figure 1.4). 
A mode of action for the proaggregating effect of thromboxane A2 
has been proposed. It is believed to act as a calcium ionophore, 
directly transporting; calcium from the platelet dense tubular system 
to the cytoplasm /activate the contractile proteins (Gerrard et al., 
1976). Calcium is critical for the activation of phospholipase A2, 
and Gerrard et al. (1978) suggested that calcium may play an important 
role in thromboxane A2 synthesis. In their model, Gerrard et al. 
suggested that the enzymes involved in arachidonic acid metabolism are 
located in close proximity to one another in the dense tubular system. 
The role of cAMP was considered to be one of promoting Ca2+ uptake into 
the dense tubular system away from these enzymes thereby inhibiting 
platelet activation and prostaglandin synthesis (Gerrard et al., 1977). 
While much research was being carried out to investigate arachidonic 
acid metabolism by blood platelets, Moncada et al. (1976) discovered a 
product of arachidonic acid metabolism in vascular tissue. This was 
initially named PGX, and was observed to induce vasodilatation of 
vascular tissue and to inhibit ADP induced aggregation of human platelets 
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(Gryglewski et al., 1976). Structure determination and total organic 
synthesis of PGX was achieved by Johnson et al. (1976) and these workers 
named the compound prostacyclin, PGI2. At about the same time Needleman 
et al. (1977) observed that arachidonic acid induced a relaxation 
response when added to bovine or human coronary artery strips. This 
group were unknowingly observing the effects of PGI2. PGI2 was 
observed to inhibit platelet aggregation and to stimulate platelet 
adenylate cyclase to synthesize cAMP(Gorman et al., 1977b; Tateson 
et al., 1977). 
Since the discoveries of thromboxane A2 and PGI2, it has been 
postulated that an intricate regulation of platelet aggregation exists 
(Gorman, 1979). A "reciprocal regulation" of cAMP levels was suggested 
between the endoperoxide-thromboxane A2 system presumed to inhibit 
adenylate cyclase and the PGI2 mediated stimulation of adenylate cyclase. 
The actions of thromboxane A2 and PGI2 are not restricted to platelets, 
but affect the cardiovascular system also. PGI2 inhibits platelet 
aggregation, relaxes smooth muscle of the coronary arteries, and 
reduces blood pressure. Thromboxane A2 opposes all the effects of 
pGI2, inducing platelet aggregation, constricting arteries and thereby 
raising blood pressure (Bailey, 1979). Both these compounds are very 
labile, and in view of the antithrombotic action of PGI2, researchers 
have been attempting to synthesize a stable analogue which would have 
clinical use. It has been shown that platelets from particular patients 
synthesized significantly more prostaglandin endoperoxides than 
platelets from normal subjects. The groups of patients studied were 
subjects with post- operative deep vein thrombosis and subjects with 
arterial thrombosis (Lagarde and Dechavanne, 1977). Since platelets 
have long been implicated in the pathogenesis of atherosclerosis and 
thrombosis (Constantinides, 1976), researchers have looked for therapeutic 
agents to inhibit platelet activity in some way (Weiss, 1976). 
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To assay platelet thromboxane A2 production in order to assess 
platelet function, two common methods have frequently been used. 
Thromboxane A2 is very unstable, and rapidly transforms to the more 
stable metabolite thromboxane B2 which is quantitated by radioimmuno- 
assay. Platelets produce equimolar amounts of thromboxane B2 HHT 
and MDA, and some researchers have assayed MDA production as an 
indicator of thromboxane A2 synthesis. The method was originally 
described by Placer et al. (1966) and was adapted for platelet MDA 
assays by Stuart et al. (1975). The method involves the detection 
of the chromagen produced by the complex formed between MDA and 
thiobarbituric acid by light absorbance at a wavelength of 532 nm. 
A fluorometric assay of this complex has more recently been developed 
for the detection of smaller quantities of MDA (McMillan et al . , 1977). 
MDA has been shown to be produced by platelets during the second 
phase of aggregation by human platelets (Macfarlane et al., 1977). 
Thromboxane synthetase,the enzyme responsible for conversion of PGH2 
to thromboxane A2 has been shown to catalyze the formation of MDA 
(McMillan et al., 1978). Recently these methods have been used to 
evaluate platelet thromboxane A2 production in platelets from diseased 
subjects. 
1.6 Hypercholesterolaemia 
As mentioned previously, Cooper et al. (1972) showed that the 
cholesterol to phospholipid molar ratio of the red blood cell membrane 
was apparently influenced by the cholesterol:phospholipid ratio of 
the plasma constituents and subsequently showed that the cholesterol: 
phospholipid molar ratio of LDL correlated well with the ratio found 
in red cell membranes(Cooper, 1977). Carvalho et al. (1974a) examined 
platelets from patients who were known to be susceptible to athero- 
sclerosis, having been diagnosed with type lla hyperbetalipoproteinaemia 
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(type lla). The common features in this disease are a high plasma 
cholesterol level (often over 400 mg per 100 ml blood) , and a high 
plasma LDL level. Hypercholesterolaemia has frequently been suggested 
as a factor involved in the pathogenesis of atherosclerosis and 
thrombosis (see for example Marx, 1976). In the disease cholesterol 
carried by LDL cannot enter extrahepatic cells and thereby inhibit the 
function of HMGCoA reductase (Brown and Goldstein, 1976, 1980). 
Because of the lack of inhibition, this enzyme is very actively 
synthesizing cholesterol which enters the blood. Type lla hyperbeta- 
lipoproteinaemia is a genetic disorder displaying the features of 
autosomal dominance and sufferers are prone to early age severe 
atherosclerosis (Lees et al., 1973). 
Carvalho et al. (19740 observed that platelets from type lla 
iy ar- 
subjects were to the aggregating agents ADP, adrenaline and 
collagen. These platelets aggregated with significantly lower 
concentrations of these agents compared to platelets obtained from 
normal subjects. Platelets from type lla subjects have therefore been 
investigated by several research groups. Bizois et al. (1977) showed 
that platelets from type lla subjects produced significantly more 
thromboxane B2 from radiolabelled arachidonic acid compared to normal 
platelets. Tremoli et al. (1979a,b) showed that platelets from type lla 
subjects showed enhanced MDA production and enhanced thromboxane B2 
production induced by arachidonic acid compared to platelets from 
normal subjects. This is an interesting observation because it was 
hypothesized by Fogelman et al. (1980) that LDL may be modified in vivo 
by MDA released from blood platelets or produced by lipid peroxidation 
at the site of arterial injury. These workers showed that this modified 
LDL was taken up by human monocyte- macrophages more readily than native 
LDL, resulting in enhanced cholesteryl ester accumulation in these cells. 
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Bennett et al. (1974) reported that platelets from type lla subjects 
had a raised cholesterol to phospholipid ratio. This was confirmed by 
Shattil et al. (1977) and these platelets were demonstrated to be 
hypersensitive to aggregating agents. The ratio was 7 per cent higher 
than in platelets from normal subjects. It was shown by Colman et al. 
(1976) that halofenate treatment for type lla subjects could reduce the 
enhanced sensitivity of platelets to aggregating agents. This was found 
to be a more effective therapy than administration of clofibrate to type 
lla subjects. Clofibrate did however reverse the hypersensitivity of 
platelets from type lla subjects (Carvalho et al. (1974b)) but to a 
lesser extent. 
Shattil et al. (1975) used the in vitro method to alter platelet 
cholesterol content which Cooper et al. (1975) used for alteration of 
the cholesterol content of red blood cells. Liposome suspensions made 
cholesterol poor, normal or rich were incubated with platelets to deplete, 
maintain or enrich them with cholesterol. Enrichment of platelets with 
cholesterol enhanced their sensitivity to ADP and adrenaline induced 
aggregation, whereas cholesterol depletion had the reverse effect. 
This study by Shattil et al. (1975) discounted the possibility of any 
plasma factor mediating the platelet hypersensitivity because the 
platelets were isolated from healthy donors. The results showed that 
a high serum cholesterol level may induce hypersensitivity by enriching 
platelets with cholesterol. In another study, it was shown that the 
cholesterol content affected the microviscosity of the platelet membrane 
(Shattil et al., 1976). Using diphenyl hexatriene it was shown that an 
increased cholesterol content increased the rigidity of the platelet 
membrane. A decreased cholesterol content caused the membrane to become 
more fluid. 
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An explanation for the enhanced sensitivity of platelets with raised 
cholesterol to phospholipid molar ratios remained obscure. Sinha et al. 
(1976) reported that altered platelet cholesterol content by this in vitro 
method caused changes in cAMP metabolism. They showed that basal 
adenylate cyclase activity was enhanced in cholesterol enriched platelets. 
Stimulation of adenylate cyclase activity by PGE, and NaF was lost in 
cholesterol enriched platelets compared to control platelets. It was 
suggested that cholesterol enrichment induced a loss of response due 
to a physical effect of cholesterol on platelet membrane phospholipids 
and hence on adenyl cyclase. In a subsequent study by Insel et al. 
(1978) it was shown that alteration of platelet cholesterol content did 
not result in changes in the level of adrenaline bound to its receptor, 
and that changes in adenylate cyclase activity seen previously by 
Sinha et al. (1976) did not occur. 
More recently it was shown by Stuart et al. (1980a) that human 
platelets with altered cholesterol content demonstrated correspondingly 
altered thromboxane B2 production. Platelets enriched with cholesterol 
by the method of Shattil et al. (1975) were shown by Stuart et al. to 
synthesize more thromboxane B2 when stimulated with thrombin compared 
to cholesterol depleted platelets. A recent study by Worner and 
Patscheke (1980) demonstrated that platelets enriched with cholesterol 
in the same way showed enhanced arachidonic acid metabolism. It has 
therefore become clear that cholesterol in the platelet membrane may 
influence the activities of systems which catalyze the release and 
subsequent metabolism of arachidonic acid. Release of arachidonic acid 
from platelet membrane phospholipids, as described above, could be a 
very important rate limiting step in the provision of substrate for 
thromboxane A2 synthesis. This initial step, probably regulated by 
phospholipase A2 and phospholipase C (Billah et al., 1980) has not been 
investigated satisfactorily in cholesterol -enriched platelets. 
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Much research has been carried out on atherosclerosis induced in 
animals. In these animal model systems platelet function has been 
investigated in order to attempt to explain the pathogenesis of the 
disease in humans. This is discussed more fully in Chapter 6. 
The hypersensitivity of platelets induced by cholesterol enrichment 
required further research to evaluate what other platelet functions were 
affected. The purpose of the present project was to continue research 
in this area. 
1.7 Experimental Approach of Project Described in this Thesis 
Cholesterol is an important component of the platelet membrane. The 
membrane performs a highly specialized function which allows the 
aggregation of platelets in the process of haemostasis. In the present 
studies the role of cholesterol in platelet membranes has been examined. 
In order to carry out these investigations, it was necessary to develop 
methods to alter the membrane cholesterol level. There were two 
possible approaches: 
1. To incubate platelets in a medium which would selectively alter 
the cholesterol content of rat and human platelets in vitro.A suitable method was 
considered to be that developed by Shattil et al. (1975) as mentioned 
above. This method had the advantage of altering cholesterol content 
only, without affecting other factors. 
2. To attempt to increase the platelet cholesterol content in vivo 
by feeding a group of rabbits a diet rich in cholesterol. This would be 
expected to raise the plasma cholesterol level thus presenting the 
circulating platelets with a cholesterol enriched medium. A group of 
lop -eared rabbits were used in these experiments (see Chapter 6). 
Assessment of platelet function was carried out with particular 
reference to membrane associated events. Aggregation was studied using 
an aggregometer by the method of Born and Cross (1963). The effect of 
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alteration of cholesterol content on phospholipase A2 activity in 
platelets has not previously been investigated satisfactorily. This 
enzyme is, at least in part, responsible for the release of arachidonic 
acid, and it was particularly pertinent to investigate the effect of 
cholesterol on the activity of this membrane bound protein. A phospho- 
lipase A2 assay was developed in order to determine whether platelet 
hypersensitivity to aggregating agents is mediated by alteration of the 
activity of this enzyme. 
To investigate further the requirement of a sterol of specific 
molecular dimensions for membrane integrity, cholesterol analogues of 
shorter length side chains were incorporated into platelet membranes 
in vitro. The platelet membrane architecture rapidly changes on 
stimulation. Cholesterol is suspected to fit precisely into membranes, 
and it was considered that a membrane performing such a specialized 
function may depend upon components which contribute to the maintenance 
of its integrity. This study was intended to investigate this possibility 
and was a continuation of the work of Craig (1978) who investigated the 
effect of cholesterol analogues in artificial membranes, and cholesterol 
metabolising systems. 
Chapter 2 
Materials and Methods 
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2.1 Animals and Diets 
Male and female rats of the Wistar strain, weighing approximately 
150 g, were obtained from the Bush Small Animal Breeding Centre of 
Edinburgh University. They were fed a normal stock diet and water 
ad libitum. Experiments involving the use of rabbits were carried out 
at ICI Pharmaceuticals Division, Alderley Park, Cheshire. White male 
Lop- earned rabbits (3 kg) were fed a stock diet or the same diet 
supplemented with cholesterol (0.5 per cent w /w) to induce 
hypercholesterolaemia. 
The normal stock diet fed to rats consisted of 70 per cent wholemeal 
flour, 25 per cent skimmed milk powder and 5 per cent dried yeast. 
The stock diet fed to rabbits consisted of Labsure animal diet CRB 
pellets which was supplied by Christopher Hill Group Ltd., Poole, 
England. A complete breakdown of constituents of this diet is provided 
in Table 2.1. 
Human subjects 
Human subjects providing blood samples for experimental purposes 
were requested not to take any medications for at least ten days prior 
to donation. 
2.2 Blood Sampling 
1. Rats: Rats were anaesthetized with ether, the thorax was cut 
open from the ventral side. Fatty tissue around the heart was removed, 
and blood was removed from the right ventricle using a syringe. 
A 20 ml syringe was used with a 21 g needle which had been rinsed with 
anticoagulant. The anticoagulant used was trisodium citrate.(3.8 
per cent w /v) to a final volume ratio of 1:9 volumes of blood. 
Approximately 10 ml of blood was obtained from a rat. The blood sample 
was put in a 10 ml plastic screw top blood sample tube and inverted 
. gently twice. 
Table 2.1. Labsure animal diet CRB pellets, supplied by Christopher Hill 
Group Ltd., Poole, Dorset, England 
1. Analysis Per cent by weight Raw materials 
Crude oil 1.92 Wheat 
Crude protein 16.1 Maize 
Crude fibre 14.0 Oat Feed 
Calcium 1.1 Soya 
Phosphorous 0.7 Fish meal 
Available Phosphate 0.52 
NaC1 0.75 
Metabolisable Energy 1900 kcal /kg 







3. Vitamins Added 
A 8000 i.u. 
D3 1000 i.u. 
B2 8 mg 
Nicotinic acid 50 mg 
Pantothenic acid 12 mg 
B12 12 Pg 
E 100 i.u. 
K 10 mg 
Folic acid 10 mg 
Choline 200 mg 
B1 4 mg 
B6 6 mg 
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2. Rabbits: Blood samples were taken from rabbits by Mrs. S. Jones 
at ICI Pharmaceuticals Division. Rabbits were restrained, and a 19 G 
needle attached to a length of plastic tubing was inserted into the ear 
artery. Blood was allowed to flow freely into a 50 ml plastic centrifuge 
tube containing 3.8 per cent (w /v) trisodium citrate to a volume ratio 
of anticoagulant of 1:9 volumes of blood. 
3. Human subjects: Units of blood were obtained from the Edinburgh 
Blood Transfusion Service. Blood was collected into citrate- phosphate- 
dextrose anticoagulant under standard BTS conditions. Blood samples 
collected from subjects by Dr. M. Stone at the Leigh Health Centre were 
taken into 3.8 per cent (w /v) trisodium citrate (1:9 volumes blood). 
The blood was collected from the antecubital vein. 
2.3 Platelet Preparation 
Blood samples were centrifuged at 100 g for one or two periods of 
10 min in an MSE bench centrifuge to sediment the red blood cells. 
The top layer of PRP was collected. PRP from rats was pooled prior to 
experimentation. In experiments using human blood, PRP from different 
subjects was never mixed. 
2.4 Platelet Counting 
Platelet counts were carried out on PRP samples, samples of PRP - 
liposome mixtures or resuspended platelet samples. In Edinburgh, 
platelet samples were kindly counted by the Blood Coagulation Unit, 
Royal Infirmary of Edinburgh using a thrombocytometer (Coulter Electronics). 
At ICI Pharmaceuticals Division, platelet samples were counted using a 
Coulter Counter type B model (Coulter Electronics) fitted with a 50 F 
orifice (Sipe and Cronkite, 1962). 6.6 j1 of the platelet sample was 
diluted in 17 ml isoton (Coulter Electronics) for the purpose of counting. 
Three determinations were made for each sample, and the mean was 
calculated.. 
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2.5 Preparation of Egg Yolk Lecithin 
/ Phosphatidylcholine was prepared from egg yolks by the method of 
Pangborn (1951), which involved an initial acetone extraction to remove 
all the neutral lipids leaving a cake of protein and phospholipids. 
A 95 per cent ethanol extraction of the cake separated the protein from 
phospholipids, which were subdivided by a combination of solvent 
extraction methods and the formation of cadmium adducts of the 
phosphatides. Sphingomyelin was retained with the phosphatidylcholine 
during this preparation but was eventually removed by precipitation 
from a cold ether solution of PC. A sample was subjected to thin layer 
chromatography developed in chloroform:methanol:water (65:35:5 v /v). 
Staining in iodine vapour gave a single spot which was identical to.a 
similarly treated sample of authentic PC thereby confirming the absence of Other 
2.6 Liposome Preparation phospholipids. 
Liposome suspensions were prepared by a method similar to that 
described by Cooper et al. (1975), and by Shattil et al. (1975). 
L- ocdipalmitoyl phosphatidylcholine (DPPC) 40 mg and unesterified 
cholesterol or cholesterol analogues in amounts up to SO mg were mixed 
and dissolved in chloroform (3 ml) in a round bottom flask. The organic 
solvent was removed by warming the flask while turning it on a rotary 
evaporator. The residue remained as a thin lipid film coated on the 
bottom of the flask. All the remaining organic solvent was removed 
by placing the flask in a vacuum dessicator for 30 min. 
10 ml of modified Tyrode's buffer was added to the lipid film. 
This buffer contained 0.137M NaC1, 2.7 mM KC1, 1.19 mM NaHCO3, 0.42 mM 
NaH2PO4.2H20 and HC1 to adjust the pH to 7.4. The flask containing 
the lipid film was held under a stream of hot water, and the Tyrode's 
buffer, preheated to 50°C was then added. The flask was vigorously 
shaken under the stream of hot water. After 3 min, all the lipid was 
removed from the surface of the glass, and a cloudy suspension of 
lipid was formed. The mixture was sealed under nitrogen and sonicated 
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by suspending the flask in a sonicating water bath (Dawe Instruments Ltd.) 
of constant power output at 55 °C for 3 -4 hours, 
At the end of this sonication period the liposome preparations were 
transferred to plastic centrifuge tubes (50 ml) and centrifuged for 
30 min at 22,000 g in a Beckman J2 -21 centrifuge at 20 °C to remove 
undispersed lipid which formed a pellet. The supernatant was decanted 
and centrifuged again under the same conditions to ensure that all the 
undispersed lipid had been removed. The liposome suspensions were 
transferred to 10 ml screw top sample tubes. Glucose and albumin were 
added to final concentrations of glucose (5 mM) and albumin (3.5 mg /ml). 
Liposome suspensions were optically clear, and were used within 15 hours 
of preparation. 
The following liposome suspensions were prepared for use in 
experiments described here. In all cases, 40 mg of DPPC was used. 
1. Cholesterol -poor liposomes were prepared with no cholesterol 
added. This medium was used to deplete blood platelets of cholesterol. 
2. Cholesterol -normal liposomes were prepared with 12.5 mg of 
cholesterol. This medium was used to maintain a normal level of 
cholesterol in platelets. 
3. Cholesterol -rich liposomes were prepared with 50 mg of 
cholesterol. This medium was used to enrich platelets with cholesterol. 
Liposomes were also prepared containing cholesterol analogues. 
Suspensions of these liposomes were used to deliver the analogues to 
the platelets. 
Q pregnene -3 -o1 (C21) -rich liposomes were prepared using 50 mg 
of this sterol with the DPPC. Z15 cholen -3ß -ol (C24) -rich liposomes 
were prepared using 40 mg of this sterol. Also 40 mg of 27 nor Q 
5 
cholestene -310 -ol (C26) was used with DPPC to make C26- analogue rich 
liposomes. 
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2.7 PRP -liposome Incubation Procedure 
PRP was mixed with an equal volume of liposome suspension (normally 
5 ml + 5 ml) in a 10 ml screw top sample tube. 
Samples were incubated in a water bath at 37°C generally for a period 
of 3 hours or longer where stated. Samples were removed at half hour 
intervals and gently inverted to ensure mixing of platelets and 
liposomes. This method is essentially the same as was used by Shattil 
et al. (1975) . 
2.8 Analysis of Platelet Protein and Lipids 
Platelets were separated from plasma constituents and liposomes by 
centrifuging 2 -4 ml of the sample of PRP at 4800 g for 15 min in a 
Beckman J2 -21 centrifuge. The supernatant was discarded, and the 
platelets were resuspended in 4 ml of platelet washing buffer containing 
NaC1 0.15M, Tris 10 mM, EDTA 0.1 mM pH 7.4. This was repeated twice 
more. Platelet samples were finally resuspended in 2 ml of the same 
buffer. 50 ¡l samples were taken for triplicate protein estimation by 
the method of Lowry (1951). Lipids were extracted from the remaining 
sample by the method of Bligh and Dyer (1959). The dried lipid extract 
was dissolved in chloroform, and aliquots were analysed for phospholipid 
by the method of McClare (1971) and cholesterol was analysed using 
cholesterol oxidase from Nocardia species (see below). When samples 
contained a mixture of cholesterol and cholesterol -analogue, sterol 
composition was determined by gas liquid chromatography with a Pye 104 
model using the same conditions as described by Craig (1978) (see below). 
1. Phospholipid assay by the method of McClare (1971) 
In this method, triphenyl phosphine was used to make up standards 
of known phosphate content. A colorimetric reagent was freshly prepared 
containing 8 per cent perchloric acid, 1 per cent ammonium molybdate and 
0.2 per cent ascorbic acid. The samples of unknown phospholipid content 
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were blown down to dryness, and all traces of organic solvent were 
removed by placing the samples in a vacuum dessicator for 30 min. 
The extracts were then digested for 1 hour by boiling with 0.5 ml 
of perchloric acid at approximately 200 °C. When the samples had 
cooled, 9.5 ml of the colorimetric reagent was added to each digest 
tube which was then covered, inverted twice and incubated for 40 min 
in a waterbath at 50 
0 
C. The phosphate content was measured by 
absorbance against a reagent blank at 825 nm and converted to pg 
phospholipid by multiplication by 25. This method detected quantities 
of phosphorus in the range 1 -7 pg. 
2. Cholesterol assay using cholesterol oxidase 
Cholesterol oxidase is an oxidoreductase which reacts specifically 
4 5 
with Q -or Q -3ß -hydroxycholestanes. Cholesterol is metabolised to 
d4- cholestenone by this enzyme with the release of hydrogen peroxide 
as a by- product. This is measured by monitoring at 500 nm the pink 
colour produced by a hydrogen peroxide, phenol, 4- aminophenazone, 
peroxidase complex (Trinder, 1969). The presence of high levels of 
peroxidase activity and sodium azide ensure that catalase does not 
interfere with colour production. 
Samples of lipid extracts to be analysed for cholesterol were 
dissolved in 100 pl of isopropanol. To these, 2.5 ml of a solution was added 
prepared by mixing equal volumes of 0.4M Tris HC1 buffer (pH, 7.0) 
containing phenol (0.144 per cent w /v) and Triton X -100 0.5 per cent, 
and 0.05M tris HC1 buffer (pH, 7.0) containing 4-aminophenazone 
(0.022 per cent, w /v). Cholesterol oxidase was added to each sample 
(0.025 E.U.) and the reaction proceeded for 15 min at 37 °C in a shaking 
waterbath. The solutions were read against a reagent blank, correcting 
for turbidity, and the absolute amounts of cholesterol present were 
determined by comparison with standards. This assay detected quantities 
of cholesterol in the range 10 -100 pg. 
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3. Cholesterol and cholesterol- analogue assay by gas liquid 
chromatography 
After removal of a sample for phospholipid analysis, the lipid 
extracts dissolved in chloroform were passed through a silica gel 
(kieselgel H60) column to remove the remaining phospholipids. 
The sterol extracts were collected in the eluate, and the volume of 
chloroform used to ensure the highest recovery was at least two bed 
volumes. The resulting sterol extracts were then blown to dryness 
under nitrogen, and finally resuspended in redistilled acetone. 
Small aliquots were taken for estimation of recovery. Pregnenolone 
acetate was added to each sample as an internal standard. Samples 
were then applied to a column of 100 -120 mesh gas chrom Q on which 
was adsorbed 1 per cent SE30. With the column oven at 2350C, the 
injection heater at 300oC and a nitrogen flow rate of 30 ml min -1 
the amounts of the sterols present in the sample were determined. 
This quantitation was achieved by comparing the peak height ratios 
for the unknown cholesterol and known pregnenolone acetate with 
standard mixtures of the two components. Table 2.2 shows the time 
interval after injection of the sample on the column that each sterol 
was eluted and detected. 
Recovery of lipids extracted and processed as described above, 
was determined by adding a small quantity of [4 -14C] cholesterol 
(50 mCi /mmol) to the platelets prior to extraction with organic 
solvents. A small aliquot of the final solution of the lipid extract 
was counted in a vial containing 5 ml of. scintillant (20 g PPO, 
150 mg POPOP, in 5 litres toluene) in a Packard Tri -carb scintillation 
counter. 
Table 2.2. Gas liquid chromatographic analysis of sterols 










Settings of Pye 104 Gas Liquid Chromatograph. 
The elution times show the period after applying a sample to the column. 
Injection heater = 300°C 
Oven = 235 °C 
N2 flow rate = 30 ml min -1 
Air flow rate = 30 ml min -1 
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2.9 Platelet Aggregation 
Platelet aggregation was studied by the method of Born and Cross 
(1963). An aggregometer (Payton Associates Ltd., Hamilton, Canada) 
was used to study the optical density changes of PRP samples) PRP - 
liposome samples, and resuspended platelet samples. Samples were 
tested for aggregation with ADP or collagen. Optical density changes 
were recorded on a Servoscribe chart recorder (Smiths Industries Ltd., 
U.K.). 
Corresponding platelet poor plasma (PPP) samples were prepared for 
each platelet sample to be tested for aggregation by centrifuging 1 ml 
of the PRP sample at 1000 g for 15 min in a JASE bench centrifuge. 
The supernatant PPP was pipetted into a siliconised cuvette containing 
a siliconised stirrer. For aggregation testing of PRP samples, 0.25 ml 
samples were added to siliconised cuvettes each containing a siliconised 
stirrer. 
Aggregation was tested and assessed by a modification of a method 
described by Dreyfus and Zahavi (1973) . Using the aggregometer 
sensitivity controls, the deflection of the chart recorder pen was 
adjusted so that 1) the deflection when a sample of PRP was placed 
in the light beam and stirred at 1000 rpm was 0 per cent and 
2) the deflection when a sample of PPP was placed in the light beam 
was 100 per cent. The distance of pen travel between PRP and PPP 
was adjusted so as to be the same for all samples tested. The percentage 
maximum extent of aggregation was calculated thus: 
Distance of maximum travel of .en on stimulation of PRP with a:onist 
Distance of deflection of pen between PRP and PPP samples 
X 100 per cent. 
The rate of aggregation was calculated thus: 
Per cent maximum extent of aggregation -1 
Time (min) 
- Per cent min . 
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Preparation of aggregating agents 
1. ADP 
ADP (501 mg) was dissolved in 10 ml distilled water. From this 
stock solution, 10 pl was made up to 10 ml with distilled water. 
This solution contained 10 
-4 
M ADP and was divided into aliquots of 
0.5 ml and stored at -20 
0 
C. A 0.5 ml aliquot was thawed on the day 
of use, and kept in ice. 
2. Collagen 
Collagen stock solution contained 1 mg /ml of native collagen type 1 
fibrils from equine tendons. The solution was stored at 4 °C and was used 
untreated or diluted 1 in 10 with modified Tyrode's buffer. 
Aggregating agents were added to 0.25 or 0.5 ml platelet samples 
using a microsyringe (Terumo Ltd., Tokyo, Japan) in volumes not 
exceeding 10 p1. 
2.10 Platelet Resuspension 
PRP or PRP-liposome samples (between 3 -6 ml) were centrifuged in 
10 ml plastic centrifuge tubes at 1000 g for 10 min in a MSE bench 
centrifuge. The supernatant plasma or plasma/liposo me mixture was 
removed and an equivalent volume of modified Tyrode's buffer was added 
dropwise down the side of the tube. When all the buffer had been 
added, the platelets were resuspended by gentle agitation using a 
plastic Pasteur pipette. This procedure ensured complete resuspension 
of the platelets within 5 min. 
2.11 Preparation of Platelet Membrane Fractions 
Platelet membrane fractions were prepared using the method described 
by Wong and Cheung (1979) to obtain a crude membrane fraction. Platelets 
were pelleted and resuspended in modified Tyrode's buffer three times 
to remove the plasma and/or liposomes. PRP was centrifuged at 1000 g 
for 10 min. After each centrifugation the platelet pellet was resuspended 
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in an equal volume of buffer. The resuspended platelet samples were then 
pipetted into siliconised 25 ml beakers placed in ice and sonicated for 
three 20 second periods with 1 min intervals using a Rapidis 150 probe 
sonicator (Ultrasonics Ltd., U.K.) with power setting 9 and tuning 
setting 6. 
Sonicated platelet samples were then centrifuged at 3500 g for 
20 min to sediment unbroken cells. The supernatants were pipetted 
into 10 ml plastic centrifuge tubes and centrifuged at 100,000 g for 
60 min in a Beckman L2 -65B ultracentrifuge. The supernatants were 
removed and the pellets were rinsed twice with buffer containing 50 mM 
Tris HC1 (pH, 9.0). The membrane pellets were resuspended in 4 ml of 
this buffer and transferred to siliconised 25 ml glass beakers in ice. 
The samples were sonicated for three 20 second periods with 1 min 
intervals to disperse the membrane pellets. The resulting membrane 
suspensions provided the source of phospholipase A2, and were kept 
on ice until used. 
2.12 Preparation of 1 -acyl -2- (1- 140) -oleoylphosphatidylcholine and 
1-ac 1-2- [1-14C] -arachidonylphosphatidylcholine 
The method used for the production of phosphatidylcholine with 
radio labelled fatty acid esterified at the sn -2 hydroxyl group of 
the glycerol moiety was carried out essentially as described by 
Mulder et al. (1965). Red blood cells were obtained from rats as 
previously described. The blood sample (10 ml) was centrifuged at 
100 g for 15 min and the supernatant platelets were removed. 
The red cells were washed and resuspended 3 times in Krebs -Ringer 
solution (Krebs and Henseleit, 1932) containing 0.9 g NaC1, 46 mg 








, in 109 ml of 
distilled water.. NaHCO 
3 
solution was prepared by dissolving 1.3 g 
in 100 ml distilled water. 21 ml of this was added to 109 ml of 
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Krebs -Ringer solution and gassed for 1 hour with 5 per cent CO2/ 
95 per cent 02 mixture before use. 
The concentrated red cell sample (5 ml) was then centrifuged at 
20,000 g for 25 min to give a packed pellet of red cells. 0.5 ml of 
the sample was taken from the bottom of the centrifuge tube where the 
cells were most concentrated, and this was used in the incubation 
system to synthesise radiolabelled phosphatidylcholine. The incubation 
system was set up as follows: 
In a 25 ml round bottom flask, 2.5 mg lysolecithin (Sigma, London) 
and 10 pCi[1- 
14 
C]oleic acid (specific activity 56 mCi /mmol) were 
sonicated in 1.0 ml Krebs- Ringer bicarbonate buffer for a few minutes 
in a sonicleaner waterbath under nitrogen. The following were added 
to this suspension. 1 mg Coenzyme A, 15 mg ATP, 1 mg glucose, 400 i.u. 
penicillin and 400 i.u. streptomycin. The 0.5 ml red cell sample was 
added, and the mixture was incubated at 37oC overnight in a slowly 
shaking water bath. 
After incubation, the lipids were extracted by the method of Bligh 
and Dyer (1959) . An equal volume of chloroform :methanol (2:1 v /v) was 
mixed with the sample. The organic solvent phase was removed and the 
process repeated twice more. The organic solvent extracts were 
pooled, the solvent was evaporated under N2 and the lipids were 
separated by tic on kieselgel H type 60 plates in a solvent system 
containing chloroform :methanol:water, 50 :40 :1 (v /v). The plate was 
scanned with a Panaxtic scanner, and radioactive peaks corresponding 
to 1- acyl -2- 11 -14C] oleoylPC and Ll -14C] oleate were identified near 
the base -line and at the solvent front respectively. The radiolabelled 
phospholipid was isolated by scraping the silica gel from the plate 
in the corresponding area into a beaker containing methanol. This was 
transferred to a small column and washed with 3 volumes of methanol. 
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The extract was then evaporated to dryness under N2, and stored in 
ethanol. 
To check the purity of the substrate, a sample was incubated in 
1 ml modif ied Tyrode's buffer with snake venom as a source of 
phospholipase A2. A control sample was also incubated under identical 
conditions but without phospholipase A2. After incubation for 30 min, 
the samples were extracted with organic solvents as described above. 
The samples were subjected to tic as described above. In the control 
sample, all the radioactivity was located on and near the baseline, 
indicating that all the radioactive fatty acid remained esterified to 
phosphospholipids. In the sample which had been incubated with 
phospholipase A2, all the radioactivity was located at the solvent 
front indicating that all the radio labelled fatty acid ester if ied to 
phospholipid had been hydrolysed. 1- acyl- 2- [1- 14C]arachidonyl PC was 
prepared in the same way using [1- 
14 
Clarachidonic acid (60 mCi /mmol). 
Phospholipid determination of the radioactive substrate showed that 
the specific activity was 3.3 mCi /mmol for both substrates. 
2.13 Phospholipase A2 assay 
The source of the enzyme was provided either by once resuspended 
platelets (0.5 ml) or by a crude platelet membrane preparation (1 ml). 
Fatty acid free albumin was included in all incubation systems at a 
final concentration of 3.5 mg /ml in resuspended platelet samples, 
and 0.5 mg/ml in membrane preparations. The Ca2+ concentration was 
0.2 mM in resuspended platelet samples and 2.0 mM in membrane 
preparations obtained by the addition of 100 mM CaC12 solution prior 
to commencement of the reaction. The reaction was started by the 
addition of radiolabelled phospholipid (10 nCi, 2.5 g of phospholipid 
in 4 pl ethanol). In membrane preparations, 300 pg of membrane 
protein was used. 
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The reaction was terminated by the addition of 1 drop of concentrated 
HC1, followed by lipid extraction with an equal volume of chloroform: 
methanol (2:1 v /v) as previously described. Three extractions were 
carried out, and the organic solvent extracts were pooled, and dried 
under N2. The lipid extracts were redissolved in 100 -200 pl chloroform, 
and phospholipids and fatty acids were separated by tic in a solvent 
system consisting of chloroform :methanol:water (50 :40:1, v /v) as 
described above. Radioactive peaks were identified using a Panax tic 
scanner, and were scraped into vials and counted as described above. 
Recovery of substrate was approximately 80 per cent. 
Phospholipase A2 activity was assessed to give per cent conversion 
of substrate to product by the formula: 
cpm of radiolabelled fatty acid peak 
100 x 
cpm of radiolabelled phospholipid peak 
+ cpm of radiolabelled fatty acid peak. 
2.14 Preparation of Indomethacin Solution 
Indomethacin (7.16 mg) provided by ICI Pharmaceuticals Division, 
was dissolved in 5 ml distilled water. This solution was mixed with 
5 ml of 2.5 mg /ml Na2CO3 solution. This mixture was stirred for 
10 min, and another 10 ml of distilled water was added. The concentration 
of indomethacin in this solution was 1 mM. 10 pi of this was added to 
1 ml of resuspended platelets assayed for phospholipase A2 activity in 
which [i- 14C]arachidonyl PC was used to give a final concentration of 
10 pM indomethacin. 
2.15 Thromboxane A2 Generation.for Thromboxane A2 Bioassay 
Thromboxane A 
2 
was generated by aggregating aliquots of rabbit PRP 
with sodium arachidonate (3 x 10-.M) in an. aggregometer. When irreversible 
aggregation had occurred (905e0 samples of plasma containing thromboxane 
A2 were rapidly transferred for bioassay. 
40. 
2.16 Bioassay for Thromboxane A2 
This bioassay was carried out by Dr. M. Johnson while at ICI 
pharmaceuticals Division. The thoracic aorta was excised and spinally 
cut from a healthy rabbit fed a normal stock diet. The tissue was 
suspended in a 5 ml bath containing oxygenated (95 per cent 02: 
5 per cent CO2) Krebs -Henseleit solution maintained at 37 
0 
C. 
Contractions of the aorta were recorded isotonically under a resting 
tension of 1 g. The following antagonists 00 
-7 
M) were added to the 
bathing solution: mepyramine, propranolol, atropine methyl azide 
in order to ensure that contractions occurred as a result of thromboxane 
A2 and not catecholamines or serotonin released during irreversible 
aggregation. Indomethacin (10 -5M) was added throughout. A standard 
curve comparing contraction with thromboxane B2 production (measured 
by radioimmunoassay) was established using normal rabbit PRP. Height 
of contraction was measured after addition of 50 Ill and 100 111 o f_ 
plasma from each test sample. Thromboxane B2 levels calculated from the 
standard curve were taken to be equal to the levels of thromboxane A2 
_produced since all A2 is converted to B2, and contraction was due_solely 
2.17 Materials to thromboxane A2. 
All common reagents were purchased from BDH, Sigma or Fisons and 
were of Analar grade. 
Syringes and needles were obtained from Becton, Dickinson and Co., 
New Jersey, U.S.A. 
Plastic blood samples tubes and tubing were obtained from Sterilin 
Ltd., Teddi ngton , England. 
All radioactive chemicals were purchased from The Radiochemical 
Centre, Amersham, England. 
Collagen was obtained from Hormon -Chemie, Munich, FRG. 
Cholesterol oxidase, ammonium molybdate and phenol were purchased 
from BDH Chemicals, Poole, England. 
PPO and POPOP were obtained from Koch -Light, England. 
ADP L -a dipalmitoylphosphatidylcholine, (DPPC), and cholesterol 
were purchased from Sigma (London). 
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Kieselgel H and kieselgel 60 were obtained from Merck, Sharp and 
Dohme. 
Phospholipase A2 was purchased from Boehringer GmbH, FRG. 
Indomethacin was supplied by ICI Pharmaceuticals Division, Cheshire, 
England. 
Cholesterol -analogues were synthesized by Dr. I.F. Craig and 
Dr. K.E. Suckling in this laboratory. 
Chapter 3 




Recent studies have shown that human platelets enriched with 
cholesterol exhibit increased sensitivity to aggregating agents. 
Conversely, when cholesterol is removed from platelets, the sensitivity 
to aggregating agents is reduced when compared to control platelets 
(Shattil et al., 1975). In order to investigate further the role of 
cholesterol in platelet function, a method for altering the platelet 
cholesterol content was required which fulfilled certain criteria. 
1. Cholesterol enrichment or depletion should be achieved without 
affecting other platelet components which may be involved in platelet 
function. 
2. The method should involve the minimum of manipulation so that 
deterioration in the non physiological environment is minimised. 
3. The platelets with altered cholesterol content must be easily 
isolated from the medium at the end of the experiment so that they can 
be analysed for cholesterol content. It is necessary to remove 
cholesterol not associated with the platelet membrane prior to analysis, 
and this includes cholesterol not taken up and cholesterol which has 
been removed from platelets. 
Cooper et al. (1975) described a method for preparing cholesterol - 
poor, cholesterol- normal and cholesterol-rich phospholipid dispersions. 
Cholesterol and DPPC were mixed in various proportions and sonicated 
in buffer to give liposome suspensions of various cholesterol: 
phospholipid molar ratios (see Chapter 2). These media were used to 
alter the cholesterol content of red blood cells (Cooper et al., 1975) 
and of platelets (Shattil et al., 1975). These workers suggested that 
the molar ratio of cholesterol to phospholipid in the plasma was 
correlated with the cholesterol content of the red blood cells and 
platelets. This method was adapted in the present study to prepare 
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liposomes of various proportions of cholesterol and phospholipid. 
This chapter describes experiments carried out to test the suitability 
of this method to alter platelet cholesterol content. 
3.2 Preparation of Phospholipid Liposomes for Incubation with PRP 
Four types of liposome preparations were used as follows: 
1. Cholesterol -poor liposomes. These contained phospholipid only 
and were used to deplete platelets of cholesterol. 
2. Cholesterol- normal liposomes were composed of cholesterol and 
phospholipid in a molar proportion of approximately 0.6. This was the 
ratio found by the author in normal rat platelets. This medium was 
used to maintain the cholesterol content at its endogenous level. 
3. Cholesterol -rich liposomes were composed of cholesterol and 
phospholipid in a molar proportion between 1.0 and 1.5 and were used to 
enrich platelets with cholesterol. 
4. Cholesterol -analogue -rich liposomes were also prepared in 
order to attempt to load platelets with these cholesterol -like molecules. 
The same method was used for preparation of all liposome suspensions. 
The sterol and phospholipid were mixed in chloroform solution in a 
round bottom glass flask. The mixture was warmed and the bulk of the 
solvent was removed using a rotary evaporator to leave a thin film of 
the lipid mixture spread on the surface of the flask. This was then 
placed in a vacuum dessicator to remove all traces of solvent from 
the film. Modified Tyrode's buffer was added to the film at 50°C, 
a temperature well above the transition temperature for the DPPC, 
so -that the lipid was in a fluid state. This allowed the lipid to 
form multilamellar dispersions in the aqueous environment. The flask 
was shaken under a stream of hot water for 3 min to ensure complete 
removal of the lipid film from the glass. The suspension of lipid 
was sealed under nitrogen and sonicated at 55 -60 °C for 3 hours. 
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At the end of this period, the lipid suspension was centrifuged to 
remove undispersed lipid, and centrifuged again to ensure no further 
sedimentation from the liposome suspension. Suspensions containing 
high proportions of sterol to phospholipid gave rise to sediments of 
undispersed lipid which were larger than sediments obtained from 
centrifugation of cholesterol -normal or cholesterol -poor suspensions. 
Table 3.1 shows the results of analysis of typical liposome 
preparations used. It can be seen that the was a greater loss of 
lipid from cholesterol -rich suspensions than from normal or cholesterol - 
poor suspensions. In cholesterol analogue rich suspensions, only the 
C26- analogue suspension showed a significantly greater loss of lipid 
compared to the cholesterol-normal or cholesterol -poor suspension. 
It is evident from these results that it is difficult to disperse 
samples which contain high molar ratios of cholesterol or C26- analogue 
to phospholipid under these conditions. 
Liposomes prepared using DPPC were used in all experiments described 
for two reasons. Firstly, egg PC was considered liable to oxidation 
of constituent unsaturated fatty acids during preparation which may 
have resulted in the liposomes having different properties. Secondly 
the fatty acid composition of PC would be heterogeneous, and any fatty 
acids released may affect platelet function (Haslam, 1964) . 
At the end of the liposome preparation, glucose and albumin were 
added to final concentrations of glucose (5 mM) and albumin (3.5 mg /ml). 
Glucose was added to the liposome suspensions at a physiological 
concentration to maintain platelet function, and albumin was added to 
stabilize the liposomes (Shattil et al., 1975). All liposome preparations 
were optically clear. PRP samples were mixed with equal volumes of 
liposome preparation, and incubated at 37oC. The samples were gently 
inverted once every half -hour to ensure thorough mixing. 
Table 3.1. Composition of lipid mixture at the start, and of the 
liposome suspension at the end of the preparation method 
Final 
Starting sterol: Final sterol: phospholipid 
Liposome phospholipid phospholipid content 




































3.3 Analysis of Platelets 
Platelets were analysed for total unesterified cholesterol content, 
total phospholipid content and total protein content, as described in 
Chapter 2. The amounts of cholesterol and phospholipid were expressed 
as ratios of weight of each lipid to weight of protein (Shattil et al., 
1975). The phospholipid to protein weight ratio was determined in 
platelets before and after incubation with liposome suspensions to 
confirm that no phospholipid had been taken up by platelets from the 
liposomes. The molar ratio of cholesterol to phospholipid was calculated. 
Since these two lipids are predominantly found in membrane structures, 
determination of the molar ratio in this way reflects changes in the 
lipid composition of the platelet membrane. 
Platelets were prepared for analysis by centrifugation and 
resuspending the resultant platelet pellet in platelet washing buffer 
(see Chapter 2). The supernatant containing plasma and liposomes was 
removed. This washing process was repeated three times to ensure 
removal of all the liposomal lipids. The buffer used for washing the 
platelets contained no inorganic phosphates. This solution differs 
therefore from buffers used previously (Gaintner et al., 1962) . 
The use of a phosphate free buffer precludes the possibility of 
phosphates being extracted with organic solvents which would give 
false results for platelet phospholipid content. 
3.4 Viability of Method for Platelet Cholesterol Content Alteration 
1. Effect of liposomes on platelet composition 
Table 3.2 show results from an experiment to observe the effect 
of liposome suspensions of different lipid content on platelet composition. 
A concentrated cholesterol- normal liposome suspension was prepared so 
that by serial dilution, liposome suspensions of decreasing lipid 
content could be obtained. The cholesterol -normal liposome suspension 
Table 3.1. Analysis of rat platelets incubated with cholesterol- 

















Rat PRP samples were incubated for 3 hrs at 37°C with liposome 
suspensions prepared with different lipid concentrations. 
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was prepared as described previously, except that lipids were sonicated 
in 6 ml instead of 10 ml of buffer. Table 3.2 showsthe four 
dilutions made from this preparation with the final phospholipid 
concentration of each. The range of concentrations of liposomal 
phospholipid prepared was wider than was found with the liposome 
suspensions used in experiments carried out in this project. 
Table 3.1 shows the results of analysis of platelets after 3 hours 
incubation with an equal volume of liposome suspension. The molar ratio 
of cholesterol to phospholipid, and the weight ratio of cholesterol to 
protein is essentially the same in all samples except for the sample 
incubated with Tyrode's buffer alone. These results were obtained from 
single tests only, but it is considered that the experimental error is 
of the order of 5 and no more than 10 per cent (see Discussion). 
2. Phospholipid uptake by platelets from liposomes 
The results in Table 3.2. indicate that platelets incubated with 
liposomes make no net gain of phospholipid. The possibility of 
phospholipid exchange between platelets and liposomes was therefore 
examined. Cholesterol -normal liposomes were prepared in the usual 
way with the addition to the lipid mixture of 150 nCi of 1- acyl -2- 
14C]oleoyl 
PC prior to sonication in buffer. This preparation was 
incubated with PRP for 3 hours. At intervals, samples of platelets 
were isolated and the lipids extracted. Total radioactivity in each 
sample was determined and the results expressed in Table 3.3 give the 
percentage of the total radioactivity in an equivalent volume of 
incubation mixture that was detected in the platelet extracts. 
Two or three washes of isolated platelets were carried out to give 
an indication of the efficiency of the washing procedure at removing 
liposomes. The results in Table 3.3 indicate very little phospholipid 
Table 3.3. Uptake of phospholipid from liposomes by rat platelets 
Incubation time (min) 10 
% radioactivity found in 
platelets 0.64, 0.63 
60 
1.73,1.56 
Number of washes of 




Rat PRP (5 ml) was incubated with a cholesterol- normal liposome 
suspension (5 ml) at 37°C with 1 hourly inversion. This liposome 
suspension contained a total of 0.15 },tCi [1 -14C 1 oleoyl PC 
(specif is activ ity 3.3 )Ci /mmol ). 1 ml PRP- liposome samples were 
prepared for analysis of uptake of radiolabelled phospholipid by 
centrifuging and resuspending either 2 or 3 times as shown. 
Radioactivity was determined in the platelet sample and calculated 
as % of total radioactivity in 1 ml PRP- liposome mixture. 
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exchange occurred during the 3 hours, and that the washing procedure was 
efficient for the removal of the liposomes. 
3. Cholesterol uptake from cholesterol -rich liposomes 
Figures3.1- 3.3summarize the results from analysis of platelets mixed 
with liposorre suspensions to either 1) maintain or 2) increase the 
cholesterol :phospholipid molar ratio during a time course of 5 hours. 
Figure 3./ shows that the cholesterol :protein weight ratio was 
increased in the cholesterol -rich platelets. This would be expected 
if there was a net transfer of cholesterol from the liposomes to the 
platelets. In the control platelets, the ratio was seen to fall 
slightly to a steady value after 3 hours. This observation suggests 
that either cholesterol was being lost, or that protein was being 
taken up by the platelets during the incubation period. Figure 3.1 
shows a comparison of the phospholipid:protein weight ratios in the 
two samples. This ratio also decreased with tine to a steady level 
after 3 hours. Phospholipid was either being lost, or protein was 
being taken up by the platelets, but this effect was the same in both 
samples. Figure 3.3 however shows that the cholesterol :phospholipid 
molar ratio remained unchanged in the control sample, whereas in the 
cholesterol enrich ing system, the ratio was increased after 3 hours 
by 40 per cent. 
These results suggest that cholesterol enrichment could be achieved 
by this method, but incubation of the platelets induced either protein 
uptake, or a loss of equimolar amounts of cholesterol and phospholipid. 
The results in Table 3.2. suggest that the concentration of liposomal 
lipid in the incubation system does not cause this effect, since ratios 
are the same in platelets incubated without liposomes, and with widely 
different amounts of liposomal lipid. These composition changes in . 
Platelets were probably due to deterioration of the cells outside the 
48 
normal physiological environment. Shattil et al. (1975) observed no 
significant changes in lipid:protein weight ratios in human platelets 
treated in this way. It is possible that rat platelets were more 
susceptible to changes in composition under these conditions. Hamid 
et al. (1980) showed that in human platelet concentrates stored at 
20 °C for 72 hours, there was a 15 per cent loss of total cholesterol, 
and a 7 -11 per cent loss of total phospholipid. The loss of lipids 
shown by Hamid et al. (1980) may be occurring by a mechanism similar 
to the composition changes observed in the present study with rat 
platelets. The process in rat platelets appeared to be more rapid, 
but this was possibly due to the temperature being 37 °C as opposed 
to 20 °C used by Hamid et al. (1980). The reason for the composition 
changes remains obscure, but it is important to emphasize that this 
process did not influence or affect platelet function and was not 
due to the presence of liposomes. 
The results shown in figure53.1 -3.3 were obtained from one experiment. 
It has consistently been found however that incubation of rat and human 
platelets for three hours with cholesterol rich liposomes leads to an 
increase in the level of cholesterol in these platelets. Table 5.1 of 
Chapter 5 shows analysis of rat platelets obtained from the six experi- 
ments reported in that chapter. The cholesterol:phospholipid molar 
ratio was increased by an average of 20 per cent. Table 7.1 of 
Chapter 7 shows that human platelets also showed a significant increase 
in cholesterol content after in vitro enrichment. Table 7.1 also shows 
that the cholesterol content of human platelets was significantly reduced 
on incubation with cholesterol -poor liposomes. Finally table 8.7 shows 
that incubation of rat platelets with cholesterol rich liposomes resulted 
in an increase in the cholesterol content of crude membrane fractions 



































































































































































































































































































































































































































































































































































































































































































































































In view of the results outlined above the present studies showed 
that incubation of rat or human platelets with phospholipid liposomes 
of differing cholesterol composition reproducibly altered platelet 
cholesterol content. 
4. Alternative methods for platelet cholesterol enrichment 
An alternative method for cholesterol enrichment and depletion of 
platelets has been suggested by Shinitzky (1978). He suggested that a 
cholesterol -rich serum could be prepared by dissolving cholesterol 
(or PC for a cholesterol- depleting medium) in DNSO which is then added 
directly to heat inactivated serum. Schinitzky showed that cholesterol 
enrichment of erythrocytes was achieved using this technique, but no 
reference was made to any investigations carried out using this method 
with platelets. This technique was not found to be suitable in the 
present study because 1) on addition of cholesterol to the serum as 
described the cholesterol crystallised and precipitated readily on 
centrifugation and 2) heat inactivated serum was less physiological 
than the liposome suspension medium described previously. 
3.5 Discussion 
The results presented in this chapter indicate that the liposome 
incubation method for alteration of cholesterol content of Shattil et al. 
(1975) can be used with rat PRP. As discussed above, this has been 
confirmed by results obtained in several experiments with rat platelets 
(chapter 5, chapter 8) and with human platelets (chapter 7). It was 
found that liposome preparations of differing cholesterol content and 
liposomes containing various cholesterol analogues are composed of 
final phospholipid concentrations (see Table 3.1). It was necessary 
therefore to test whether the composition of platelet samples was 
influenced by phospholipid concentration of cholesterol -normal liposomes 
with which they were incubated. Table 3.2 shows analyses of single 
oua 
samples of rat platelets incubated with cholesterol normal liposomes of 
different final phospholipid concentration. Statistical analysis was 
therefore not possible but the range of error for any single result was 
found to be normally - 5 per cent, but certainly no more than 10 per 
cent. Allowing for an error within this range, the results indicate 
that no difference in platelet composition occurred as a result of 
different phospholipid concentrations. However, the platelet sample 
incubated with Tyrode's buffer alone showed a low cholesterol content, 
although in subsequent experiments where rat PRP samples have been 
incubated with Tyrode's buffer alone, analysis shows that the cholesterol 
content of these platelets is most probably not significantly different 
from platelets incubated with cholesterol -normal liposomes (see tables 
8.3, 8.4, chapter 8) . 
It was also important to test whether phospholipid uptake by 
platelets from liposomes occurred. This would be an undesirable event, 
one problem would be interpretation of analysis data if part of the 
phospholipid measured was derived from liposomes. The results of table 
3.3 indicate that very little liposome phospholipid was taken up by 
platelets, even after three hours incubation, showing that reliable 
platelet analysis could be carried out. 
The technique of alteration of platelet cholesterol content by 
the liposome incubation method has been used in all the present studies. 
Precautions have been taken however to ensure the reliability of all 
analysis results. In each experiment a control sample of PRP incubated 
with cholesterol -normal liposomes was included and treated in the same 
way as the other samples. Also, analysis for platelet protein, 
cholesterol and phospholipid was carried out on all samples to confirm 
that platelets did not take up liposome phospholipid. 
This method of cholesterol content alteration has been used with 
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Liman platelets (chapter 7) and rat platelets (chapter 8). In addition 
arious cholesterol analogues have been incorporated into rat platelets 
y this method (chapter 8). It has been possible to investigate platelets 
nriched with cholesterol in aggregation studies and in assays for phospho- 
ipase A2 activity. The technique used to assay for phospholipase A2 
Lctivity is described in the following chapter. 
Chapter 4 
Phospholipase A Assay Methods 
51. 
4.1 Introduction 
It is now generally accepted that platelets synthesize thromboxane 
A2 when stimulated by various aggregating agents. It has been suggested 
that the thromboxane A2 formed induces irreversible aggregation and 
secretion (Blackwell et al., 1977; Hamberg et al., 1975). Inhibition 
of thromboxane A2 synthesis from PGH2 was suggested by Gorman et al. 
(1977a) to be responsible for the inhibition of the second wave of 
aggregation induced by ADP or adrenaline observed in human platelets. 
As was discussed in Chapter 1, it may be that the synthesis of PGH 
2 
is more important than thromboxane A2 in mediating platelet aggregation 
arra secretion (Westwick et al., 1981). However, it is clear that 
metabolism of arachidonic acid is very important (Marcus, 1978). 
Very little free arachidonic acid is present in unstimulated platelets 
(Marcus, 1969) and a prerequisite for the conversion of arachidonic 
acid to prostaglandins is that the precursor is in the free acid form 
(Lands and Samuelsson, 1968). 
Phospholipase A2 in platelets hydrolyses the sn -2 ester bond between 
the fatty acid carboxyl group and the 2nd carbon atom of the glycerol 
moiety of the phospholipid (Jesse and Franson, 1979). The enzyme is 
membrane bound (Lapetina et al., 1978) and when activated releases 
fatty acids from membrane phospholipids (Kannagi and Koizumi, 1979). 
It was shown by Bills et al. (1976) and Blackwell et al. (1977) that 
platelets prelabelled with [1 -14C] arachidonic acid released this fatty 
acid from membrane phospholipids when stimulated with either collagen 
or thrombin. This reaction catalysed by phospholipase A could therefore 
2 
be an important rate limiting step in the supply of free arachidonic 
acid (Wong and Cheung, 1979; Blackwell et al., 1977). 
Cholesterol- enriched human platelets showed increased sensitivity 
to aggregating agents compared to control or cholesterol- depleted 
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platelets (Shattil et al., 1975) and also showed increased thromboxane B2 
production compared to cholesterol -depleted platelets (Stuart et al., 
1980a). In the study by Stuart et al. it was possible that the enhanced 
thromboxane B2 production in cholesterol- enriched platelets was a 
result of enhanced arachidonic acid release from membrane phospholipids 
by phospholipase A2. In the present project, it was therefore of 
interest to investigate further the possible influence of cholesterol 
on phospholipase A2 activity. In order to investigate the possible 
effect of the important membrane component cholesterol on the membrane 
bound enzyme, methods of assay of phospholipase A2 activity were 
investigated in the present work. 
4.2 Approaches to Phospholipase A2 Assay 
An important consideration for an assay method for a membrane bound 
enzyme is the problem of delivering the substrate to the enzyme. 
In the case of phospholipase A2, the lipid environment in which it is 
situated provides the substrate. Arachidonic acid is released from the 
membrane and metabolised further. The other product, the corresponding 
lysophospholipid, is presumed to be reacylated very rapidly (Billah 
et al., 1980). Two principal methods of assaying phospholipase A2 
activity have been investigated. In the first, the method of prelabelling 
platelet phospholipids with radiolabelled fatty acid, and studying the 
extent of release of this fatty acid on stimulation of the platelets 
was investigated. In the second, the method involved presenting a 
phospholipid substrate with radiolabelled fatty acid esterified at the 
sn -2 carbon atom to either resuspended platelets or a crude 'platelet 
membrane fraction. 
4.3 Prelabelling Rat Platelets with Radiolabelled Fatty Acid 
The method adopted for incorporation of radiolabelled fatty acid 
into platelet phospholipids was that described by Bills et al. (1976). 
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Tables 4.1 and 4.2 show results for the incorporation of [1- 14C]oleic 
acid (specific activity 56 mCi/mmol) and [1-14C] arachidonic acid 
(specific activity 60 mCi/mmol). The incorporation of [1-14C] oleic 
acid was investigated because oleic acid released by the action of 
phospholipase A2 would not be subject to further metabolism by enzymes 
involved in arachidonic acid metabolism. Further metabolites of 
arachidonic acid such as PGH2 and thromboxane A2, potent pro -aggregating 
agents, may influence the activity of phospholipase A2. It was 
anticipated that an inhibitor would be required to prevent further 
metabolism of arachidonic acid so that the arachidonic acid released 
could be isolated by tic as described in Chapter 2. 
The results in Table 4.1 show that of the total radiolabelled oleic 
acid added to the platelet rich mixture, only 0.8 per cent was 
incorporated after incubation at 37°C for one hour. The incorporation 
was increased to 2.2 per cent when once resuspended platelets (in 
buffer) were incubated in the same way. As Table 4.1 shows, when lipids 
were extracted from platelets incubated with [1 -14C] oleate, much of the 
radiolabel remained unincorporated and in the free acid form. Of the 
total radiolabelled oleate added, 3.3 per cent was recovered as 
unincorporated fatty acid when incubated in PRP, and 14 per cent when 
incubated with resuspended platelets. The results show that even 
after washing the platelets, a significant amount of fatty acid remains 
associated with platelets which has not been incorporated. 
Table 4.2 shows the results for incorporation of [1 -14C] arachidonic 
acid incubated in PRP which was carried out under the same conditions as 
for [1 -14C] oleic acid incorporation. The results show that the 7.4 
per cent of the [1 -14C] arachidonic acid originally added was 
incorporated into platelet phospholipids. This indicates that arachidonic 
acid may be more readily incorporated than oleic acid into platelet 
14 
Table 4.1. [1- C] Oleic acid incorporation into rat platelets 
[1 -14C] oleate 
incorporated into 
platelet phospholipids (70) 
[i -14C] oleate 





C] oleate [1 -14C a oleate 
incubated with incubated with once 
PRP resuspended platelets 
0.6, 1.0 2.0, 2.4 
3.2, 3.4 12.9, 15.1 
5 ml rat PRP (left column) or 5 ml rat platelets resuspended in 
modified Tyrode's buffer (right column) were incubated at 37 °C 
for 60 min with 0.1 pCi [1 -14C] oleate (56 mCi/mmol) in ethanol 
(20 I1). Platelet sampl6s (1 ml) were washed 3 times and analysed 
for 14C content. Duplicate tests were carried out on each sample. 
Results show the percentage of the total radiolabel added located in the 
platelets. 
Table 4.2. [1-14C] Arachidonic acid incorporation into and release 





[1 -14C] arachidonate 
recovered as free 
fatty acid 
(unincorporated) ( %) 
14 14 
[1- C] [ - C] arachidonate labelled 
arachidonate resuspended platelets 
incubated stimulated with 20 ?g/ml 
with PRP collagen 
(.A -t) Cheri) 
7.4 7.0 
18.0 20.0 
Rat PRP (10 ml) was incubated with 0.1 ìCi [1- 14C]arachidonic acid 
(60 mCi/mmol) added in 20 ul ethanol at 37°C for 60 min. 
Platelet samples were washed 3 times and resuspended in modified 
Tyrode's buffer. An aliquot of this platelet sample was 
analysed for 
14C 
content (left column). The remaining sample 
was incubated for 10 min with 20 pg/ml collagen, and was then 
analysed for 
14C 
content (right column). 
Results show the proportion of the total radiolabel added 
located in the platelets and are for single tests only. 
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phospholipids in general agreement with the results of Bills et al. 
(1977). However using the technique of fatty acid incorporation and 
the platelet washing procedure described by Bills et al. (1976) to 
remove unincorporated fatty acid, it was found in the present study 
that unincorporated fatty acid remained in the platelets. 
14 
As shown in Table 4.2, [1- C] arachidonic acid was incorporated 
into rat platelets when incubated with PRP. Of the total added, 7.4 
per cent was incorporated into phospholipids, and 18 per cent remained as 
free fatty acid. It was of interest to see whether any of the ' 
14 incorporated [1- C] arachidonic acid was released by stimulation of 
these platelets with collagen. Samples of platelets containing 
[1 -14C] arachidonic acid were stimulated with a concentration of collagen 
(typically 20 ii.g /ml) which induces irreversible aggregation. 
The results in the second column of Table 4.2 show that 10 min 
incubation of platelet samples with 20 yg/ml of collagen did not 
induce a significant change in the [1 -14C 1 arachidonic acid content 
of platelet phospholipids. These findings indicated that this 
approach was unsuitable for assaying phospholipase A2 activity in 
rat platelets. 
Compared to the work of Bills et al. (1976, 1977) with human 
platelets, far less arachidonic acid was incorporated into rat platelet 
phospholipids in the present study. Human platelets were reported by 
Bills et al. (1976) to have incorporated between 12 and 40 per cent 
of the total [1 -14C] arachidonic acid added to PRP, and in a subsequent 
study this figure was 45.9 per cent (Bills et al., 1977). 
4.4 Use of Radiolabelled Phospholipid Substrate for Phospholipase A2 
Assam 
Cl -14C] oleoyl PC has been used previously to assay for platelet 
membrane phospholipase A 
2 
activity (Blackwell et al., 1977; Jesse and 
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Franson, 1979). 1- acyl -2 -[1- 
14 
C] oleoyl PC was preppared as described 
in Chapter 2 by the method of Mulder et al. (1965). The positional 
specificity of the labelled fatty acid was confirmed by incubating a 
sample with snake venom containing phospholipase A2. After 30 min, 
no labelled PC was detected, indicating that all the [1 -14C] oleic 
acid was originally esterified at the sn -2 position of the glycerol 
moiety. As described in Chapter 2 the percentage conversion of [1 -14C] 
oleoyl PC to [1- 
14 
C] oleic acid was determined and used as an index of 
phospholipase A2 activity. [1-14C] Arachidonoyl PC was also prepared 
and used as a substrate in studies discussed in Chapter 6. 
4.5 Assay for Phospholipase A2 in once Resuspended Rat Platelets 
Table 4.3 summarizes results of two experiments carried out to 
investigate the effect of Cat+ concentration and different doses of 
collagen on phospholipase A2 activity in once resuspended rat platelets. 
A PRP sample was centrifuged and the platelet button was resuspended 
in modified Tyrode's buffer with glucose (5.5 mM) and fatty acid free 
albumin (2 mg /ml). 0.5 ml samples of resuspended platelets were used 
for each assay. The samples were incubated at 37 °C and stirred at 
1000 rpm prior to treatment. [l -14C] Oleoyl PC (10 nCi) was added to the 
sample, and after 1 min preincubation the collagen was added to the same 
sample . After incubating and stirring for 10 min the lipids were 
extracted from the phospholipase A2 assay sample by the method of 
Bligh and Dyer (1959) as described in Chapter 2. Phospholipids and 
fatty acids extracted from this sample were separated by tic, and the 
percentage conversion was calculated. The results in Table 4.3 
demonstrates a possible requirement of calcium ions for phospholipase 
A2 activity in once resuspended rat platelets. 
Table 4.4 summarizes the results of another experiment where 
phospholipase A2 activity of resuspended platelets was recorded to 
Table 4.3 Effect of [Ca 
2+ 
] and collagen on phospholipase A2 activity 











0 0 2 
0 0.2 6.0 2.8 
2 0.2 9.0 3.5 
10 0 5.0 2.0 
10 0.2 15.0 4.3 
Platelets were resuspended in modified Tyrode's buffer pH 7.4 glucose 
(5.5 mM) alubmin (2 mg /ml). Samples (0.5 ml) were incubated at 37 °C 
and stirred at 1000 rpm. Phospholipase A2 assays were carried out 
by the addition of [1- 14C]oleoyl PC (10 nCi) followed after 1 min by 
the collagen. The reaction was terminated and lipids extracted as 
described in Chapter 2 after 10 min incubation. 
Table 4.4 Relationship between A2 activity and collagen concentration 




Phospholipase A2 activity 
per cent conversion 
0 1.7, 1.7 
1 1.9, 2.1 
4 2.9, 4.3 
8 5.3 
Results shown are for two tests carried out for all collagen 
concentrations except for 8 }i.g /ml collagen, this result being for a 
single test. 
Samples of platelets (0.5 ml) 
1000 rpm, [CaC12] = 0.2 mM. 
and after 1 min, collagen was 
lipids extracted as described 
were incubated at 37 °C and stirred at 
[1- 14C]oleoyl PC (10 nCi) was added, 
added. The reaction was terminated and 
in Chapter 2, after 10 min incubation. 
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different concentrations of collagen. Platelets were resuspended as 
described above, and CaC12 (100 mM) was added to give a final concentra- 
tion of 0.2 mM Ca 
2+ 
. This concentration of Ca 
2+ 
could not be exceeded 
without the induction of spontaneous aggregation of platelets on 
stirring at 1000 rpm. All other conditions were the same as for the 
experiments recorded in Table 4.3. The results in Table 4.4 suggested 
that there was a correlation between collagen concentration and phospho- 
lipase A2 activity. 
The results in Tables 4.3 and 4.4 revealed that phospholipase A2 
activity could be assayed in once resuspended rat platelets. This 
method has therefore been used to compare the phospholipase A2 activity 
of normal and cholesterol enriched resuspended platelets from rats 
(Chapter 5) and rabbits (Chapter 6). 
4.6 Assay for Phospholipase A2 in a Crude Rat Platelet Membrane 
Preparation 
Crude platelet membrane fractions were prepared as described in 
Chapter 2 following essentially the method of Wong and Cheung (1979). 
Platelets were resuspended in modified Tyrode's buffer and sonicated 
to rupture the platelets. The first low speed centrifugation was then 
carried out to sediment large fragments and unbroken platelets. 
The supernatant was removed and centrifuged again at high speed to 
give a pellet of concentrated membranous material. The supernatant 
from this centrifugation was discarded, and the pellet was rinsed 
with membrane suspending buffer in order to remove soluble proteins. 
The membrane pellet was dispersed and resuspended by sonication. 
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Samples of this suspension were analysed for protein. In this way it was 
possible to incorporate the same concentration of membrane protein in 
each sample to be tested for phospholipase A2 activity. Fatty acid 
free albumin was added to each of the final reaction mixtures to 
sequester fatty acid released by hydrolysis of the phospholipid 
substrate. Lipid extraction was carried out on all samples for 
determination of phospholipase A2 activity at the end of the incubation 
period as described previously. Small aliquots of the crude membrane 
preparations were set aside for analysis of cholesterol and phospholipid 
content. Lipids were extracted from samples by the method of Bligh and 
Dyer (1959) as described in Chapter 2. 
Preliminary experiments revealed that phospholipase A2 activity 
could be assayed in crude platelet membrane preparations. Figures 4.1- 
4.4 show results for conversion of [1 -14C3 oleoyl PC to [1 -14CJ oleic 
acid by membrane preparations under various conditions. The five 
figures represent results obtained from experiments using five different 
crude membrane preparations. Figure 4.1 shows the conversion of 
[1 -14C3 oleoyl PC to [1 -14C] oleic acid was time dependent, and Sìr1 It 
assays with fatty acid free albumin (0.5 and 1.0 mg /ml) showed that 
this protein enhanced phospholipase A2 activity in agreement with other reports 
(see Discussion) . Figure 4.2 confirms that phospholipase A2 activity as 
measured by this method was time dependent in the presence of 0.5 mg/ml 
albumin and 2.0 mM Ca2+ at pH 9.0. The results in Figures 4.1 and 4.2 
were obtained from different membrane preparations. Since there were 
variations between the phospholipase A2 activities of different 
preparations, the results of Figures 4.1 and 4.2 cannot be compared 
directly with each other. The results in Figure 4.1 suggests that 
albumin is required for optimal conversion of substrate to product. 
Figure: 4.3 shows the phospholipase A 
2 
activity is dependent on the 
concentration of Ca2 +. 2.0 mM Ca2+ was considered to be a suitable 







10 20 30 
TIME (min) 
L0 50 
Samples of platelet membrane fractions (0.3 mg in 1.0 ml) were incubated 
at 37oC with 2.0 mM Ca2+ at pH 9.0. 
= samples incubated without FFA albumin 
x = sample incubated with FFA albumin (0.5 mg/ml) 
A = sample incubated with FFA albumin (1.0 mg/M1) 
Figure 4.2. Time dependence of phospholipase A2 activity in rat platelet 
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TIME (min) 
Platelet membrane samples (0.3 mg in 1.0 ml) were incubated at 37 °C 






























































































































































































































































































































































































































































































































































concentration to use in this assay because the rate of conversion of 
substrate to product was sufficiently high, and this was approximately 
the physiological concentration that may be found within the cell 
(Pickett et al., 1977). Figure 4.4 shows that phospholipase A2 
activity was not linearly related to the concentration of membrane 
protein present ,therefore in subsequent assays a standard amount of 
protein was used. This non linearity is not unusual in membrane bound 
proteins and this was found with acyl coenzyme A transferase (Rae, 1980). 
4.7 Discussion 
Experiments have been carried out in the present study to determine 
suitable conditions for a phospholipase A2 assay technique in both 
platelet membrane preparations and whole platelets. It was necessary 
2+ 
to investigate the effect of Ca concentration on the phospholipase A2 
activity of membrane preparations. This was because several workers 
who have studied this enzyme used a wide range of Ca 
2+ 
concentrations. 
Kannagi and Koizumi (1979) studied the activity of a purified form of 
phospholipase A2 from rabbit platelets with 0.01 mM Ca 
2+ 
. Rittenhouse- 
Simmons and Deykin (1978) used 10 mM Ca2+ with platelet lysates, and 
Trugnan et al. (1979) used 10 mM Ca2+ with human platelet membrane 
fractions. Wong and Cheung (1979) used 0.2 mM Ca2+ in their studies 
of phospholipase A2 activity in membrane preparations. In the present 
study, 0.2 mM Ca2+ was found to be too low for membranes prepared from 
rat platelets. 
The results shown in figure 4.1 suggested that fatty acid free 
albumin was required in the incubation medium for optimum conversion' 
of [1- 14C]p1eoy1 PC to [1- 14C]oleic acid. Stuart et al (1980b) showed 
that when human platelets prelabelled with [1 -14C] arachidonic acid 
were stimulated with thrombin (5.0 U /ml), 28 per cent of this arachidonic 
acid was released in the presence of albumin (0.7 g /100 ml) compared to 
18 per cent without albumin. 
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Kupferberg et al (1981) showed that the activity of phospholipase A2 
(from Crotalus atrox) was inhibited by lysolecithin which is a product 
of the hydrolysis of PC catalysed by this enzyme as a result of the 
formation of a lysolecithin- phospholipase A2 complex. Kupferberg et al. 
demonstrated that bovine serum albumin bound to the lysolecithin 
mitigating its inhibitory activity providing the albumin was present 
in excess. The single assays carried out using two different 
concentrations of albumin (Figure 4.1) tend to confirm that albumin 
serves to stimulate phospholipase A2 activity in rat platelet membrane 
fractions. This is presumed to occur possibly by way of abolishing 
the inhibitory effect of products as seen in studies of phospholipase 
A2 isolated from Crotalus atrox by Kupferberg et al. (1981). Alternatively 
the albumin could act by combining with the substrate and delivering 
it to the enzyme more efficiently. 
The buffer in which crude membrane preparations were finally 
dispersed was pH 9. Many investigators have reported that the pH 
optimum for phospholipase A2 activity was in the range 8.0 to 10.5 
(see Jesse and Franson, 1979). As mentioned above, the concentration 
of Cat+ for resuspended platelets was 0.2 mM because above this 
concentration spontaneous aggregation frequently occurred on stirring. 
It was necessary to use platelets resuspended in a suitable buffer 
so that lipid extraction (for the phospholipase A2 assay) was possible. 
It was necessary to use these unphysiological conditions because 
extraction of lipids from platelets in plasma would have been extremely 
difficult due to the very high protein concentration in the sample. 
The method of prelabelling platelets with radiolabelled fatty acids 
was not found to be suitable. The assay technique developed for 
resuspended platelets and platelet membrane preparations has been used 
in further investigations of the effect of the platelet membrane of 
59a 
alteration of cholesterol content and cholesterol -analogue incorporation. 
In view of the finding by several workers that the activities of other 
membrane bound enzymes are influenced by their lipid environments 
(McMurchie and Raison, 1979; Agutter and Suckling, 1981), these 
further investigations of phospholipase A2 were very pertinent to 
the present project. 
Chapter 5 
Aggregation and Phospholipase A2 Studies 
in once Resuspended Rat Platelets 
60. 
5.1 Introduction 
Phospholipase A2 is considered to play an important role in the 
platelet membrane in the regulation of release of arachidonic acid from 
platelet membrane phospholipids(Blackwell et al., 1977). After hydrolysis 
of membrane phospholipids, arachidonic acid is made available for 
metabolism to PGH2 and th romboxa ne A2 which are believed to be 
important potent proaggregating agents (see Chapter 1). In a study 
related to the present work, Stuart et al. (1980a) altered the 
cholesterol content of human platelets in vitro by the method of 
Shattil et al. (1975). 
Stuart et al. (1980a) incubated human platelets with liposomes to 
either increase or decrease the platelet cholesterol content. To the 
4 
same incubation system, [j -C] arachidonic acid was added in order to 
label the platelet phospholipids. After incubation for 5 hours the 
platelets were washed to remove liposomes and [14C] arachidonic acid 
not incorporated into platelet phospholipids. Platelet samples were 
then treated with thrombin. Control samples were treated with buffer 
alone. The results obtained by Stuart et al. (1980a) showed that in 
cholesterol- enriched platelets there was increased synthesis of cyclo- 
oxygenase products and slightly reduced synthesis of lipoxygenase 
products compared to cholesterol- depleted platelets after thrombin 
induced aggregation. These workers suggested that there was an 
increased release of [14C ] arachidonic acid from prelabelled phospho- 
lipids in the cholesterol -enriched platelets. The amount of arachidonic 
acid released was calculated by determining the percentage of the 
radioactivity in the arachidonic acid and metabolite fractions and 
subtraction of the values obtained when buffer instead of thrombin 
was added to the platelets. .Stuart et al. (1980a) did not however 
14 state if there was any difference in the amount of [C] arachidonic 
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acid taken up by cholesterol- depleted or cholesterol -enriched platelets 
during the 5 hour incubation period. Also, no mention was made of the 
percentage release of [14C] arachidonic acid from platelets incubated 
with buffer instead of thrombin. If there was any difference in either 
of these parameters between the cholesterol -depleted and cholesterol - 
enriched platelets, the suggestion that there was a greater release of 
14 
[ C] arachidonic acid from cholesterol- enriched platelets on stimulation 
with thrombin is not well supported. 
The suggestion by Stuart et al. that there was "a serious derange- 
ment of arachidonic acid metabolism" is however well founded. The 
differences in percentages of total radioactivity found in metabolites 
of the lipoxygenase ani cycloxygenase pathways indicated that arachidonic 
acid metabolism was directed preferentially toward the cyclo -oxygenase 
pathway in the cholesterol- enriched platelets. These workers suggested 
that membrane cholesterol may affect the enzymes diacylglycerol lipase 
and /or phospholipase A2. Both these enzymes are involved in the release 
of arachidonic acid from platelet phospholipids (Billah et al., 1980). 
The methods used by Stuart et al. (1980a) to determine the per cent 
release of arachidonic acid would not have distinguished between these 
two enzyme systems. It was therefore necessary to investigate further 
the effect of cholesterol enrichment on platelets using a technique 
designed to specifically assay for phospholipase A2. 
Recent research has revealed that there are at least two mechanisms 
for the release of arachidonic acid from platelet membrane phospholipids 
(Billah et al . , 1980). One mechanism involves the hydrolysis of the sn -2- 
acyl ester bond of phospholipids by phospholipase A2. The other involves 
a phospholipase C which cleaves phosphatidylinositol at the phosphate 
bond to produce the corresponding 1,2 diacylglycerol and inositol 
phosphate (Rittenhouse- Simmons, 1979). The 1,2 diacylglycerol is then 
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either phosphorylated by diacylglycerol kinase to form phosphatidic acid 
(Call and Rubert, 1973; Billah et al., 1979) or degraded further by a 
diacylglycerol lipase to release the monoacylglycerol and arachidonic 
acid (Bell et al., 1979). It has been shown by Lapetina and Cuatrecasus 
(1979) that platelets stimulated with thrombin rapidly form phosphatidic 
acid from phosphatidylinositol within 5 seconds prior to the appearance 
of arachidonic acid. Phosphatidic acid production may occur in stimulated 
platelets before phospholipase A2 activation, and may in some way 
activate this enzyme (Lapetina and Cuatrecasus, 1979; Lapetina et al., 
1980). 
It has been suggested by Bell et al. (1979) that sufficient 
arachidonate may be provided by the combined activities of phospholipase 
C and diacylglycerol lipase far the synthesis of prostaglandins and 
thromboxanes on stimulation of platelets with thrombin. The phospho- 
lipase C is reported to be specific for phosphatidyl inositol 
(Rittenhouse- Simmons, 1979; Billah et al., 1979; Bell et al., 1979) 
and is also called phosphatidylinositol -phosphodiesterase. It had 
been reported previously by other workers that phospholipase A2 activity 
was responsible for the release of arachidonic acid (Bills et al., 1976; 
Blackwell et al . , 1 977; Lapetina et al., 1977; Bills et al., 1978; 
Lapetina et al., 1978). The view generally accepted to date is that 
phospholipase C activation is an early event following platelet 
stimulation, and phospholipase A2 is activated subsequently (Lapetina 
and Cuatrecasus, 1979). 
Platelet phospholipase A2 activity has been investigated by several 
workers (see for example Pickett et al., 1977 and Rittenhouse -Simmons 
and Deykin, 1978), and it is quite clear that phospholipase A2 plays an 
important role in arachidonic acid metabolism in platelets, and 
Broekman et al. (1980) suggested that the "phosphatidylinositol -specific" 
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and phospholipase A2 pathways of phospholipid metabolism exist in 
stimulated platelets. It seems unlikely therefore that arachidonic 
acid is released exclusively by phosphatidylinositol phospholipase C 
as suggested by Bell et al. (1979). It is generally considered that 
phospholipase C specifically cleaves the phosphate ester bond of 
phosphatidylinositol whereas the major substrates for phospholipase A 
are reported to be phosphatidylethanolamine (Broekman et al . , 1980; 
2 
Jesse and Cohen, 1976) and phosphatidylcholine (see for example Bills 
et al., 1977). Phospholipase C is a cytosolic protein whereas 
phospholipase A2 is a membrane bound enzyme (Billah et al . , 1980) . 
It was of particular interest in the present study to investigate the 
activity of phospholipase A2 in platelets with altered cholesterol 
content in order to examine the possibility of increased release of 
arachidonic acid as a result of alteration of the physical properties 
of the membrane. Since there are two pathways by which arachidonic 
acid may be released from platelet membrane phospholipids, as discussed 
above, an important criterion in an assay of phospholipase A2 activity 
is that the substrate presented to platelets should not be available 
to phospholipase C activity. The method for the assay of phospholipase 
A2 described in Chapter 4 satisfies this condition. [ 1 -14C3 Oleoyl PC 
would not be a substrate for phospholipase C because of its specificity 
for phosphatidylinositol. Using the method described in Chapter 4 
for the assay of phospholipase A2 activity the oleic acid released 
would not be available for further metabolism by enzymes normally 
involved in arachidonic acid metabolism, and would therefore give a 
good index of general phospholipase A2 activity. 
In Chapter 4, results were presented which indicated that it was 
feasible to assay phospholipase A 
2 
activity in once resuspended rat 
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platelets. In this chapter experiments which have been carried out to 
investigate the relation between phospholipase A2 activity and sensitivity 
to aggregation are reported. Firstly however the difficulties involved 
in measuring platelet aggregation will be described. 
5.2. Platelet Aggregation studies 
The general background (see Chapter 1) and the methodology used to 
test aggregation (see Chapter 2) have already been described. Preliminary 
initial aggregation studies were carried out using ADP with human 
platelets (see Figure 7.1, Chapter 7) but subsequently the use of 
collagen was adopted. Although either agent could be used to test 
aggregation, collagen was considered the more suitable. Collagen is a 
strong agonist of aggregation which is capable of stimulating the basic 
platelet reaction to the final event of granule secretion. ADP is a 
comparatively weak agonist which although stimulates aggregation does 
not induce granule secretion as discussed in Chapter 1. 
Initial observations showed that the rate and per cent maximum 
extent of aggregation measured essentially the same thing (see for 
example Table 5.4A and 5.4B). The extent of aggregation has subsequently 
been measured in place of rate of aggregation. This precluded the 
theoretical possibility that two platelet samples could show the same 
rate when in one sample the platelets aggregated sooner but to a lesser 
extent than in the other sample. During the current studies however 
this phenomenon has not been observed. 
In the present studies, it is evident that platelets isolated from 
different groups of rats showed variable sensitivity to collagen and 
ADP induced aggregation after three hours incubation with liposomes. 
This is summarized in Figure 5.1 which shows all the results of extent 
of aggregation induced by the various concentrations of collagen used 
in samples of rat platelets incubated with cholesterol -normal liposomes. 
The variation seen from one experiment to another may be due to a 













. 1 _ . . > I I 1 j
1 2 3 4 5 6 7 8 
Final concentration of collagen added to PRP- 
liposome sample (}ig /ml) 
Figure 5.1 shows extent of aggregation of platelets incubated with 
cholesterol - normal liposomes after 3 hrs incubation. This figure 
summarizes data collected from all the experiments reported in this 
thesis. Aggregation tests were carried out as described in Chapter 2. 
Table 5.1. Analysis of rat platelets 
Phospholipid: Cholesterol: Cholesterol: 
protein protein phospholipid 
weight ratio weight ratio molar ratio 
Control ( n = 6) 0.187 ± 0.011 0.054 ± 0.005 0.567 ± 0.035 
Cholesterol (n=6) 
enriched 
0.182 ± 0.008 0.062 ± 0.005 0.674 + 0.028 
p < N.S. 0.05 0.001 
Rat PRP samples were incubated with an equal volume of either 
cholesterol -normal or cholesterol -rich liposomes at 37°C for 
3 hr. The results show means 
± 
S.E.M. of 6 experiments. p values were 
calculated for significanc using students t -test. 
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difference in sensitivity of platelets from different groups of rats, 
and this sensitivity may be further altered by the incubation process. 
Therefore before commencing aggregation studies for each experiment, 
it was necessary to test platelet samples with a wide range of collagen 
concentrations in order to find one intermediate between no response 
and maximum stimulation. 
Six experiments were carried out to assay phospholipase A2 activity 
in resuspended control and cholesterol- enriched rat platelets. Platelets 
were enriched wi th cholesterol or alternatively in control platelets the 
normal cholesterol content was maintained using the incubation method 
with liposomes as described in Chapter 3. The six experiments were 
divided into two groups of three. In the first group (Tables 5.1A -5.3B) 
platelets were resuspended once at the end of the incubation period 
and were assayed for phospholipase A2.activity by incubation in a 
shaking waterbath at 37°C without added collagen. In the second group 
(Tables 5.4A -5.6B) collagen was added to resuspended platelet samples 
in order that aggregation could be recorded in the sample being assayed 
for phospholipase A2 activity. The results in Table 5.1 give the means 
of analysis of platelet samples from the six experiments carried out. 
The mean increase in the cholesterol:phospholipid molar ratio was 
20 per cent in the cholesterol -enriched platelets. Aggregation studies 
were carried out on PRP -liposome samples in all the experiments, and 
samples of PRP -liposome mixtures were taken for counting to ensure 
the platelet counts were not significantly different. 
1. Experiment 1. (Tables 5.1A and 5.1B) 
In Table 5.1A, the results show hypersensitivity to collagen induced 
aggregation in cholesterol- enriched platelets. This was particularly 
obvious with a collagen concentration of 2.0 p /ml where control 
EXPERIMENT 1 
Table 5.1A. Aggregation results of PRP- liposome samples (0.5 ml) 
Aggregat ion Platelet count in sample 




jg /ml 1.6 2.0 2.4 
Control 0 0 50 594 
Cholesterol -rich 4 41 66 590 
Aggregation tests were carried out as described in Chapter 2. 
Table 5.1B. Phospholipase A2 assay of resuspended rat platelets 
Control Platelets Cholesterol -rich platelets 
Platelet Phospholipase A2 Platelet Phospholipase A2 
count activity coun6 activity 
x 10 /litre % conversion x 10 /litre % conversion 
1420 14.8 1130 13.0 
710 24.5 560 15.5 
350 51.5 280 14.0 
170 42.0 140 33.0 
85 37.0 70 24.0 
Samples of platelets of different count were obtained by resuspending 
platelets in half the original volume (in PRP) and diluting with 
buffer. Phospholipase A 
2 
assay was carried out by the addition of 
[1 -14C] oleoyl PC (10 nCi). [ Ca2 
+J 
= 0.2 mM; FFA albumin 
concentration = 3.5 mg/ml; incubation time = 40 min at 37°C; 
Glucose = 5 mM; pH = 7.4. 
Results shown in Tables 5.1A and 5.1B are for single tests only 
EXPERIMENT 2 
Table 5.2A. Aggregation results of PRP- liposome samples 
Aggregation Platelet count 




1g /m1 1.0 2.0 
Control 0 22 634 
Cholesterol -rich 10 48 641 
0.25 ml PRP -liposome samples were tested for aggregation as 
described in Chapter 2. 
Results shown are for single tests only 
Table 5.2B. Phospholipase A2 assay of samples of resuspended 
control and cholesterol -rich rat platelets of 
different platelet counts 
Platelet Phospholipase A2 activity % conversion 
coun 










Phospholipase A2 assays were carried out using [1 -14Ca oleoyl PC 




] = 0.2 mM; incubation time = 15 min at 37°C; FFA albumin 
concentration = 3.5 mg/ml; [Glucose] - 5 mM; pH 7.4. 
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platelets failed to aggregate and cholesterol -enriched platelets 
aggregated to 41 per cent of the maximum extent. Phospholipase A2 
assays were carried out on samples of resuspended platelets of 
different platelet count. These samples were obtained by serial 
dilution with modified Tyrode's buffer. The results may suggest a 
higher phospholipase A2 activity in the control platelets, but a 
direct comparison was not possible because the counts were not the 
same in both samples. 
2. Experiment 2. (Tables 5.2A and 5.2B) 
The results in Table 5.2A show that cholesterol- enriched platelets 
were more sensitive to collagen induced aggregation than control 
platelets. Phospholipase A2 activity (see Table 5.2B) was assayed in 
platelet samples of different platelet counts. This was a repeat of 
experiment 1, except that in this experiment, control and cholesterol - 
enriched platelet samples contained the same platelet count. The 
results indicate no obvious difference in phospholipase A2 activity 
between the control and cholesterol- enriched platelets. A shorter 
incubation period was used in order to reduce the amount of substrate 
converted to product, so that substrate removal would not limit the 
rate of reaction. However, the per cent conversion retained high 
(above 20 per cent in most samples) which was not desirable. 
3. Experiment 3. (Tables 5.3A and 5.3B) 
The results in Table 5.3A indicate that cholesterol- enriched 
platelets were more sensitive to collagen induced aggregation than 
control platelets. In this experiment phospholipase A2 activity was 
assayed at intervals during an incubation at 37oC in both control and 
cholesterol- enriched platelets. The results suggest the possibility 
that phospholipase A 
2 
activity was detectable at an earlier stage in 
cholesterol -enriched platelets than in control platelets. 
EXPERIMENT 3 
Table 5.3A. Aggregation results of PRP- liposome samples (0.25 ml) 
Aggregation Platçlet count 






Cholesterol -rich 52 
641 
676 
Table 5.3B. Time course for phospholipase A2 activity in 
resuspended control and cholesterol- enriched 
rat platelets 
Phospholipa se A activity 
% conversion n 
Time (min) Control Cholesterol -rich 
1 0.35 3.5 











x 109 /litre 637 575 
Phospholipase A2 assays were carried out using [1 -14C] oleoyl PC 
(10 nCi) as substrate. [Ca2 +] = 0.2 mM; incubation at 37oC; 
FFA albumin concentration = 3.5 mg /ml; [Glucose] = 5 mM; pH = 7.4. 
Results shown in Tables 5.3A and 5.3B are for single tests only 
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However, the per cent conversions in all the samples was low, and this 
could have hidden any small differences that may have existed in the 
phospholipase A2 activity. 
The results obtained from the three experiments discussed above do 
not indicate an obvious difference in phospholipase A2 activity in 
unstimulated platelets. It was shown in Chapter 4 (Table 4.3) that 
resuspended platelets could be stimulated with collagen and the 
phospholipase A2 activity could be assayed in the same sample. The 
results indicated apossiblecorrelation between Lonwarihn,fión. odl- 
collagen and phospholipase A2 activity. In the three 
experiments described above, cholesterol- enriched platelets in PRP- 
liposome mixtures were consistently more sensitive to collagen induced 
aggregation. The next three experiments therefore centred on assaying 
phospholipase A2 activity in once resuspended platelets which were 
stimulated to aggregate with collagen. 
4. Experiment 4. (Tables 5.4A and 5.4B) 
The results in Table 5.4A show the enhanced sensitivity of cholesterol - 
enriched rat platelets to collagen induced aggregation. The rate of 
aggregation is given in brackets, and this was also enhanced. The 
results in Table 5.4B show that in once resuspended platelets, 
cholesterol enriched platelets are less sensitive to collagen induced 
aggregation than control platelets. The rate of aggregation is also 
reduced. Phospholipase A2 activity was not different between the two 
samples. 
5. Experiment 5. (Tables 5.5A and 5.5B) 
The results obtained in experiment 5 confirmed the results from 
experiment 4. Cholesterol enriched platelets in PRP- liposome samples 
were more sensitive to collagen induced aggregation than control 
platelets (Table 5.5A), but were less sensitive after resuspension 
EXPERIMENT 4 
Table 5.4A. Aggregation results of PRP- liposome samples 
Aggregation Platelet count 
% max. extent x 101litre 






pg /ml 1.0 2.0 
Control 9.2(3.4) Irreversible 479 
Cholesterol -rich 19.0(8.5) Irreversible 472 
Results shown are for single tests only 
Aggregation results in brackets are rates of aggregation. 
See Chapter 2 for details of method. 
Table 5.4B. Aggregation results and phospholipase A2 assays of 
resuspended control and cholesterol -rich rat platelets 
Phospholipase A2 Platelet 
Aggregation activity count 






Cholesterol -rich 53(13) 
5.3 - 0.87 380 
p< N.S. 
4.7 - 0.32 395 
Aggregation results are for single tests only Platelets were 
resuspended in an equivalent volume of buffer and phospholipase A2 
in triplicate 14 
assays were carried out using [1- C] oleoyl PC (10 nCi) as 
substrate. [ Ca2+ ]= 0.2 mM; incubation time = 10 min at 37 C; 
FFA albumin concentration = 3.5 mg/mi; [Glucose] = 5 mM; pH =.7.4. 
EXPERIMENT 5 




% max. extent 
to collagen 
(1.2 jg/ml ) 
Platelet count 
x 10w /litre 
0 450 
60 430 
Samples (0.25 ml) were tested for aggregation as described 
in Chapter 2. Results shown are for single tests only 
Table 5.5B. Aggregation results and phospholipase A2 assays 
of resuspended control and cholesterol -rich rat 
platelets 
Aggregation 
Phospholipase A Platelet 
2 
activity count 





Control 62 ± 3.16 3.5 ± 0.29 289 
Cholesterol -rich 28 ± 1.73 3.5 ± 0.79 246 
p< 0.001 
N.S. 
Aggregation tests and phospholipase A2 assays were carried out 
in triplicate samples from each incubation system. Phospholipase A2 
assays were carried out using [1- 14C]arachidonoyl PC (10 nCi) as 
substrate. Results show means ± S.E.M. Significance was tested using 
students t-test. Phospholipase A2 assay conditions:- [Ca2 ±] = 0.2 mM; 
incubation time = 10 min at 37oC; FFA albumin concentration = 3.5 mg/ml; 
[Glucose] = 5 mM; pH = 7.4. 
EXPERIMENT 6 
Table 5.6A. Aggregation results of PRP- liposome samples 
Aggregation Platelet count 




pg/ml 2.4 4.0 
Control 0 67 498 
Cholesterol -rich 40.5 65 499 
Samples (0.25 ml) were tested for aggregation as described 
in Chapter 2. 
Results shown are for single tests only 
Table 5.6B. Phospholipase A2 assay of resuspended control and 





activity Platelet count 
% conversion x 10y /litre 
5.8 ± 0.50 499 
6.1 -- 0.71 451 
p < N.S. 
Phospholipase A2 assays were carried out using [1-14 C3 oleoyl PC 
(10 nCi) as substrate. Collagen was added to each sample in a 
final concentration of 2 31g/ml. Results show means ± S.E.M. for 510,51e 
asswÿ; carried, out cv. 6 scav pie. ;50tare, froNik (ybike covtiv PRP - lip©seme 
;Ai;baiu.A ,0v4, fo fi-ovh aot ckele,sreroL PRP- ritiosome .fnwÌxLt'c°n 
[Ca2 +] = 0.4 mM; incubation time = 10 min at 37 °C; FFA albumin 
concentration = 3.5 mg /ml; [Glucose] = 5 mM; pH 7.4. 
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14 
compared to controls. [ 1- C] arachidonoyl PC was used as substrate for 
A assay to test the [1- 
14 
C) the phospholipase 2 Y 
possibility that ] oleoyl PC 
was not a suitable substrate which could have prevented the detection of 
any difference in activity of this enzyme. No difference was detected 
even with this substrate, suggesting that the substrate [i -14C J oleoyl PC 
was equally suitable as [1- 
14 
C.] arachidonyl PC in this system of 
phospholipase A2 assay. 
6. Experiment 6. (Tables 5.6A and 5.6B) 
The results in Table 5.6A again confirmed that cholesterol- enriched 
rat platelets in PRP- liposome samples were more sensitive to collagen 
induced aggregation than control platelets. Six samples each of the 
resuspended control platelet sample and of the resuspended cholesterol 
enriched platelet sample were assayed for phospholipase A2 activity. 
The Ca concentration was raised to 0.4 mM to test 
whether any difference in phospholipase A2 activity was detectable 
under these conditions. Collagen was added to each sample at a final 
concentration of 2 pg /ml which was the concentration used in the previous 
two experiments. All samples aggregated irreversibly probably due to 
the high Ca2+ concentration used. The range of values obtained for 
per cent conversion in the two groups overlapped considerably, indicating 
no difference in phospholipase A2 activity under these conditions. 
5.3 Discussion 
In all six experiments, cholesterol- enriched platelets in PRP- 
liposome samples were consistently more sensitive to collagen induced 
aggregation than control platelets treated in the same way. The 
results for phospholipase A 
2 
activity suggest that there was no 
detectable difference in the activity of this enzyme in cholesterol - 
enriched platelets compared to control platelets, either when stimulated 
with collagen or unstimulated. The results obtained from the last 
three experiments (Tables5-4A -6B) regarding aggregation testing of 
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resuspended platelets show that the sensitivity of cholesterol -enriched 
platelets to collagen induced aggregation was reduced. This sensitivity 
was less than for control platelets treated in the same way. In samples 
of resuspended platelets tested for aggregation, the aggregation pattern 
was distinctly different from the normal pattern. The initial swelling 
phase, which is easily recognised in normal collagen induced aggregation 
traces, was lost. When aggregation occurred it was always irreversible. 
These results are in agreement with Manucci (1972), who showed that the 
aggregation pattern of resuspended platelets was altered in this way. 
It was possible that the resuspending procedure activated cholesterol - 
enriched platelets to a greater extent than control platelets. If this 
was the case, the cholesterol- enriched platelets would then become less 
responsive to stimuli, giving rise to the observed decreased aggregation 
extent. It remains a possibility therefore that the activity of 
phospholipase A2 would be diminished correlating with the decreased 
sensitivity to collagen. The level of phospholipase A2 activity detected 
by this method may therefore have been artificially low in the 
cholesterd- enriched platelets. No difference in phospholipase A2 
activity was detected in platelets .which were not stimulated, and as 
previously mentioned, it is possible that any difference in activity 
of this enzyme would occur when platelets were stimulated by agents 
inducing thromboxane synthesis. 
In view of these findings, it was considered that the method of 
phospholipase A2 assay in once resuspended platelets was unsuitable. 
Therefore an alternative method for phospholipase A2 assay was developed 
to avoid the problems encountered with resuspended platelets. The 
method developed involved using a crude platelet membrane fraction as a 
source of phospholipase A2 as described in Chapter 4. This method was 
subsequently used to investigate phospholipase A in human 
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platelet membranes (Chapter 7) and rat platelet membranes of various 
sterol compositions (Chapter 8). The technique of assaying for 
phospholipase A2 activity in once resuspended platelets was reinvestigated 
in freshly obtained platelets from rabbits (Chapter 6), in order to avoid 
the 3 hour incubation period used in the experiments described in this 
chapter which could be responsible in part for loss of platelet 
sensitivity. 
Chapter 6 
Investigations of Platelets from Rabbits 
Fed,a Cholesterol Rich Diet 
70. 
6.1 Introduction 
It is generally accepted that subjects with a high serum cholesterol 
level may be at greater risk of developing atherosclerosis than subjects 
with a normal serum cholesterol level (Marx, 1976). Altered platelet 
function has been implicated as a contributing factor in the development 
of thrombosis and atherosclerosis (see for example Colman, 1978; 
Lees and Carvalho, 1978). Carvalho et al. (1974a) investigated the 
function of platelets from type IIa hyperbetalipoproteinaemic subjects 
(type IIa) Subjects diagnosed with this disease have abnormally high 
serum levels of cholesterol and LDL (Lees et al., 1973) as discussed 
in Chapter 1. It was shown by Carvalho et al. (1974a) that platelets 
from type I:Ia subjects were more sensitive to aggregation induced 
in vitro with adrenaline, ADP and collagen than normal platelets. 
In a preliminary report by Bennett et al. (1974) and in a later 
report by Shattil et al. (1977) it was shown that platelets from type 
IIa subjects contained a cholesterol;phospholipid molar ratio 7 per cent 
higher than platelets from normal subjects. Platelets from type IIa 
subjects were shown to be hypersensitive to aggregation induced by ADP 
and adrenaline. 
Many researchers have investigated the pathogenesis of atherosclerosis 
using the approach of studying the disease induced in animal models. 
Some workers have induced atherosclerosis by mechanically damaging 
endothelial tissue in rats (Hornstra et al., 1973) and in rabbits 
(Weigensburg et al., 1975; Day et al., 1974). Other workers have 
attempted to induce atherosclerosis or thrombosis in animals by feeding 
them atherogenic diets. Thomas and Hartcroft (1959) fed rats a diet 
containing an abnormally high proportion of fats including cholesterol. 
Thiouracil and sodium cholate were included in this diet so that blood 
cholesterol levels would rise. The diet induced a signif icant increase 
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in the serum cholesterol level in these rats giving rise to a higher 
incidence of myocardial infarctions than in rats fed a normal diet. 
Frost (1969) fed rabbits a diet rich in cholesterol for 7 weeks. 
After this time, numerous platelets were observed to have adhered 
to the wall of the abdominal aorta in tissue sections prepared from 
the carcasses of these rabbits. Aortic sections prepared from rabbits 
fed a normal diet showed no signs of platelet adherence. 
The results of the studies just discussed show that dietary lipid 
composition influences the cholesterol level in the blood, and appears 
to affect platelet function. The finding that platelet activity was 
increased in a cholesterol -rich environment in animal models was 
consistent with the findings in hypercholesterolaemic human subjects. 
The studies in animal models discussed above did not however investigate 
platelet function in detail. 
Joist et al. (1976) induced hyperlipidaemia in rabbits by feeding 
them a diet enriched with egg yolk for 16 weeks. These workers showed 
that platelets from the hyperlipidaemic rabbits resuspended in Tyrode's 
albumin solution showed a significant increase in collagen and thrombin 
induced aggregation compared with similarly treated platelets from 
rabbits fed a control diet. The plasma cholesterol level was 617 mg/ 
1.00 ml compared to 17 mg/100 ml in control rabbits. In this 
investigation by Joist et al . , analysis of platelet cholesterol content 
was not carried out. It is not possible to determine therefore, 
whether the high serum cholesterol level influenced the platelet 
cholesterol content in vivo, and whether this might have been a factor 
influencing platelet function. In the light of evidence from Shattil 
et al. (1977) that platelets from human type i1a subjects had a raised 
cholesterol:phospholipid molar ratio, it was of interest in the present 
study to analyse platelets from animals with induced hypercholesterolaemia 
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to observe whether the platelet cholesterol content is influenced by the 
cholesterol level in the plasma environment. 
A clear indication of the effect on platelet cholesterol content of 
feeding animals a cholesterol -rich diet was reported by Yoshida et al. 
(1977). These workers fed a cholesterol -rich diet to guinea pigs for 8 
weeks and showed that platelets from animals fed this diet became 
increasingly sensitive to ADP induced aggregation during the dietary 
regimen compared to platelets from animalsmaintained on a normal diet. 
Yoshida et al. (1977) analysed platelets for cholesterol and phospholipid 
content. Calculation based on the results they presented show that 
cholesterol :phospholipid molar ratio of platelets from guinea -pigs fed 
the cholesterol diet was increased by approximately 40 per cent after 8 
weeks compared to platelets from the control group. The results 
presented by this group demonstrated that cholesterol feeding not only 
increased the serum cholesterol level, but also raised the platelet 
cholesterol content. The enhanced activity seen in the platelets from 
the cholesterol fed animals may in part be due to the cholesterol 
err ichment . 
Some researchers have attempted to explain why platelets become 
hyperactive in atherosclerosis. Srivastava (1974) studied the synthesis 
of prostaglandins (PGE1, PGE2, PGF) by platelets isolated from rabbits 
fed a normal diet. Since PGE1 is a potent anti -aggregating agent, and 
PGE2 is a mild pro -aggregating agent, Srivastava considered the 
possibility that the capacity of the platelet to synthesize these 
prostaglandins could be altered. In fact, no differences were detected. 
The results showed great variations in amounts of prostaglandins 
synthesized by platelets from individual rabbits within the same 
group, and this may have tended to hide any small differences that 
. could have existed between the two groups. More importantly, 
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the prostaglandins studied by Srivastava may play much less significant 
roles in platelet aggregation than thromboxane A2 which was identified 
more recently (Ramberg et al., 1974). It was shown by these workers 
that two orders of magnitude more thromboxane B2 (a degradation product 
of thromboxane A2), HHT and HETE were produced by human platelets than 
PGF2 
0. 
or PGE2 . 
More recently, research into atherosclerosis by the approach of 
studying animals fed a cholesterol -rich diet has focussed more closely 
on investigations into arachidonic acid metabolism. It has been shown 
that platelets synthesised the potent pro -aggregating agent thromboxane 
A2 from arachidonic acid (Ramberg et al., 1975). More recently, it was 
recognised that arachidonic acid was metabolised by arterial and venous 
tissues into a potent anti- aggregating agent,prostacyclin ( Moncada 
et al., 1976; Gryglewski et al., 1976; Moncada et al., 1977) . 
Researchers became more interested in arachidonic acid metabolism in 
atherosclerosis because it was suggested that there may exist an 
intricate balance between the synthesis of these two compounds (Bailey, 
1979). On the one hand, thromboxane A2 synthesised by platelets 
promotes aggregation and vasoconstriction, whereas prostacyclin 
synthesised by endothelial tissue prevents platelet clumping and 
reduces vasomotor tone thus inducing vasodilatation. 
Dembinska -Kiec et al. (1977) investigated the generation of prosta- 
cyclin by coronary vascular bed tissues isolated from atherosclerotic 
rabbits compared to these tissues isolated from normal rabbits. 
Atherosclerosis was induced by feeding a group of rabbits a normal diet 
supplemented with 1 per cent cholesterol, and prostacyclin production 
was significantly reduced in coronary vascular tissue from these 
animals compared to control animal coronary vascular tissue. These 
findings suggested that atherosclerosis induced by cholesterol feeding 
upset the intricate balance between production of thromboxane A2 and 
74. 
prostacyclin. Subsequently Zmuda et al. (1977) showed that platelets 
from atherosclerotic rabbits (induced by feeding a cholesterol -rich diet) 
were more sensitive to arachidonic acid induced aggregation, and that 
thromboxane A2 generation was increased compared to platelets from 
animals fed a normal diet. A more critical examination of arachidonic 
acid metabolism in cholesterol fed atherosclerotic rabbits was carried 
out by Gryglewski et al. (1978). Rabbits were fed a 1 per cent 
cholesterol diet for 5 months, and arachidonic acid induced aggregation 
of platelets in PRP was found to be increased at 3 months compared to 
platelets from control animals. Prostacyclin production induced with 
arachidonic acid in perfused hearts and spontaneous generation of 
prostacyclin by mesenteric arteries and aortae were strongly suppressed 
after 1 and 3 months from rabbits fed the cholesterol- enriched diet 
compared to normal control rabbits . Platelet sensitivity to the pro- 
aggregating action of ADP and to the anti -aggregating action of 
prostacyclin was increased after 1 month on the cholesterol- enriched 
diet. Gryglewski suggested therefore that the first stage of athero- 
sclerosis may be casually related to the strong suppression of prostacyclin 
generation by arteries, whereas arachidonic acid metabolism in platelets 
remains unchanged. Gryglewski also suggested that in the early stage of 
atherosclerosis the increased susceptibility of platelets to ADP and 
prostacyclin may be due to the lowering of cAMP levels in platelets 
as a consequence of prostacyclin deficiency. Dembinska -Kiec et al. 
(1979) have investigated further platelets from atherosclerotic rabbits. 
These workers showed that intact platelets from atherosclerotic rabbits 
(induced by cholesterol diet) synthesised more thromboxane B2 and HJlE 
than platelets from normal rabbits when incubated with [14C] arachidonic 
acid. No difference was found in the synthesis of these metabolites by 
platelet homogenates from normal and atherosclerotic animals. 
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These results suggested that the pathway synthesising thromboxane A2 from 
arachidonic acid is more active in whole platelets from atherosclerotic 
rabbits compared to whole platelets from normal rabbits. This may reflect 
enhanced activities of the cyclo -oxygenase and thromboxane synthetase 
enzymes. The increased HETE production also observed indicated an 
enhanced lipoxygenase activity. 
In the four studies discussed above, there are several important 
points with regard to the present study. In all the experiments discussed 
above (Dembinska -Kiec et al., 1977; Zmuda et al., 1977; Gryglewski 
et al., 1978; Dembinska -Kiec et al., 1979) this research team have fed 
rabbits a diet supplemented with 1 per cent cholesterol, and athero- 
sclerosis was confirmed by post mortem examination. However, neither 
blood cholesterol levels, nor the cholesterol content of platelets were 
monitored during these experiments. In all the studies in platelets of 
metabolism of arachidonic acid, exogenous arachidonic acid was added to 
platelet preparations. The release of arachidonic acid from platelet 
phospholipids is considered to be a critical step in the generation of 
thromboxane A2 (Blackwell et al., 1977). In the studies discussed above 
this reaction has not been tested, so it is not possible to say whether 
the platelets from atherosclerotic rabbits were capable of synthesising 
greater quantities of thromboxane A2 derived from membrane phospholipids 
containing arachidonic acid when compared to platelets from normal 
rabbits. 
In the many animal studies reported, few researchers have considered 
the possible importance of a raised blood cholesterol level which may 
lead to a raised cholesterol content in the blood platelets in these 
animals. Investigations into the release of arachidonic acid from 
platelet phospholipidshave not previously been carried out. The present 
chapter therefore reports experiments carried out on platelets from 
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rabbits fed either a cholesterol supplemented diet or a normal diet, 
in order to answer some of the problems discussed above. These were: 
1. Whether hypercholesterolaemia in rabbits gives rise to 
platelets enriched with cholesterol. 
2. Whether platelets from hypercholesterolaemic rabbits show 
altered phospholipase A2 activity. 
3. Whether these platelets can synthesise more thromboxane A2 
than platelets from rabbits fed a normal diet. 
6.2 Summary of Investigations 
These experiments were carried out in the laboratory of Dr. M. Johnson 
at ICI Pharmaceuticals Division. Lop -eared rabbits weighing approximately 
3 kg were divided into two groups. One group of 3 rabbits were fed a 
normal diet, while another group of 9 rabbits were fed the same diet 
supplemented with 0.5 per cent cholesterol. The dietary regimen was 
maintained for 35 days. 
1. Blood samples were taken once a week from each rabbit to assay 
the serum cholesterol content. 
2. After 27 -29 days, blood samples were taken from rabbits for 
the following investigations: 
a) Platelets were analysed for cholesterol and phospholipid content; 
b) Aggregation was tested in PRP samples; 
c) Platelet MDA production was assayed by the method of Stuart 
et al. (1975); 
d) Thromboxane A2 production by platelets was assayed by bioassay. 
Rabbits were used for this cholesterol feeding experiment because 
hypercholesterolaemia was easily induced in these animals by dietary 
means. Rats were found not to be suitable for cholesterol feeding 
experiments. Platelets. isolated from rats fed a diet supplemented 
with 1 per cent cholesterol were found to have a cholesterol :phospholipid 
molar ratio which was the same as platelets from rats fed a normal diet. 
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6.3 Serum Cholesterol and Platelet Analysis 
Blood was taken weekly and assayed for serum cholesterol content by 
Mrs. S. Jones. Blood samples (1 ml) were allowed to clot and serum 
cholesterol was determined by an automated technique using the cholesterol 
oxidase assay method as described in Chapter 2. Table 6.1 shows that 
there was a significant difference in serum cholesterol levels between 
control and cholesterol -fed rabbits within 7 days of commencement of diet. 
Samples of platelets were prepared for analysis after 27 -29 days of 
the dietary regimen. On the 27th, 28th and 29th day, 50 ml of blood was 
taken from 1 control and 3 cholesterol fed rabbits for preparation of 
platelets for investigation. Samples of platelets were taken from the 
same blood sample for analysis of cholesterol and phospholipid. 
Table 6.2 shows that the cholesterol:phospholipid molar ratio was 
significantly higher in platelets from the cholesterol -fed group of 
rabbits. This result is in agreement with the results of Yoshida et al. 
(1977) in cholesterol -fed guinea-pigs. 
6.4 Aggregation Studies 
Samples of platelets in PRP were prepared from blood taken from each 
animal and were tested for aggregation in response to collagen. The 
results showed great variation of response in samples from different 
rabbits within the same group, and so no difference in either the extent 
or rate of aggregation of platelets from hypercholesterolaemic and 
normal rabbits could be detected. Zmuda et al. (1977) had reported 
enhanced sensitivity of PRP samples from atherosclerotic rabbits to ADP. 
Thus enhanced sensitivity of PRP samples from cholesterol -fed rabbits 
might have been expected in these experiments. Joist et al. (1976) 
showed that platelets from hypercholesterolaemic rabbits when resuspended 
in Tyrode's albumin buffer showed enhanced aggregation to collagen. 
It was possible therefore that the altered plasma lipid environment may 




(DAY-12. Control diet Cholesterol -enriched diet P 
(n =3) + (n =9) + L 
0 26.7 -2.9 25.8 -2.63 N.S. 
7 26.3 -1.5 174 - 35 0.05 
14 35.0 -4.0 314 52 0.02 
21 31.0 -4.0 405 - 72 0.02 
27 -29 34.0 -4.7 488 -104 0.05 
35 26.0 -8.5 835 97 0.001 
All results are shown - S.E.M. p values were calculated using 
students t -test. 






(n = 3) 
Cholesterol diet P 
(n = 9) 
0.621 -0.047 0.755 -0.028 0.05 
Cholesterol and phospholipid were assayed by the standard 
techniques as described in Chapter 2. 
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have interfered with the mechanism by which collagen stimulated platelets 
to aggregate in rabbit PRP thereby masking any difference in aggregability, 
and this effect may be absent in resuspended rabbit platelets. 
6.5 Phospholipase A2 Assays 
Phospholipase A2 activity was assayed using the technique described 
in Chapter 4 for once resuspended cells to determine whether the activity 
of this enzyme was altered in platelets from hypercholesterolaemic 
rabbits. It was shown previously that phospholipase A2 activity could 
be detected in once resuspended rat platelets (Chapter 4), but that no 
difference in activity could be detected when platelets were enriched 
with cholesterol by the in vitro method compared to control platelets 
(Chapter 5). In these rat platelet phospholipase A2 studies (Chapter 5), 
[1 -14C] oleoyl PC was used as the phospholipase A2 substrate. In the 
present rabbit platelet study [ 1 -14C ] arachidonyl PC was used because it 
was considered possible that [1 -14C] oleoyl PC may not be a suitable 




C] arachidonoyl PC would not be available to phospholipase C 
catalysed hydrolysis as the substrate for this enzyme is thought to be 
specifically phosphatidylinositol (Lapetina et al., 1980). Further 
metabolism of arachidonic acid by the platelets was restricted by the 
fatty acid free albumin incorporated in the resuspending buffer which 
was included to sequester the released fatty acid. 
Indomethacin was used in the phospholipase A2 assays to inhibit 
cyclo -oxygenise activity which may'metabolise the released arachidonic 
acid. Jesse and Franson (1979) showed that partially purified platelet 
phospholipase A2 activity was 50 per cent inhibited in the presence of 
75 pM indomethacin. 10 pM indomethacin was used in the present 
experiments, a concentration where inhibition of phospholipase A2 
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activity was minimal (see Jesse and Franson, 1979). Siegel et al. 
(1979) have shown that indomethacin can affect platelet lipoxygenase 
activity, in that arachidonic acid could be directed toward this pathway 
away from the cyclo -oxygenase pathway. However, at a concentration of 
10 pM indomethacin, the results of Siegel et al. (1979) indicate little 
or no change in lipoxygenase activity, whereas at 100 pM indomethacin, 
there may be a considerable increase in lipoxygenase activity. Blackwell 
et al. (1977) had reported previously that indomethacin did not inhibit 
phospholipase A2 activity at a concentration of 100 pM indomethacin in 
platelet homogenates. Indomethacin at a concentration of 10 pM used 
in the present work was therefore considered unlikely to interfere 
with phospholipase A2 activity. 
Phospholipase A2 activity was assayed in platelet samples prepared 
from rabbits after 27 -29 days on the dietary regimen. These were either 
stimulated with collagen or unstimulated (see Table 6.3). Platelet 
concentrations were adjusted so that the platelet counts were 
approximately the same in the two groups tested. The results show that 
there was a significantly enhanced phospholipase A2 activity on 
stimulation with collagen in platelets from cholesterol -fed rabbits 
compared to platelets from normal rabbits. There was no difference 
in the activity of this enzyme between the two groups in unstimulated 
platelets. The results suggest therefore that an enhanced phospholipase 
A2 activity was detectable only when the platelets were stimulated. 
The background unstimulated activity may be slightly higher in 
cholesterol -fed rabbit platelets, but the difference was not significant 
in these stùdies. 
Table 6.4 shows results for a further phospholipase A2 assay which 
was carried out on the 35th day of the dietary regimen. Platelet samples 
were prepared from the 6 cholesterol fed rabbits which had the highest 
Table 6.3. Phospholipase A2 activity of rabbit platelets after 
27 -29 days of dietary regimens 
Control diet 
(n = 3) 
Cholesterol diet 
(n = 9) 
Phospholipase A2 activity 
Stimula ted 
Unstimulated % conversion (2 pg/ml collagen) 
0.27 -0.23 0.10 -0.021 
1.14-0.50 1.26-0.256 
p < N.S. 0.05 
Phospholipase A2 assays were carried out on platelets resuspended 
once in modified Tyrode's buffer containing fatty acid free albumin 
(3.5 mg/ml), glucose (5 mM), [Ca 
2+ 
] (0.2 mM) pH 7.4. [ 1-14C ] 
arachidonçyl PC was added to 0.5 ml platelet sample and stirred in 
the aggregometer. After 1 min, collagen was added to stimulate the 
platelets, or buffer was added. The incubation was terminated after 
10 min as described in Chapter 4. Phospholipase A2 activity is 
expressed as per cent conversion of [1 -14C] arachidonyl PC to 
[l -14C] arachidonic acid. All platelet samples of 0.5 ml contained 
8 2.2 x 10 platelets. 
Table 6.4. Phospholipase A2 activity of rabbit platelets after 
35 days of dietary regimen 
Control diet (n = 3) 
Cholesterol diet (n = 6) 






Platelet samples (0.5 ml) were stimulated with 4 pg /ml collagen 
[Ca2 
+J 
= 0.4 mM. 
Control 
8 
platelet samples contained 1.58 x 10 ml. 
Platelet samples from cholesterol -fed rabbits contained 
1.66 x 10 
8 
platelets /0.5 ml. 
Legend as for Table 6.3. 
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serum cholesterol levels, and from the 3 control rabbits. Higher concen- 
trations of Ca 
2+ 
and collagen were used in an attempt to stimulate the 
phospholipase A2 activity to show greater conversion of substrate to 
product, and to increase the difference in activities observed in the 
previous assay. No significant difference was detected between the 
two groups, but the activities, given as per cent conversion, were 
increased slightly in both groups compared to the assays carried out 
during days 27 -29. The low activity suggests that there may be 
restriction of availability of substrate to the enzyme. 
In the phospholipase A2 assay carried out on the 35th day, it was 
observed that in 3 of the 6 samples of platelets from cholesterol -fed 
rabbits tested, aggregation of the platelets took place on addition of 
collagen even though indomethacin was present. This did not occur in 
any of the control samples. This suggests the possibility that some 
arachidonic acid was available for further metabolism to prostaglandins 
and thromboxanes, but this would not be expected to give artificially 
low conversions of substrate to product. Metabolites of arachidonic 
acid would be located in the fatty acid peak in the tic system used 
for separation of [1 -14CJ arachidonoyl PC and 1 -14C3 arachidonic acid. 
6.6 Metabolism by Platelets of Exogenous Arachidonic Acid 
These assays were performed on platelet samples prepared from 
blood on the 27th -29th day of the dietary regimen. Platelet samples 
were tested for arachidonic acid metabolism in two ways: 
1. MDA production was assayed by the method of Stuart et al. 
(1975) . 
2. Thromboxane A 
2 
production was assayed by bioassay by the method 
described in Chapter 2. These two assays were carried out by 
Dr. M. Johnson. 
Table 6.5. Thromboxane A2 assay of rabbit platelets after 27 -29 days 
of dietary regimen 
Control diet (n = 3) 
Cholesterol diet (n - 9) 
P 





Thromboxane A2 production was induced in PRP samples by the 
addition of arachidonic acid (3.0 x 10 -4M). 
For details of method see Chapter 2. 
Table 6.6. MDA production by rabbit platelets after 27 -29 days 
of dietary regimen 
Unstimulated Stimulated 




(n = 9) 
(nmol /109 platelets) 
1.72 -0.19 6.42 -0.326 
2.37 -0.23 8.15 -0.579 
0.05 0.05 
Stimulation of the samples was by the addition of arachidonic 
acid (1 x 10 -3M). 
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The results obtained from these assays are shown in Tables 6.5 and 
6.6 respectively, and clearly indicate that the arachidonic acid 
metabolic pathway was more active in the platelets from the cholesterol - 
fed rabbits. MDA production is considered to be a good index of the 
activity of the prostaglandin synthesising pathway in platelets (Smith 
et al., 1976). It has been reported to be produced by platelets during 
secondary aggregation (Macfarlane et al., 1977) and MDA formation is 
catalysed by the activity of thromboxane synthase (McMillan et al., 1978). 
6.7 Discussion 
The results from the present investigation showed that: 
1. Rabbits fed a 0.5 per cent cholesterol supplemented diet 
developed significantly increased serum cholesterol levels. 
2. Platelets from the hypercholesterolaemic rabbits had a raised 
cholesterol :phospholipid molar ratio. The ratio was 21.6 per cent 
higher than in platelets from rabbits fed a normal diet. 
3. Platelets from the hypercholesterolaemic rabbits showed 
enhanced phospholipase A2 activity under certain specific conditions. 
4. Platelets from the hypercholesterolaemic rabbits showed 
enhanced metabolism of exogenously added arachidonic acid to thromboxane 
A2 and MDA compared to platelets from rabbits fed a normal diet. 
The phospholipase A2 activity was significantly increased in 
platelets from hypercholesterolaemic rabbits when stimulated with 
collagen at a final concentration of : 2 pg/ml in the presence of 0.2 mM 
Ca2 +. In unstimulated platelets there was no significant difference 
in phospholipase A2 activities. Phospholipase A2 assays were repeated 
on the 35th day of the dietary regimen under different conditions 
(Table 6.4). Collagen was added to a final concentration of 4 pg /ml 
in the presence of 0.4 mM Ca2 +. The phospholipase A2 activities were 
stimulated to the same extent in both the normal and cholesterol -rich platelets. 
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This suggests that the conditions used in the latter experiment stimulated 
the enzyme superoptimally, thus obscuring any subtle differences. 
Since this investigation was carried out, a similar study has been 
reported by Kawaguchi et al . (1981 ). These workers fed rabbits a diet 
supplemented with 1 per cent cholesterol for 3 months. The investigations 
carried out on platelets from these animals included 1) assay of 
thromboxane B2 production 2) assay of phospholipase A2 activity 
3) assay of phospholipase C and diacylglycerol lipase activities and 
4) assay of cholesteryl esterase activity. Some of the results from 
the study by Kawaguchi et al. confirm some of the findings reported in 
this chapter. These include the increased production of thromboxanes 
from arachidonic acid by platelets from hypercholesterolaemic rabbits 
compared to those from control rabbits. Also, the cholesterol fed 
rabbits showed a markedly increased plasma cholesterol level (745 mg/ 
100 ml) compared to control rabbits (78 mg /100 ml blood). Kawaguchi 
et al. assayed for the cholesterol content of platelets, and showed 
that platelets from the hypercholesterolaemic rabbits contained 3 times 
as much cholesterol as normal control platelets. These workers did not 
specify whether this result was for total cholesterol or unesterified 
cholesterol, although it can be assumed that these results relate to 
total cholesterol. Kawaguchi et al. therefore did not report whether 
platelet membrane unesterified cholesterol content was altered; 
a result which would have been of interest to the present study. 
As mentioned above, Kawaguchi et al. assayed for cholesteryl esterase 
activity and also for cholesterol hydrolase activity. They showed 
that esterification of cholesterol was enhanced, and hydrolysis of 
cholesterol esters was reduced in platelets from hypercholesterolaemic 
rabbits compared to platelets from control rabbits. These results 
probably explain the finding of increased total cholesterol content 'in 
these platelets. 
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Kawaguchi et al. carried out assays to determine the activity of 
enzymes catalysing the hydrolysis of platelet membrane phospholipids 
to release arachidonic acid. Their results showed that there were no 
differences in either phospholipase A2 activity, or phospholipase C/ 
diacylglycerol lipase activities between platelets from normal and 
hypercholesterolaemic rabbits. In the present study reported in this 
chapter, a significant increase in phospholipase A2 activity was observed 
in cholesterol rich rabbit platelets and it is therefore necessary to 
review and compare the technique used for the assay of this enzyme 
described in this chapter and the technique described by Kawaguchi et al. 
In the phospholipase A2 assay described by Kawaguchi et al., one 
of two substrates was used. This was either [l -14C ]arachidonyl PC or 
platelets prelabelled with [ 1 -14C ]arachidonic acid. The prelabelling 
was achieved by a combination of the methods described by Rittenhouse - 
Simmons et al. (1976) and Bills et al. (1976). When [1 -14C] arachidonyl 
PC was used in the incubation system, carrier PC was also included. 
Buffer was added to these dry lipids and the mixture sonicated. 
The reaction was started by the addition of sonicated platelets. 
The final mixture (1 ml) contained 0.05M glycine -NaOH buffer (pH 9.5), 
10 m11í CaC12 , 200 nmol of substrate and carrier PC, and 1 mg of 
protein from sonicated platelets. Where assays were carried out using 
labelled platelets as substrate, 10 jig of adrenaline was added to the 
incubation system. 
In their assays using 
14 
C] arachidonyl PC as substrate for 
phospholipase A2, Kawaguchi et al. showed that the per cent release 
of radioactivity (due to [1 -14C] arachidonate) in the control and 
hypercholesterolaemic rabbit platelets after 10 min was 22.6 and 22.9 
respectively, and after 20 min was 36.0 and 35.0 respectively. 
These results indicated that there was no difference in phospholipase A2 
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activity between platelets from the two groups. The conditions used in 
the assay by Kawaguchi et al. described above are different in many 
respects from the conditions used in the assays described and used in 
this thesis. Kawaguchi et al. used a pH of 9.5 as opposed to 7.4 in 
the present project. This high pH is known to be optimal for 
phospholipase A2 activity (Billah et al., 1980), and would possibly 
2+ 
stimulate the enzyme. The concentration of Ca used by Kawaguchi 
et al. was 10 mM, another factor likely to stimulate the enzyme. 
The effect of a large quantity of substrate used by Kawaguchi (approx- 
imately 1.5 mg of exogenous phospholipid added to 1 mg of platelet 
protein as opposed to approximately 8 pg per mg used in the present 
project) on the activity of the enzyme is unknown. It could be that 
so much substrate enhances the activity of the enzyme. In the assays 
carried out by Kawaguchi et al. using [1 -14C] arachidonyl PC as substrate, 
it is very likely that the phospholipase A2 was stimulated super - 
optimally, thereby obscuring any subtle differences in activity between 
different samples. The results presented from the work carried out in 
this chapter using slightly different conditions to assay for phospho- 
lipase A2 activity strongly suggests that differences in activity of 
this enzyme may only be observed under very specific conditions 
(see Tables 6.4 and 6.5). Kawaguchi et al. stated that when platelets 
prelabelled with [1 -14C ]arachidonic acid were used as substrate for 
the phospholipase A2 assay, "the total amount of radioactive arachidonic 
acid released showed almost no change between control and hyper - 
cholesterolaemic platelets ". The data these workers presented does 
not support this statement. Firstly, the proportion of the total 
[1 -14C ] arachidonic acid incorporated into the phospholipids PC and PI 
were different in the two kinds of platelets. Of the radioactivity 
incorporated, 47.2 per cent was located in PC in normal platelets, 
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whereas 61.7 per cent was located in PC in hypercholesterolaemic 
platelets. Also, incorporation of radioactivity into PI was 17.5 
per cent and 7.5 per cent respectively. Secondly, after incubation 
of prelabelled platelets with adrenaline for the assay of phospholipase 
A2 activity, the radioactivity located in PC was 17.9 and 26.1 per cent, 
and the radioactivity in PI was 16.2 per cent and 5.2 per cent in 
control and hypercholesterolaemic platelets respectively. 
These results suggest that the extent of incorporation of [1 -14C] 
arachidonic acid into these two phospholipids is different in the two 
types of platelets. By calculation, the proportion of [1 -14C] 
arachidonic acid released from PC was 29.3 per cent in control platelets, 
and 35.6 per cent in hypercholesterolaemic platelets. Also, the 
proportion released from PI was 1.3 and 2.3 per cent respectively. 
It remains unknown whether these differences were significant but 
clearly it is extremely difficult to compare phospholipase A2 activities 
in prelabelled platelets when the rate of incorporation of the fatty 
acid is different between the two types of platelets. 
In view of the results presented in this chapter, that hyper - 
cholesterolaemic rabbit platelets showed an increased cholesterol: 
phospholipid molar ratio and enhanced phospholipase A2 activity under 
specific conditions, experiments were carried out on human platelets 
(Chapter 7). This was carried out to determine whether platelets 
from hypercholesterolaemic subjects had a raised cholesterol content, 
and whether these platelets showed enhanced phospholipase A2 activity. 
Phospholipase A 
2 
assays were carried out on crude human platelet 
membrane fractions (Chapter 7) and rat platelet membrane fractions 
(Chapter 8), because it was shown that the per cent conversion of 
substrate to product could readily be detected (Chapter 4) in membrane 
preparations. It was preferred that the per cent conversion should 
be higher than detected with resuspended rabbit platelets as reported 
in this chapter. 
Chapter 7 
Investigation of Human Platelets 
86. 
7.1 Introduct ion 
Cooper (1969) studied the sera and red cells of 3 patients with 
severe liver disease. He described the red cells as "spur cells ". 
The term "spur cell" has been applied to these bizarre red cells to 
describe their unusual thorny projections and to distinguish them 
from the morphologically similar but chemically dissimilar acanthocytes 
seen in patients with abetalipoproteinaemia (Ways et al., 1963). 
Cooper (1969) observed that the unesterified cholesterol content of 
spur cells was on average 52 per cent higher than in normal red cells 
from normal subjects. He reported that the cholesterol content of 
normal red cells incubated in spur cell serum increased and they took 
on a spur cell like appearance. Conversely spur cells incubated in 
normal serum lost cholesterol and took on a normal red cell appearance. 
It was apparent that red cells served as a repository for cholesterol 
which was at a high concentration in the blood in these subjects. 
Cooper suggested that the cholesterol taken up by the red cells was 
initially loosely bound to serum lipoproteins. 
In a further investigation, Cooper et al. (1972) carried out an 
analysis of lipoproteins and red cell membranes from patients with 
liver disease. They shaved that there was no correlation between 
serum cholesterol concentration and red cell content of free cholesterol. 
However they observed a close relationship between red cell and serum 
(or isolated LDL) free cholesterol content when each was considered 
relative to phospholipid. Spur cells were considered to be red cells 
which took up cholesterol in amounts relative to the cholesterol: 
phospholipid molar ratio of the serum. 
Cooper et al. (1975) undertook to establish an artificial system 
that reproduced the cholesterol disproportion in the serum of patients 
with spur cells in order to study this factor in the absence of other 
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possible influencing factors. These workers prepared cholesterol - 
phospholipid dispersions (as discussed in Chapters 1 and 3). They 
shaved that when normal red cells were incubated with cholesterol -rich 
dispersions they developed spur cell -like morphology concomitant with 
becoming enriched with cholesterol. Cooper et al. also showed in the 
same study that incubation of spur cells in a cholesterol- depleted 
medium gave rise to red blood cells which were morphologically normal 
and which had a normal cholesterol content. In a more recent study, 
Cooper et al. (1978) showed that the membrane fluidity of red cells 
was decreased as a result of cholesterol enrichment by this in vitro 
technique. 
Human subjects with familial hyperbetalipoproteinaemia (type lla) 
are at higher risk than normal subjects to severe early-age atherosclerosis 
(Lees et al., 1973). Type lla subjects are recognised as having an 
elevated blood cholesterol level. These subjects may have xanthomatosis 
(the appearance of fat- containing lesions in the skin and subcutaneous 
tissues) and this often occurs in the Achilles tendon region. Grayish 
opacification may be observed at the corneal limbus in young adult type 
lla subjects. This is described as arcus corneae (Lees et al., 1973). 
Both altered platelet function and a high blood cholesterol level have 
been implicated as factors in the pathogenesis of atherosclerosis and 
ttr ombosi s (Davignon, 1978; Steinberg, 1978). It was shown that 
platelets from type lla subjects were more sensitive to the aggregating 
agents adrenaline, ADP and collagen when compared to platelets from 
normal subjects (Carvalho et al., 1974a; Shattil et al., 1977). 
It appeared from the latter study that there was a good correlation 
between the proportion of cholesterol to phospholipid in the serum LDL 
and in the platelets in the subjects examined. However the cholesterol 
to phospholipid molar ratio was not altered in red cells in the type lla 
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subjects of the study by Shattil et al. (1977) and this suggested that a 
simple cause and effect relationship did not appear to exist for the red 
cell cholesterol content. It has been reported that platelets from 
type lla subjects were capable of synthesising greater quantit ies of 
thromboxane A2 than normal platelets (Colman, 1978; Tremoli et al., 
1979a), and of showing enhanced platelet factor 3 availability (Nordoy 
and Rodset, 1971). In the studies carried out by Tremoli et al. 
(1979a) and by Nordoy and Rodset (1971) raised plasma cholesterol levels 
were reported in the type lla subjects examined. However, in neither 
of these studies were platelet cholesterol levels determined, therefore 
it remained unknown whether a raised platelet cholesterol to phospho- 
lipid molar ratio was in part responsible for the observed hyperactivity 
of platelets from type lla subjects. 
Ina recent study, Shastri et al. (1980) confirmed that platelets 
from type lla subjects were hyperactive to the aggregating agents 
adrenaline, ADP and collagen. These subjects had a raised plasma 
cholesterol level compared to control subjects, but they reported that 
platelet cholesterol content was not significantly higher than that 
found in normal platelets. It was not clear from the study by Shastri 
et al. (1980) whether the proportion of cholesterol to phospholipid 
was elevated in the plasma of the type lla subjects examined which, 
as discussed above, may be an important factor in influencing the 
cholesterol : phosphol ipid molar ratio in the platelets. 
Most recently, Owen et al. (1981) studied the lipid composition and 
aggregation of platelet from human subjects with liver disease. These 
workers showed that the choler tero 1; phos phol ipid molar ratio was raised 
by 13 per cent in the platelets from these patients compared to 
platelets from normal healthy subjects. The cholesterol content was 
also raised in erythrocytes from the subjects with liver disease. 
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No plasma cholesterol determinations were reported from this study by 
Owen et al. (1981), but the subjects with liver disease may have had 
high blood cholesterol levels and whether this would have influenced 
the cholesterol content of platelets and erythrocytes remains unknown. 
These workers carried out aggregation studies and showed that platelets 
from subjects with liver disease (with raised cholesterol content) 
were not more sensitive than normal platelets and in some cases were 
less sensitive. Platelets from patients were found to contain 
proportionately leas arachiáonic acid and the phosphatidylcholine: 
sphin5omyelin ratio was raised compared to normal platelets. These 
two factors may have influenced platelet aggregating ability, and any 
hypersensitivity due to increased cholesterol content may have been 
masked by these and other differences in platelet composition. 
As has been discussed in Chapter 1, Shattil et al. (1975) showed 
that the proportion of cholesterol to phospholipid in platelets could 
be increased in vitro, and the result of this treatment was to induce 
hypersensitivity to ADP and adrenaline stimulated aggregation. Platelet 
membranes enriched with cholesterol in this way had increased micro - 
viscosity (Shattil and Cooper, 1976) and further investigations 
suggested the possibility that cAMP production in these platelets may 
be enhanced (Sinha et al., 1976; Insel et al., 1978). 
In attempts to normalise the sensitivity of platelets from type lla 
subjects, clofibrate administration to these subjects and the resultant 
effect on platelet function has been investigated by Carvalho et al. 
(1974b). These workers showed that clofibrate therapy resulted in 
platelets isolated from type lla subjects requiring the same minimum 
concentration of adrenaline to give a full aggregation response as for 
normal control platelets. The effect of halofeaate was also investigated. 
It was found to be more potent in its effect than clofibrate, 
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and normalised the sensitivity of platelets from type lla subjects to 
the aggregating agents ADP, adrenaline and collagen (Colman et al., 
1976). It was subsequently shown that halofenate therapy did not 
inhibit arachidonic acid induced aggregation or MDA production by 
platelets from type lla subjects (Favis and Colman, 1977). Thus 
halofenate possibly acted by inhibiting mechanisms involved in the 
release of arachidonic acid from platelet phospholipide. This suggests 
the possibility that increased thromboxane A2 production by type lla 
platelets may be due to an increased rate of hydrolysis of arachidonic 
acid from platelet membrane phospholipids, this reaction being considered 
by some researchers to be an important rate limiting step in the 
metabolism of arachidonic acid (Blackwell et al., 1977). 
In view of the findings discussed above, and the observations 
that platelets from hypercholesterolaemic rabbits had an increased 
cholesterol :phospholipid molar ratio which showed enhanced phospholipase 
A2 activity (Chapter 6), a study was undertaken to examine platelets 
isolated from human hyperlipidaemic subjects and were compared to 
platelets from normal subjects. This study was carried out in the 
laboratory of Dr. M. Johnson at ICI Pharmaceuticals Division in 
collaboration with Dr. M. Stone at the Leigh Health Centre. Before 
this trial was carried out, experiments were carried out in Edinburgh 
to alter the cholesterol content of human platelets by the in vitro 
method described by Shattil et al. (1975) (see Chapter 3) . 
7.2 Cholesterol Enrichment and Depletion of Human Platelets In Vitro 
Human blood was kindly provided by donors at the Blood Transfusion 
Service (BTS), Royal Infirmary of Edinburgh. Units of blood were 
collected under standard BTS conditions. These units of blood were 
tested for hepatitis B antigen by Dr. R. Hopkins prior to any 
experimentation. PRP was generally prepared within 2 -3 hours after 











Tyrode's incubated 0.595 ±0.021 0.071 ±0.003 0.250 1'0.019 
Cholesterol depleted 0.462 10.016 0.053-F0.001 0.232 10.012 
Cholesterol normal 0.565 1-0.027 0.0631-0.004 0.245 ±0.01 
Cholesterol enriched 0.656 ±0'.012 0.0821-0.003 0.250 1-0.021 
Samples of human PRP (5 ml) were incubated for 3 hrs at 37 °C with 
an equal volume of either modified Tyrode's buffer, cholesterol -poor 
liposomes, cholesterol -normal liposomes, or cholesterol -rich liposomes 
prepared as described in Chapter 2. 
Results show means ± S.E.M. of 4 experiments. Significance was 
calculated using students t -test. This showed that:- 
1) The cholesterol:protein ratio in the cholesterol -depleted 
platelets was significantly reduced compared with Tyrode's incubated 
control platelets (p< 0.01), and significantly reduced when compared 
with control platelets incubated with cholesterol -normal liposomes 
(p<0.05). Cholesterol enriched platelets showed a significantly 
increased cholesterol:protein ratio compared with Tyrode's incubated 
controls (p < 0.05) and control platelets incubated with cholesterol - 
normal liposomes (p< 0.001). 
2) The cholesterol:phospholipid ratio was significantly reduced 
in cholesterol depleted platelets compared with Tyrode's incubated 
controls (p< 0.01) and liposome incubated control platelets (p< 0.05). 
Cholesterol enriched platelets showed a cholesterol:phospholipid ratio 
which was significantly increased compared to both liposome incubated 
control platelets (p< 0.05) and Tyrode's incubated control platelets 
(p <0.05). 
Figure 7.1. Aggregation of human platelets after 5 hrs incubation with 
liposomes to alter platelet cholesterol content 
Traces show aggregation induced by ADP (0.2 pL4). 
Trace A shows irreversible aggregation of cholesterol- enriched platelets. 
Trace B shows slow irreversible aggregation of control- (cholesterol- 
normal) pla tele is . 
Trace C shows reversible aggregation of cholesterol- depleted platelets. 
Figure 7.1. 
I 1 min 
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blood collection, and samples were incubated with liposome suspensions to 
alter platelet cholesterol content as described for rat PRP in Chapter 3. 
Table 7.1 shows mean results for analysis of human platelets from 3 
experiments to deplete and increase the proportion of cholesterol to 
phospholipid. Figure 7.1 shows traces obtained from one experiment where 
PRP- liposome samples were stimulated to aggregate with 0.2 jil ADP. 
This concentration of ADP was selected to clearly show the differences 
in sensitivity of platelets of different cholesterol content. Figure 7.1 
(trace B) shows that control platelets were only just sufficiently 
stimulated to induce 2nd wave aggregation. Cholesterol- depleted 
platelets (trace C) were stimulated by the same dose of ADP, and under- 
went rapid reversible primary aggregation. Cholesterol -rich platelets 
(trace A) were observed to readily aggregate irreversibly. These 
results confirm the findings of Shattil et al. (1975) that platelet 
sensitivity was correlated with their cholesterol content. 
7.3 Study of Platelets from Normal and Hyperlipidaemic Subjects 
1. Phospholipase A2 studies in human platelet membrane preparations 
In the study of platelets from human subjects, phospholipase A2 
assays were carried out on crude platelet membrane preparations. Two 
preliminary investigat ions were carried out on normal human platelets 
prior to the main study to determine the suitability of the assay. 
These experiments were carried out at ICI Pharmaceuticals Division. 
Human platelet membrane fractions were prepared by the method of Wong 
and Cheung (1979) as described for rat platelets in Chapter 4. 
Phospholipase A2 assays were carried out on membrane fractions rather 
than resuspended platelets in view of the low activities found in 
preparations of resuspended rabbit platelets (Chapter 6). The substrate 
used for the assay was [1- 
14 
C ] oleoyl PC rather than [1 -14C] 
arachidonyl PC, in order to exclude the possibility of influence of 
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arachidonic acid metabolites on phospholipase A2 activity. The incubation 
period used was 35 min at 37 °C and 1 ml samples contained 300 pg of 
membrane protein, 2.0 mM Ca 
2+ 
and fatty acid free albumin (0.5 mg/ml ) 
in tris HC1 buffer pH 9.0. This incubation system was the same as 
described for use with rat platelet membranes in Chapter 4. An incubation 
period of 35 min was used to provide optimal conditions for detection of 
phospholipase A2 activity. 
In the first experiment, PRP samples were left to stand for 11 hours 
at 20 °C. The purpose of this was to simulate the treatment the samples 
would receive during the experimental procedure in the main study of 
platelets from hyperlipidaemic subjects. This was the period of time 
it was anticipated it would take after venepuncture before processing 
of samples for preparation of membrane fractions. In this first 
experiment, the phospholipase A2 activity was very low. The mean 
conversion of [1 -14C oleoyl PC to Li -140] oleate was less than 3 per cent 
in triplicate samples. In the second preliminary experiment, PRP was 
processed for preparation of membrane fractions within 30 min of 
venepuncture. In triplicate samples, the mean conversion was 7.5 per cent. 
It was clear from the results that membrane fractions prepared from 
human platelets contained less detectable phospholipase A2 activity, 
and that this activity was very labile. 
2. Experimental details and results of study of platelets from 
normal and hyperlipidaemic subjects 
Subjects under the care of Dr. M. Stone were selected to take part 
in the study. Six control subjects were selected who had a history of 
low or normal blood cholesterol levels (below 200 mg/100 ml) . Six 
hyperlipidaemic subjects were selected who had been diagnosed with 
either type lla or type llb hyperbetalipoproteinaemia. These subjects 
had histories of high blood cholesterol levels (above 500 mg/100 ml) 
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and high LDL levels (above 300 mg /100 ml). Three of these subjects had 
suffered cardiovascular complications during the previous 2 years. 
Blood samples were taken from 3 normal (control) and three test 
subjects by Dr. M. Stone at the Leigh Health Centre on one day, and 
samples were taken from the remaining subjects on another day. The 
subjects had fasted overnight for at least 12 hours. 
60 ml of blood was taken from each subject from the antecubital 
vein of one arm into 3.8 per cent sodium citrate for platelet samples 
to be examined at ICI Pharmaceuticals Division. 
PRP samples were prepared from the 60 ml blood sample, and approxi- 
mately 20 ml of PRP was obtained from each subject. These samples were 
then transferred to ICI Pharmaceuticals Division as quickly as possible 
for processing. Investigations commenced within approximately 2+ hours 
after the blood samples were obtained. The tests carried out were: 
1. Phospholipase A2 assay (Table 7.3) 
2. MDA assay (Table 7.3) 
3. Aggregation of PRP samples (Table 7.4) 
4. Analysis of cholesterol, phospholipid and protein of samples 
of platelet membrane prepared for the phospholipase A2 assay (Table 7.2). 
Membrane samples prepared for phospholipase A2 assays were analysed 
for protein prior to the assay of phospholipase A2 activity in order 
that samples could be prepared containing the same amounts of membrane 
protein. Aliquota of these membrane preparations were then stored at 
-10 
oC 
until the lipids were extracted by the method of Bligh and Dyer 
(1959) as described in Chapter 2 for analysis of cholesterol and 
phospholipid. MDA assays were carried out on resuspended platelet 
samples by Dr. M. Johnson by the method of Stuart et al. (1975). 
In the experiments carried out in this study, the following 
observations were made: 
Table 7.2. Analysis of human platelet membrane preparations 
Control group 
(n = 4) 
Hyperlipidaemic group 
(n = 6) 
P < 
Cholesterol: Cholesterol: Phospholipid: 
phospholipid protein protein 
molar ratio weight ratio weight ratio 
0.568 ±0.031 0.050 -0.005 0.178 -0.024 
0.591±0.020 0.059±0.007 0.204±0.026 
N.S. N.S. N.S. 
Results are presented S.E.M.. p values were calculated using 
students t -test. 
In the control group, 2 samples had insufficient lipid for accurate 
assay, hence results for the remaining 4 are included. 
Table 7.3. Phospholipase A2 assay of human platelet membrane 
preparations 
Control group 
(n = 6) 
Hyperlipidaemic group 








0.93 -0.09 11.5 -2.04 
1.00±0.36 8.04±1.15 
N.S. N.S. 
Phospholipase A2 activity was assayed by determining % conversion 
of [1 -14C] oleoyl PC to [1 -14C] oleate in 35 min in 1 ml samples 
containing 0.3 mg membrane protein, Ca 
2+ 
(2.0 mM) albumin 
(0.5 mg/ml) in tris HC1 buffer at pH 9.0. 
MDA production was assayed in resuspended platelets induced by 
1 mM arachidonic acid. 
Table 7.4. Aggregation of human PRP samples 
Extent Rate 
(% max) (% min-1) 
Control group 
(n = 6) 61.8 -6.54 20.0 -1.97 
Hyperlipidaemic group 
(n = 5) 65.7 -2.75 17.4 -2.05 
p N.S. N.S. 
Samples of PRP (0.25 ml) were tested fcr aggregation induced 
by collagen (final concentration of 1.6 pg/ml) . Samples of 
PRP from one hyperlipidaemic subject aggregated spontaneously 
on stirring in the aggregometer. This result is not included 
in the figures above. 
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1. There was no detectable difference in the cholesterol:phospho- 
lipid molar ratio in the membrane preparat ions from platelets of the 
two groups (Table 7.2) . 
2. Phospholipase A2 activity and Mtt production were not significantly 
different between the two groups (Table 7.3). 
3. Sensitivity of PRP samples to the aggregating agent collagen was 
not significantly different. However , PRP from one hyperlipidaemic 
subject aggregated spontaneously on stirring in the aggregometer. 
7.4 Discussion 
In the present study, platelets from normal control subjects and 
from hyperlipidaemic subjects were compared. No differences in sensitivity 
to collagen induced aggregation, or in arachidonic acid induced MDA 
production were detected between the two groups. Phospholipase A2 
activity was very low in all platelet samples, and any small difference 
in activities there may have been were not detected. It is clear that 
phospholipase A2 activity in human platelet membranes was very labile 
when compared to similar studies carried out on rat platelets (see 
Chapters 4 and 8). It is difficult to conclude from the analysis results 
that the cholesterol content of platelets from these hyperlipidaemic 
subjects was not different from normal platelets because of the variation 
between samples from within the same group, and the low number of 
subjects in each group. This made statistical analysis unreliable and 
could only have been improved with a larger number of subjects in each 
group. The difference in cholesterol:phospholipid molar ratio of 
platelets from type lla subjects compared to control platelets was 
reported by Colman (1978) to be 7 per cent. It is unlikely that a 
difference of this small amount would have been detected in the present 
study. 
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The experiments reported in Chapter 6 where platelets from hyper - 
cholesterolaemic rabbits were examined and compared with platelets from 
normal control rabbits had one major advantage over the present study 
with human subjects. This was that the two groups of rabbits studied 
were both very homogeneous groups each with very well defined 
characteristics. A common problem frequently encountered in human 
studies is the great variability between subjects within a given group. 
There are often differences in age, activities, diets and as was the 
case in the present study, the nature of the hyperlipidaemic condition 
could not be precisely defined. In respect of age, environment and 
activities the two groups of rabbits studied in Chapter 6 were very 
similar. The diet constituents were the same except for the one group 
taking the diet supplemented with cholesterol. Such well controlled 
conditions for human studies is often impossible and makes interpretation 
of results more difficult. 
The results presented in this chapter reinforce the need for 
carefully controlled conditions for research of the type described 
here. It is clear that to investigate the effect of cholesterol 
enrichment on the platelet membrane, the in vitro technique described 
in Chapters 3 and 5 has several advantages. In the in vitro technique, 
it is only cholesterol which is altered, and no complications arise due 
to alteration of other platelet lipids such as described in the study 
of platelets from human subjects with liver disease by Owen et al. 
(1981). 
In the final group of investigations described in the following 
chapter, rat platelets have been incubated in vitro to alter their 
cholesterol content, and also to enrich platelets with cholesterol 
analogues. Studies were carried out in the knowledge that essentially 
all conditions were well controlled and the cause and effect relationship 
between platelet sterol content and platelet function could be investigated. 
Chapter 8 
Effect of Alteration of Cholesterol Content 
and Cholesterol Analogue Enrichment on Rat 
Platelet Function 
96. 
8.1 Introduct ion 
It has been shown in the present project that rat platelets enriched 
with cholesterol by the in vitro method demonstrated enhanced sensitivity 
to collagen induced aggregation (Chapter 5). Human platelets which had 
been depleted of cholesterol by this method showed reduced sensitivity 
to ADP induced aggregation, and cholesterol- enriched platelets showed 
enhanced sensitivity to ADP induced aggregation compared to control 
platelets (Chapter 7). Also, it has been shown in the present project 
that platelets from hypercholesterolaemic rabbits were enriched with 
cholesterol, and under specific conditions showed enhanced phospholipase 
A2 activity compared to platelets from normal rabbits. 
It has been demonstrated that rat platelet membrane preparations 
provided a good source of phospholipase A2 activity (Chapter 4). Details 
are reported in this chapter of investigations which were carried out 
to alter the rat platelet membrane cholesterol content by the in vitro 
technique (Chapter 3), and to study the phospholipase A2 activity in 
membrane preparations. Much work has been carried out recently which 
demonstrated that sterols containing side chains of lengths different 
from that found in cholesterol dramatically altered the properties of 
artificial membranes (Suckling and Boyd, 1976; Craig, 1978; Suckling 
et al., 1979) , as discussed in Chapter 1. The platelet membrane is a 
very important structure involved in the aggregation process. The 
platelet, when it is stimulated by a suitable agonist, swells to a 
spherical shape, and then pseudopodia foam which are long extensions 
of membrane protruding out from the surface of the platelet. To investigate 
the importance of the precise dimensions of the cholesterol molecule in 
biological membranes, rat platelets were enriched with cholesterol 
analogues with side chains of different lengths. 
97. 
8.2 Summary of Investigations of Rat Platelets 
Results from 7 experiments are reported in which combinations of 
various investigations were carried out. Membrane dependent events, 
namely aggregation and phospholipase A2 activity have been routinely 
studied except where otherwise stated. The importance of cholesterol 
for the normal function of rat platelets has been investigated by 
studying the effect of alteration of platelet cholesterol content. 
Further studies have been carried out to investigate the effect of 
incorporation of various cholesterol analogues into platelets. 
Cholesterol analogues were synthesised in this laboratory and kindly 
provided by Dr. I. Craig and Dr. K. Suckling. 
1. By using the in vitro incubation method described by Shattil 
et al. (1975) and discussed in Chapter 3, cholesterol enrichment and 
depletion of rat platelets was carried out. The same technique was 
used to enrich rat platelets with the C21 -, C24- and C26- sterol analogies. 
2. Analysis was routinely carried out to determine the sterol, 
phospholipid and protein content of crude platelet membrane fractions. 
These fractions were prepared for the phospholipase A2 assays, and 
aliquots were retained for analysis. 
3. Aggregation characteristics of the PRP-liposone mixtures were 
studied in the aggregometer when stimulated with collagen. 
4. Scanning electron micrographs of platelet samples were kindly 
carried out by the Teaching and Research Centre, Western General Hospital, 
Edinburgh. Platelet samples were prepared after the incubation period 
and preserved in a glutaraldehyde fixative. 
5. Platelet counts were carried out by the Coagulation Unit, 
Royal Infirmary of Edinburgh. 
6. Phoapholipa se A2 assays were carried out on crude platelet 
membrane preparations after the incubation period. 
98. 
8.3 Alteration of Cholesterol Content of, and Incorporation of Cholesterol 
Analogues into Rat Platelets 
In the present project, it has been shown that rat platelets could 
be enriched with or depleted of cholesterol. Also, it has been possible 
to enrich rat platelets with cholesterol analogies by incubating PRP 
with liposomes loaded with analogues. Preliminary investigations 
revealed that C21- analogue enriched platelets demonstrated different 
characteristics compared to normal, cholesterol -depleted or cholesterol - 
enriched platelets. It was observed that in order to sediment C21- 
analogue- enriched platelets, a prolonged period of centrifugation was 
required. Also, it was found that these platelets (in PRP- liposome 
mixtures) aggregated spontaneously in a cuvette on stirring the sample 
in the aggregometer. These observations suggested that the integrity 
of platelets was disrupted by incorporation of this cholesterol analogue. 
Tables 8.1 -8.8 show results for analysis of crude platelet membrane 
fractions. The results show that cholesterol depletion and enrichment 
of rat platelets occurred in each experiment, and the incorporation of 
the 3 cholesterol analogues was also successful. 
Table 8.8 shows mean values for the cholesterol :phospholipid molar 
ratio and cholesterol:protein weight ratio calculated from the values 
in Tables 8.1 -8.3, 8.5 and 8.6. The results show that the proportion 
of cholesterol to phospholipid and protein was signif icantly increased 
in cholesterol- enriched platelets compared to control platelets. 
Tables 8.2 -8.4 show that after incubation for 3 hours, between 55 and 
63 per cent of the total sterol present was the C21- analogue in platelets 
incubated with C 
21-analogue 
rich liposomes. Table 8.5 shows that the 
C24- analogue was incorporated to a similar extent as the C21- analogue, 
whereas in Table 8.6 it can be seen that incorporation of the C26- 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 8.6. Cholesterol and C26- analogue enrichment of rat platelets 
Analysis Aggregation (% max. extent) 
to collagen (2.0 1ig/ml) 
Sterol :PL Sterol :Pr PL:Pr after incubation for: 
2 hrs 31 hrs 6 hrs 
C26-analogue- 
enriched 0.684 (25%) 0.070 0.184 64 64 67 
Cholesterol- 
normal 0.600 0.051 0.170 44 51 45 
Cholesterol- 
enriched 0.632 0.055 0.164 56 56 58 
Experimental details and abbreviations are as described in the legends 
to Tables 8.1 and 8.2. In this experiment a sample of PRP was 
incubated with C26- analogue -rich liposomes. Aggregation was tested 
after 2, 31 and 6 hrs incubation of PRP with liposome suspensions. 
The aggregation traces obtained after 6 hrs incubation are shown in 
Figure 1.2. 
Analysis was carried out on whole platelets in this experiment. 
Table 8.7. Enrichment of rat platelets with cholesterol in vitro 
Cholesterol:phospholipid Cholesterol :protein 
molar ratio weight ratio 
Control (n = 5) 0.604 -0.018 0.053 -0.002 
Cholesterol- 
enriched (n = 5) 0.716±0.023 0.064±0.003 
p 0.01 0.05 
Results show means calculated from values obtained from Tables 8.1- 
8.3, 8.5 and 8.6. 
Results include S.E.M.s and significance was calculated using 
students t -test. 
Table 8.8. Cholesterol depletion and enrichment, and C21- analogue 
enrichment of rat platelets 
Analysis 
Sterol :PL Sterol :Pr PL :Pr 
C21- analogue- 
enriched 0.903 (83 %) 0.094 0.210 
Cholesterol- 
depleted 0.560 0.051 0.176 
Cholesterol- 
normal 0.650 0.055 0.169 
Cholesterol- 
enriched 0.700 0.060 0.171 
Abbreviations are as described in legends of Tables 8.1 and 8.2. 
Rat PRP samples were incubated with liposome suspensions for 5 hr 
and then analysed, or prepared far scanning electron micrographs. 
C21- analogue- enriched samples are shown in Plate 8.2, cholesterol - 
depleted in Plate 8.3, cholesterol-normal in Plate 8.4 and 
cholesterol -rich in Plate 8.5. 
Analysis was carried out on whole platelets in this experiment. 
99. 
total sterol present was the C26- analogue. Analysis of platelet lipid 
extracts which contained a mixture of cholesterol and analogue was 
carried out by gas liquid chromatography as described in Chapter 2. 
In view of the observation that C21- analogue incorporation into rat 
platelets dramatically altered their properties, further investigations 
were carried out. These investigations included aggregation, scanning 
electron microscopy and phospholipase A2 assays. 
8.4 Aggregation Studies 
PRP- liposome samples were tested with various concentrations of 
collagen in order to identify submaximal concentrations which showed 
differences in sensitivity of the various samples. A supramaximal dose 
of collagen would induce maximum a ggre gat ion in all platelet samples 
masking small differences in sensitivities which may exist between the 
different groups. A concentration of collagen which was too low would 
not induce aggregation in any of the samples. Hence it was important 
to identify the concentration of collagen which would show small 
differences in sensitivity between different platelet samples. 
The aggregation results showed that rat platelets enriched with 
cholesterol were more sensitive to collagen induced aggregation than 
control platelets (Tables 8.1-8.3, 8.5 and 8.6) . These results agree 
with those presented in Chapter 5. In one experiment no difference 
was seen in sensitivity to collagen between normal and cholesterol -rich 
platelets. This was most likely due to the amount of collagen used 
being a supermaximal concentration. In three experiments, rat PRP was 
incubated with cholesterol -poor liposomes, and the platelets were 
depleted of cholesterol (Tables 8.1 -8.3, 8.8). In three of these 
experiments, PRP -liposome samples were tested for aggregation with 
collagen (Tables 8.1 -8.3). In two experiments, cholesterol- depleted 
rat platelets were more sensitive to collagen induced aggregation than 
100. 
control platelets (Tables 8.1, 8.2). In the other experiment (Table 8.3), 
the extent of aggregation was very slightly less than control samples. 
When ADP (0.2 JIM) was used to stimulate rat PRP -liposome samples, 
cholesterol -enriched platelets were more sensi tive to aggregation than 
control platelets. At the same concentration of ADP, cholesterol - 
depleted platelets aggregated irreversibly. Hence cholesterol- depletion 
of rat platelets has the opposite effect to cholesterol -depletion of 
human platelets with regard to ADP induced aggregation (see Figure 7, 
Chapter 7). This finding emphasises the need for caution in relating 
results obtained in platelets from one species to another. 
As mentioned previously, C21- analogue enriched rat platelets 
underwent spontaneous aggregation on stirring in the aggregometer. 
The pattern of aggregation was quite different from platelets with a 
normal or altered cholesterol content. Figure 8.1 shows aggregation 
traces obtained from PRP- liposome samples containing normal platelets 
(trace A) cholesterol -rich platelets (trace B) C21- analogue enriched 
platelets (trace C) and C24- analogue enriched platelets (trace D). 
It can be seen that trace B shows an irreversible aggregation pattern 
whereas trace A was reversible, showing the enhanced sensitivity of 
cholesterol- enriched platelets. The traces of analogue enriched 
platelets initially had a lower optical density, indicated by the 
position of the recorder pen further to the right. This suggested that 
the platelets were either smaller and /or fewer in number, and it can be 
seen that aggregation was much slower than control platelets, and 
irreversible. C24- analogue enriched platelets required prolonged 
centrifugation for sedimentation and were similar to C21- analogue 
enriched platelets in this respect also. 
Incorporation of C26- analogue enrichment of rat platelets occurred 
to a lesser extent than either the C21- or C24- analogue (Table 8.6). 
Figure 8.1. Aggregation of rat platelets after 3 hrs incubation with 
liposomes to alter platelet sterol content 
Trace A shows reversible aggregation of control (cholesterol -normal) 
platelets induced by 2.4 jg/ml collagen. 
Trace B shows irreversible aggregation of cholesterol- enriched platelets 
induced by 2.4 pg/ml collagen. 
Trace C shows the spontaneous, slow, irreversible aggregation of C21- 
analogue enriched platelets. 
Trace D shows the spontaneous, slow, irreversible aggregation of C24- 





Figure 8.2. Aggregation of rat platelets after 6 hrs incubation with 
liposomes to alter platelet sterol content 
Trace A shows reversible aggregation of control (cholesterol- normal) 
platelets induced by 2.0 pg /ml collagen. 
Trace B shows reversible aggregation of cholesterol- enriched platelets 
induced by 2.0 pg /ml collagen. 
Trace C shows aggregation of C26- analogue enriched platelets induced by 
2.0 pg /ml collagen. This concentration of collagen was almost sufficient 





C26- analogue enriched rat platelets did not show similar characteristics 
to platelets enriched with the other analogues, but were instead very 
similar to cholesterol- enriched platelets. Figure 8.2 shows aggregation 
traces of normal platelets (trace A), cholesterol -enriched platelets 
(trace B) and C26- analogue enriched platelets (trace C). The C26- 
analogue enriched platelets were more sensitive to collagen induced 
aggregation than control platelets, and did not aggregate spontaneously 
as did platelets enriched with C21- or C24- analogues. The results 
obtained with the C26- analogue enriched platelets suggested that 
enrichment of rat platelets with an analogue bearing a side chain 
reduced by only one carbon atom had the same effect as cholesterol 
enrichment. 
In all the experiments reported, except for the C26- analogue 
enrichment experiment (Table 8.6), platelet counts were carried out on 
PRP -liposome preparations by the Blood Coagulation Unit, Royal Infirmary 
of Edinburgh. This was done to ensure that platelet counts in samples 
were approximately the same so that variation in platelet count would 
not affect the aggregation studies. Platelet counts of PRP -liposome 
samples (except for C21- analogue enriched samples) were in the range 
378 -542 x 109 /litre, and in any one experiment, the difference in 
count between the different samples was less than 5 per cent. Platelet 
count would not therefore have been a factor contributing to the 
observed differences in collagen induced aggregation between samples 
of platelets of different cholesterol content. Platelet counts of C - 
9 
analogue ranged between 59 -143 x 10 /litre after 3 hours incubation. 
It is likely that the C21- analogue enriched platelets were not counted 
by the Coulter counter because they were too small to be detected as 
they passed through the 50 p aperture. The prolonged centrifugation 
required to sediment C21- analogue enriched platelets, and the lower 
1 02 . 
optical density of PRP- liposome samples supports the theory that these 
platelets have disintegrated or become reduced in size. 
In order to investigate this possibility and to study platelets 
from all the incubation systems more carefully, scanning electron 
microscopy was carried out on platelets after incubation. 
8.5 Scanning Electron Microscopy of Rat Platelets 
An experiment was carried out to examine platelets after incubation 
of rat PRP samples with liposome suspensions. After 5 hours incubation, 
platelets were analysed for sterol, phospholipid and protein content 
(Table 8.8) , and samples of platelets were prepared for scanning electron 
microscopy. Samples of platelets were prepared for scanning electron 
microscopy by resuspending platelets in an equal volume of modified 
Tyrode's buffer, and adding five drops of this suspension to 5 ml of 
glutaraldehyde fixative. Samples of platelets for scanning electron 
microscopy were prepared from 1) a PRP sample incubated with an equal 
volume of modified Tyrode's buffer containing glucose (5 mM) (Plate 8.1); 
2) a PRP sample incubated with C21- analogue -rich liposomes (Plate 8.2); 
3) a PRP sample incubated with cholesterol -poor liposomes (Plate 8.3); 
4) a PRP sample incubated with cholesterol -normal liposomes (Plate 8.4); 
5) a PRP sample 
Plates 8.1 
incubated with cholesterol -rich liposomes (Plate 8.5). 
and 8.3 -8.5 show that these platelet samples were 
slightly activated either by the resuspending process or by the 
incubation of 5 hours. The activation is indicated by the formation 
of pseudopodia on the platelet surface. This activation was not due 
to incubation with liposomes specifically, because platelets incubated 
in buffer alone show a similar morphology. Plate 8.2 shows that the 
morphology of platelets which were enriched with the C21- analogue was 
very different. These platelets were reduced to between 4 and i the 
size of normal platelets, and they had become spherical. It also appears 
that some of the platelets were budding off smaller platelet vesicles. 
This micrograph (8.2) confirmed the decreased size of C21- analogue 
enriched platelets suspected from the different centrifugation and 
aggregation characteristics discussed above. 
Plate 8.1. Scanning electron micrograph (S.E.M.) of control rat 
platelets incubated for 5 hr at 37°C. X 2500 
Plates 8.1 -8.5 are S.E.M.s prepared with once -resuspended platelets. 
X 2500 
Plate 8.2. S.E. "S. of rat platelets enriched with C21- analogue by 
incubation with C21- analogue rich liposomes for 5 hr 
at 37oC. X 2500 
Plate 8.3. S.E.M. of rat platelets depleted of cholesterol by 
incubation with cholesterol-poor liposomes for 5 hr 
at 37 
o 
C. X 2500 
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Plate 8.4. S.E.M. of rat platelets incubated with cholesterol-normal 
liposomes for 5 hr at 37°C. X 2500 
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Plate 8.5. S.E.M. of rat platelets enriched with cholesterol by 
incubation with cholesterol -rich liposomes for 5 hr 
at 37oC. X 2500 
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Plate 8.6. S.E.M. of PRP- liposome sample of C24- analogue- enriched 
platelets incubated with C24 -analogue 
-rich liposomes for 
3i hr at 37°C. X 2500 
Plates 8.6 and 8.7 are S.E.M.s prepared by the addition of 025 ml 
of the PRP -liposome suspension to the fixative. 
Plate 8.7. S.E.M. of PRP- liposome sample of normal platelets and 
cholesterol- normal liposomes incubated for 31 hr at 37oC. 
X 2500 
l U.S . 
In a separate experiment, scanning electron microscopy was performed 
on C24- analogue enriched platelets and control platelets prepared after 
3 hours incubation. Plate 8.6 shows C24- analogue enriched platelets, 
and plate 8.7 shows control platelets incubated with cholesterol -normal 
liposomes prepared from the same experiment. In these preparations, 
0.25 ml of PRP- liposome mixture was added directly to the glutaraldehyde 
fixative. The C24- analogue enriched platelets appear smaller than 
control platelets, and this smaller size explains the lower optical 
density recorded compared to control platelets (see figure 8.1). These 
latter two micrographs also indicate some activation of the platelets, 
and since these samples were not resuspended, this suggests that rat 
platelets incubated for 3 hours or more are activated specifically by 
this incubation procedure, and do not therefore represent normal 
platelet physiology. 
8.6 Phospholipase A2 studies 
Phospholipase A2 assays were carried out in the experiments reported 
in Tables 8.1 -8.5. These assays were carried out using crude membrane 
fractions of platelets prepared by the method described in Chapter 2. 
As mentioned previously, the analyses of sterol, phospholipid and 
protein were carried out on aliquots of each membrane preparation. 
Protein estimation was carried out on freshly prepared membrane 
fractions so that phospholipase A2 assay systems could be set up 
containing the same amount of membrane protein in each. 
In all the experiments carried out for assay of phospholipase A2 
except for one (see Table 8.5) the cholesterol- enriched platelet 
membranes consistently showed significantly higher activity than in 
control membranes. Cholesterol- depleted membranes (Tables 8.1 -8.3) 
showed mean phospholipase A2 activities which were higher than for 
control membranes,, but this was significantly higher in only one 
experiment (Table 8.3). The phospholipase A2 activity of C21- analogue 
1U4. 
enriched platelet membranes showed mean values which were generally lower 
than for control membranes (Tables 8.2; 8.3) but this was significantly 
lower in only one experiment (Table 8.3). The phospholipase A2 activity 
of C24- analogue enriched membranes was not significantly different from 
control membranes (Table 8.5). 
In one experiment (Table 8.3) a sample of PRP was incubated with 
buffer alone. In this sample, the phospholipase A2 activity was 
significantly higher than in the control sample, which indicated the 
possibility that phospholipase A2 activity was affected by incubation 
with liposomes. However, since the cholesterol :phospholipid molar ratio 
in the membrane fraction of the platelets incubated in buffer alone was 
higher (0.620) than the control platelets incubated with cholesterol - 
normal liposomes (0.555), it is likely that the higher cholesterol 
content gave rise to the higher phospholipase A2 activity. 
8.7 Discussion 
The analysis and aggregation results presented in this chapter 
confirmed that cholesterol enrichment of rat platelets in PRP- liposome 
incubation systems gave rise to enhanced sensitivity to collagen 
induced aggregation in these platelets compared to control platelets. 
These results agree with those presented in Chapter 5 which also 
show enhanced sensitivity to collagen of cholesterol -rich PRP -liposome 
samples. Enrichment of rat platelets with the C21- analogue gave rise 
to deleterious alterations in these platelets. The aggregation pattern 
of these cells became very different from the normal pattern and 
scanning electron microscopy confirmed that gross structural alterations 
of these platelets had taken place. Platelets enriched with the C24- 
analogue showed a similar aggregation pattern to C21- analogue enriched 
platelets (Figure 8.1). It is clear from the results for aggregation 
obtained with platelets enriched with these two analogues, that cholesterol 
105. 
is of the utmost importance for normal platelet function. These results 
suggest that for the normal function of platelets in haemostasis to be 
maintained, platelet cholesterol cannot be replaced by analogues with 
side chains shorter by 3 or more carbon atoms. The results obtained 
with C26- enriched platelets (Figure 8.2) in which the normal 
aggregation pattern was maintained indicated that these rat platelets 
could perhaps tolerate partial replacement of membrane cholesterol with 
the C26- analogue without the adverse effects observed with C21- and 
C24- analogue enrichment. A further investigation is required to test 
whether platelets containing a mixture of cholesterol and C26- analogue 
with a normal total sterol :phospholipid molar ratio showed similar 
sensitivities to collagen induced aggregation as normal platelets. 
This would determine more precisely whether platelet cholesterol could 
be replaced with the C26- analogue without affecting platelet function. 
It has also been shown by the results presented in this chapter 
that cholesterol- enriched rat platelet membrane fractions had 
significantly enhanced phospholipase A2 activity compared to control 
platelet membrane fractions. In Chapter 5, once resuspended rat 
platelet samples did not show any difference in phospholipase A2 
activities between control and cholesterol- enriched platelets. It is 
possible that the substrate used for the assay (exogenous radiolabelled 
phospholipid) was not freely available to the enzyme for hydrolysis. 
The delivery of substrate to the enzyme may have been a rate limiting 
factor, thus masking any difference in phospholipase A2 activities 
between the two types of platelets. In the study presented in this 
chapter, sonication of membrane fractions most probably revealed the 
enzyme to make it more available to the substrate. 
In Chapter 6 of this thesis, cholesterol- enriched platelets were 
obtained from rabbits fed a cholesterol -rich diet. These platelets were 
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compared with platelets obtained from normal rabbits. It was shown in 
once resuspended rabbit platelets, that cholesterol- enriched platelets 
had a higher phospholipase A2 activity compared to control platelets, 
when this activity was assayed after stimulation with collagen under 
specific conditions. The results reported from the rabbit study in 
Chapter 6, and the results presented in this chapter, strongly suggest 
that the enhanced sensitivity of cholesterol- enriched platelets to 
collagen induced aggregation may in part be mediated through an 
increased activity of phospholipase A2 catalysed hydrolysis of membrane 
phospholipids. The mode of action by which cholesterol enrichment may 
make this enzyme hyperactive remains unclear, but it is possible that 
in cholesterol- enriched platelet membranes the phospholipid substrate 
is made more readily available to phospholipase A2. 
Chapter 9 
General Discussion 
Extensive research has been carried out over the last two decades to 
investigate the factors responsible for inducing thrombosis and athero- 
sclerosis. Hypercholesterolaemia is generally considered to be a possible 
factor, and many projects have been conducted to investigate this in 
human subjects and in animal models. Platelets are found in athero- 
sclerotic plaques and thrombi (Haft, 1979) and it is generally accepted 
that platelets are involved in the development of the disorders. 
Human subjects with type lla hyperbetalipoproteinaemia have a high 
risk of severe early age atherosclerosis (Lees et al., 1973). Shattil 
et al. (1975) showed that when normal human platelets were enriched with 
cholesterol in vitro they became more sensitive to the aggregating agents 
ADP and adrenaline. Shattil et al. (1977) showed that platelets from 
type lla subjects had a raised cholesterol content and were hypersensitive 
to aggregating agents. Stuart et al. (1980a) used the same in vitro 
cholesterol enrichment and depletion technique as used by Shattil et al. 
They showed that cholesterol- enriched human platelets synthesised greater 
quantities of arachidonic acid metabolites in resporse to thrombin 
stimulation compared to platelets depleted of cholesterol. Worrier and 
Patscheke (1980) also used this in vitro technique, and demonstrated 
enhanced arachidonic acid metabolism in cholesterol- enriched human 
platelets compared to control human platelets. 
The evidence discussed above suggested the possibility that cholesterol 
enrichment of platelets may have given rise to hypersensitivity in part 
through enhanced arachidonic acid metabolism. Phospholipase A2 is 
considered to be an important enzyme responsible for the release of 
arachidonic acid from platelet phospholipids (see for example Blackwell 
et al., 1977). More recently a different pathway far the release of 
arachidonic acid has been identified. A phospholipase C enzyme which 
specifically cleaves phosphatidylinositol at the sn -3 position to 
1 08 . 
produce a diacylglycerol has been well characterised (Billah et al . , 
1980). This enzyme is present in the cytosol of the platelet whereas 
the phospholipase A2 is membrane bound. The diacylglycerol produced by 
phospholipase C activity is then available for hydrolysis by diacyl 
glycerol lipase to release arachidonic acid (Bell et al., 1979). 
The proportion of free arachidonic acid generated by these two pathways 
to the total pool available for further metabolism in activated platelets 
is the subject of much current research and will be discussed later. 
The aim of the present project was to investigate the effect of 
alteration of the cholesterol content of platelet membranes on platelet 
function. Phospholipase A2 may be an important rate limiting step in 
the metabolism of arachidonic acid to the pro -aggregating agents PQi2 
and thromboxane A2, therefore experiments were carried out to investigate 
the influence of membrane cholesterol content on this membrane bound 
enzyme. Two principal approaches were undertaken in this project to 
alter the cholesterol content of platelets. These were 1) in vitro 
alteration essentially by the method of Shattil et al. (1975) as 
described in Chapter 3 and 2) in vivo enrichment of platelets by feeding 
rabbits a diet supplemented with cholesterol (Chapter 8). 
These two methods are referred to as the "in vitro" and "in vivo" 
methods of alteration of platelet cholesterol content. Rat platelets 
were enriched with cholesterol using the in vitro method (Chapter 3). 
After 3 hours incubation with cholesterol -rich liposomes, rat platelets 
were enriched with cholesterol by between 10 to 40 per cent which 
resulted in enhanced sensitivity to collagen induced aggregation 
(Chapters 5 and 8) . The same technique was used to enrich and 
deplete human platelets of cholesterol (Chapter 7). In human platelets, 
cholesterol- depletion gave rise to reduced sensitivity, and cholesterol - 
enrichment gave rise to enhanced sensitivity to ADP induced aggregation. 
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This is in agreement with the results of Shattil et al. (1975). Rat 
platelets enriched with cholesterol consistently showed greater 
sensitivity to collagen than control rat platelets. However, in any 
one experiment few aggregation tests were performed. In some cases 
only one sample was tested. As was discussed in Chapter 5, samples of 
rat PRP obtained from different groups of animals demonstrated widely 
different sensitivities to collagen. It has not been possible therefore 
to make a statistical analysis on the rat platelet experiments in order 
to test the significance of differences between control and cholesterol 
enriched platelets with respect to aggregation. In future studies 
therefore it would be possibly more suitable to determine platelet 
sensitivity by using threshold concentrations of aggregation agents. 
This would be expected to induce aggregation in the more sensitive 
platelet sample, whereas no response would be elicited in the less 
sensitive sample. 
In addition to cholesterol enrichment of rat platelets, three 
experiments are reported where rat platelets were depleted of cholesterol 
(Chapter 8). In two experiments, cholesterol depletion resulted in 
enhanced sensitivity to collagen induced aggregation, whereas in one 
experiment this sensitivity was reduced when compared to control rat 
platelets. Interpretation and explanation of these findings are severely 
restricted due to the low number of experiments performed. However, 
these results contrast markedly when compared with results obtained 
with human platelets. Cholesterol depletion of human platelets leads 
consistently to decreased sensitivity to aggregation as shown in the 
present studies (Chapter 7) and in the current literature as previously 
discussed. These 'different' results of rat platelets and human 
platelets serves to highlight the difficulty of interpreting data 
obtained from different species along a common biochemical mechanism. 
109a 
It is very evident that platelets from different species have 
important differences in their biochemistry. Much of the work presented 
in this thesis has been carried out on rat platelets and some on rabbit 
platelets. This therefore severely limits interpretation of data in 
the human context. 
Scanning electron microscope studies of rat platelets incubated 
with liposomes for three and five hours have been carried out (Chapter 8). 
This is discussed in more detail below, but as has been pointed out in 
Chapter 8, this incubation procedure may cause activation of platelets. 
This was demonstrated by the micrographs which showed that platelets 
had developed small pseudopodia. The possibility that the incubation 
procedure may activate platelets has been demonstrated and cannot be 
excluded. It is evident however that the liposomes are not responsible 
for this activation since platelets incubated in buffer alone showed the 
same characteristics. 
In the experiments discussed in Chapter 5, phospholipase A2 
activity was assayed in once resuspended rat platelets. No difference 
in activity of this enzyme was detected between cholesterol -enriched 
and control (cholesterol -normal) platelets. As has already been mentioned, 
cholesterol -enriched rat platelets showed enhanced sensitivity to 
aggregating agents. It was observed that cholesterol- enriched platelets 
that had been resuspended once showed a very much reduced sensitivity to 
collagen induced aggregation compared to control platelets. It is 
possible that the resuspending process activated the cholesterol - 
enriched platelets to a greater extent than control platelets, giving 
rise to the reduced sensitivity to collagen and reduced phospholipase A2 
activity. This may explain why the phospholipase A2 activities in 
cholesterol- enriched and control platelets were not different as 
measured in once resuspended platelet samples. 
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The alternative appraoch to enrich platelets with cholesterol, 
referred to here as the in vivo method was carried out by feeding a 
group of rabbits a diet supplemented with cholesterol (Chapter 6). 
This dietary regimen raised the serum cholesterol level, and resulted 
in an increase in the platelet unesterified cholesterol:phospholipid 
molar ratio compared to platelets from rabbits fed a normal diet. 
The cholesterol -enriched platelets from the cholesterol fed group 
showed a significantly more active arachidonic acid metabolic pathway. 
The phospholipase A2 activity of once resuspended cholesterol -enriched 
rabbit platelets was enhanced compared to once resuspended platelets 
from rabbits fed a normal diet. The enhanced activity was only 
detected under very precise conditions (see Chapter 6 for details). 
Phospholipase A2 activity was significantly increased in cholesterol 
enriched samples when resuspended platelets were stimulated with collagen 
(2íµg /ml) in the presence of 0.2 mM Ca2 +. In unstimulated samples, 
average phospholipase A2 activity was increased in cholesterol- enriched 
compared with control platelets, but this was not significant at the 
p = 0.05 level. When the experiment was repeated using twice the 
concentration of Ca2+ and twice the final concentration of collagen, 
phospholipase A2 activity was stimulated equally in cholesterol -enriched 
and control platelet samples. 
It was recently reported by Kawaguchi et al. (1981) that the 
phospholipase A2 activity in platelets isolated from normal rabbits 
was not different from the activity in platelets isolated from rabbits 
fed a cholesterol- enriched diet. As was discussed in Chapter 6, the 
conditions used by this group to assay phospholipase A2 probably 
stimulated the enzyme superoptimally so' as to effectively hide any subtle 
difference. It would appear from the results discussed above and in 
Chapter 6 that very precise conditions are required to assay phospholipase 
A2 activity and to show differences in phospholipase A2 activity between 
normal and cholesterol- enriched platelets isolated from rabbits. 
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As discussed above, rat platelets enriched with cholesterol by 
the in vitro technique and resuspended once did not show any difference 
in phospholipase A2 activity compared to control platelets treated in the 
same way. A possible reason for this may have been that the rate of 
delivery of substrate to the enzyme was limited or restricted. Fu Cher 
experiments were carried out to test the viability of assaying 
phospholipase A2 activity in crude platelet membrane preparations (see 
Chapter 4). It was shown that rat platelet membranes provided a good 
source of phospholipase A2. In view of this, experiments were carried 
out to assay phospholipase A2 activity in crude rat platelet membrane 
fractions prepared from platelets enriched with cholesterol by the 
in vitro technique (Chapter 8). It was consistently shown that 
cholesterol -enriched platelet membranes had a significantly higher 
phospholipase A2 activity than control platelet membranes. Phospholipase 
A2 assays were also carried out on crude membrane fractions prepared 
from cholesterol depleted rat platelets. In two experiments there was 
no significant difference compared to control samples, whereas in ocie 
experiment there was a significant increase in phospholipase A2 activity. 
As discussed previously, interpretation of few results is risky, but the 
mean levels of phospholipase A2 activity in all three experiments were 
higher than the control samples. This suggests that the normal cholesterol: 
phospholipid molar ratio may maintain a degree of inhibition of phospho- 
lipase A2 activity in rat platelets, but in further experiments larger 
numbers of samples would be required. In the three experiments reported 
here, only four samples of crude membrane fraction were assayed for 
phospholipase A2 activity which reduces the reliability of statistical 
analysis. 
A trial was also carried out to study platelets isolated from human 
hypercholesterolaemic subjects. This study was of interest because 
lila 
Shattil et al. (1977) had shown that platelets from type lla hyperbeta- 
lipoproteinaemic subjects were hypersensitive to aggregating agents 
compared to normal human platelets. In order to study phospholipase A2 
activity, crude human platelet membranes were prepared by the method 
described for rat platelets. No difference in phospholipase A2 
activity was detected in platelet membranes prepared from the hyper - 
cholesterolaemic and control groups of subjects (Chapter 7). 
Phospholipase A2 activities in human platelet membranes were very 
low, which may explain why no differences were observed. 
The investigations carried out in this project showed that 
cholesterol -enrichment of rat and rabbit platelets resulted in enhanced 
phospholipase A2 activity. The mechanism by which this effect occurred 
remains unclear, but there are a number of possibilities: 
1. Cholesterol may exert a direct effect on the phospholipase 
A2 enzyme. 
2. Cholesterol may exert an effect on phospholipids in the 
membrane which in turn affect the enzyme or 
3. cholesterol may have an effect on phospholipids which affects 
the properties of the substrate phospholipid. 
The technique developed in the present study could be used for 
further investigations. Of particular interest would be the study of 
phospholipase A2 activity in cholesterol- enriched platelets in the 
presence of anti -lipaemic drugs. Colman et al. (1976) showed that 
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halofenate reduced the hypersensitivity to aggregating agents of platelets 
isolated from type lla hyperbetalipoproteinaemic subjects. Carvalho 
et al. (1974b) showed similar resulta with clofibrate. 'Cholesterol - 
enriched platelets could be assayed for phoapholipase A2 activity in the 
presence of these drugs. This would show whether the anti -platelet 
effect of these drugs was due to a reduction of arachidonic acid 
metabolism by phoapholipase A2 inhibition. 
Recently much research has been carried out to determine the source 
of arachidonic acid which is liberated from membrane phospholipids when 
platelets are stimulated. Also, the pathways of release of arachidonic 
acid from membrane phospholipids have been investigated. It was generally 
accepted that phoapholipase A2 was the enzyme responsible for hydrolysis 
of arachidonic acid from platelet membrane phospholipids (Blackwell 
et al., 1977; Smith et al., 1976). Very recently, it has become 
clear that phoapholipase A2 activity is not the only pathway for 
arachidonic acid release. A phospholipase C has been identified which 
cleaves specifically phosphatidylinositol at the phosphate bond to 
produce the corresponding diacylglycerol (Rittenhouse -Simmons, 1979). 
The diacylglycerol is then available for further metabolism by two 
enzymes (see Figure 9.1). Diacylglycerol kinase, identified by Call and 
Rubert (1973) forms phosphatidic acid from the diacylglycerol. This 
pathway has been investigated by several researchers (Billah et al., 
1979; Lapetina and Cuatrecasus, 1979; Broekman et al., 1980). It has 
been suggested by Bell et al. (1979) that a diacylglycerol lipase 
exists which hydrolyses the arachidonic acid from the an -2 position of 
the glycerol moiety. It was shown by Broekman et al. (1979) that it 
was only phosphatidylinositol which decreased in mass in platelets on 
stimulation with thrombin which suggested that phospholipase A2 activity 
was less important in providing free arachidonic acid than the 


















































































































































































































































































































































































































Billah et al. (1980) suggested that when platelets are stimulated 
with thrombin, the cytosolic phospholipase C is firstly stimulated to 
produce diacylglycerol which is converted to phosphatidic acid by the 
kinase. This phoaphatidic acid may then act as a calcium ionophore 
which is responsible for inducing phospholipase A2 activity. In the 
studies by Billah et al. (1980), conclusions regarding the different 
properties of phospholipase C and phospholipase A2 were based on the 
results obtained in platelet sonicates in the presence of deoxycholate. 
The same results were not obtained when deoxycholate was excluded from 
incubations described by Billah et al. (1980). Deoxycholate is a 
detergent which is commonly used to solubilise or disperse membranes, 
therefore conclusions drawn from these results may not be relevant 
to in vivo platelet physiology. 
In further studies, Lapetina et al. (1981) provided evidence that 
one third of the total platelet phosphatidylinositol was converted to 
phosphatidic acid on stimulation with thrombin. These workers suggested 
that formation of this phosphatidic acid results in the subsequent 
release of arachidonic acid from various phospholipids. Billah et al. 
(1981) suggested the existence of a phospholipase A2 activity specific 
for the phosphatidic acid produced by thrombin stimulation as being a 
possible mechanism for the production of arachidonic acid in platelets. 
However, Rittenhouse -Simmons (1981) recently reported that in platelets 
stimulated by A23187, phosphatidylinositol was hydrolysed primarily by 
an enzyme other than phospholipase C, and this may have been a 
phospholipase A. 
It has been suggested by Lapetina and Cuatrecasus (1979) that the 
format ion of diacylglycerol may play an important role in platelet 
shape change. Diacylglycerol formation in erythrocytes induced by 
exogenous phospholipase C, or by treatment with ionophore A23187 is 
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thought to be, at least in part, responsible for shape change, microvesicle 
formation and membrane curvature (Allan et al., 1978). Further research 
which could be carried out of relevance to the present project would be 
investigations into the phospholipase C activity of cholesterol- enriched 
platelets. It is possible that cholesterol -err is hed platelets, as well 
as showing enhanced phospholipase A2 activity, have a raised phospholipase 
C activity giving rise to increased amounts of diacylglycerol. The 
result of this might be to make the platelets change shape more readily. 
This, together with enhanced phospholipase A2 activity to synthesise 
increased quantities of PGH2 and thromboxane A2 could explain the 
observed hyperaggregability of these platelets. 
As was discussed previously (Chapter 1), it has been suggested that 
cholesterol fitted very precisely into artificial membranes. Liposome 
lipid bilayers had reduced rigidity when they contained analogues of 
cholesterol with different side chain lengths instead of cholesterol 
(Suckling et al., 1979). The platelet membrane has the specialised 
function of changing shape, and was therefore a suitable biological 
membrane in which to study the precise requirement for the cholesterol 
side chain. Rat platelets have been enriched with three cholesterol 
analogues of shorter side chain length than cholesterol in the present 
study (Chapter 8). The in vitro method was used to enrich rat platelets 
with these sterols. Initial observations of platelets enriched with the 
C21- analogue suggested that major changes of platelet structure had 
occurred. Spontaneous aggregation of these platelets occurred on stirring 
PRP- liposome samples in an aggregometer. The pattern of aggregation was 
abnormal as shown by the recorded traces (Chapter 8). It was also 
noticed that prolonged centrifugation was required to sediment these 
platelets. These findings suggested that the platelets had become 
smaller and lighter. Scanning electron microscopy confirmed this 
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(Chapter 8, Plates 8.1 -8.7). Platelets enriched with the C24- analogue 
showed similar characteristics to C21- analogue- enriched platelets, but 
C26- analogue- enriched platelets showed characteristics very similar to 
cholesterol -enriched platelets. C26- analogue- enriched platelets showed 
enhanced sensitivity to collagen, and the pattern of aggregation was the 
same as the pattern for cholesterol -enriched platelets. These results 
show that analogues with the shorter side chains have the most disruptive 
effect on rat platelets. 
The sterol content has been shown to be maintained precisely for 
the stability of red cell membranes.(Lange et al., 1980). The studies 
carried out in the present project suggest this may also be true for 
platelets. Very recently, Lange et al. (1981) have provided evidence 
that the movement or flip -flop of cholesterol between the two leaflets 
of the red cell membrane bilayer is extremely fast (3 seconds). These 
workers suggested that a rapid redistribution of bilayer sterols could 
relieve the resistance of a membrane to bend and therefore facilitate 
and stabilise changes in shape. It is possible that this mechanism is 
more easily initiated in red cells and platelets that are enriched with 
cholesterol. The unusual characteristics which have been observed in 
C21- analogue and C24- analogue- enriched rat platelets may be due to three 
most likely factors. 
1) Displacement of membrane cholesterol by an analogue of 
significantly different dimensions may disrupt interactions between 
membrane proteins and contractile proteins so as to cause sphere formation 
2) The cholesterol flip -flop mechanism suggested by Lange et al. 
(1981) for red cells, if it exists in platelets, may be interfered with 
by cholesterol analogues 
3) Enzymes which are responsible for the formation of products 
concerned with shape change may become activated as a result of 
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enrichment of the platelet with cholesterol analogue. 
Clearly these sterol analogues do not have the precise properties 
required to maintain platelet integrity. 
The effects of the cholesterol analogues on platelet aggregation 
and of cholesterol on phospholipase A2 activity reported in this 
thesis further demonstrate the importance of the sterol component in 
the platelet membrane. Effects can be observed at the cellular and enzyme 
level and it is likely that cholesterol -enrichment of platelets induces 
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